The role of novel transmembrane serine proteases : implications for arthritis by Patel, Amit
  
 
 
 
 
The role of novel transmembrane serine proteases: 
implications for arthritis 
 
Amit Patel BSc(Hons) 
 
 
 
 
 
Thesis submitted in partial fulfilment of the requirements  
of the regulations for the degree of Doctor of Philosophy 
Newcastle University 
Faculty of Medical Sciences 
Institute of Cellular Medicine 
October 2010 
ii 
 
Declaration 
 
The work reported in this thesis was performed from October 2007 to September 2010. 
The work in this thesis was carried out in the Musculoskeletal Research Group, Institute 
of Cellular Medicine, Newcastle University. Except for commonly held concepts, and 
where specific reference is made to other work, the content of the thesis is original. All 
experiments were carried out by myself under the guidance of my supervisors, Prof. 
Drew Rowan and Dr Jenny Milner. 
 
No part of this thesis has been submitted for the award of any other degree. 
  
iii 
 
Abstract 
In the arthritides, the breakdown of articular cartilage and the erosion of subchondral 
bone lead to loss of efficient joint function. Matrix metalloproteinases (MMPs) can 
collectively degrade the extracellular matrix of cartilage, and have been strongly 
implicated in cartilage destruction. MMPs are produced as inactive precursors requiring 
activation. Addition of interleukin-1 (IL-1) and oncostatin M (OSM) to bovine cartilage 
in explant culture results in a synergistic loss of the collagen matrix, accompanied by a 
dramatic increase in pro-MMP synthesis and activation. Increasing evidence implicates 
serine proteinases in pathologic tissue turnover and the transmembrane serine proteases 
fibroblast activation protein-α (FAPα), dipeptidyl peptidase IV (DPPIV) and matriptase 
were recently found to be up-regulated in osteoarthritic (OA) cartilage compared to 
normal cartilage. The aim of this work was to identify whether these transmembrane 
serine proteases have roles in cartilage collagen breakdown. 
Inhibition of IL-1+OSM-mediated collagen breakdown was not observed using 
selective FAPα inhibitors, indicating that FAPα enzyme activity per se plays no direct 
role in collagen breakdown. In contrast, DPPIV inhibition showed significant protection 
of IL-1+OSM-mediated collagen breakdown. However, the mechanism of action of 
DPPIV remains to be elucidated. 
Matriptase was demonstrated to activate pro-MMPs as well as induce MMP expression 
in OA cartilage via protease-activated receptor 2 activation. This makes matriptase a 
key protease in the pathology of OA.  
Overall, this study has identified matriptase as a key serine protease in OA pathology 
and confirmed a potential role for DPPIV in cytokine-mediated cartilage degradation. 
These findings support the need for further research in order that therapeutic 
interventions targeting these enzymes may be realised. 
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CHAPTER 1 
Introduction 
1.1 Cartilage 
Cartilage is a highly specialised connective tissue, which falls into the following three 
distinct categories: elastic; fibro-cartilage and hyaline. The composition of the cartilage 
matrix thereby determines its classification. Articular cartilage, a specialised form of 
hyaline cartilage, is found covering the ends of long bones in all synovial joint cavities. 
Articular cartilage is a unique connective tissue as it is both aneural and avascular 
(Martel-Pelletier et al., 2008, Kuettner, 1992). It contains only one cell type, the 
chondrocyte (section 1.1.1), that maintains the large extracellular matrix (ECM) 
network of the tissue. The ECM is primarily composed of proteoglycans (section 1.1.2) 
and collagens (section 1.1.3) but other minor matrix components are also present 
(section 1.1.4) (Bhosale and Richardson, 2008). 
Adult articular cartilage displays a zonal architecture (Ikemefuna et al., 2009) (Figure 
1.1). The zones are distinguished according to their differing morphologies and 
comprise: 
 The superficial zone; 
 The middle (or transitional) zone; 
 The deep (or radial) zone; 
 The calcified zone. 
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Figure 1.1 Zonal architecture of articular cartilage.  
Cross-section of cartilage showing the transition from the articular surface to the 
subchondral bone. Adapted from Newman (1998). 
 
The superficial zone is exposed to the synovium and represents the thinnest layer of the 
cartilage. This zone has the highest rate of collagen synthesis in the entire tissue and its 
chondrocytes are small and flattened surrounded by a matrix composed of thin collagen 
fibres and little aggrecan. The transitional zone has an extensive ECM composed of 
aggrecan and large collagen fibres. Here, the chondrocytes are less abundant and exhibit 
a spherical morphology (Bhosale and Richardson, 2008, Ikemefuna et al., 2009). In the 
radial zone, the chondrocytes are arranged in parallel to the collagen fibres (Martel-
Pelletier et al., 2008) and appear to form columns. The proteoglycan content here is the 
highest in the whole tissue but its cell density is the lowest. The calcified zone contains 
a small volume of cells embedded in a calcified matrix and displays low metabolic 
activity (Bhosale and Richardson, 2008, Ikemefuna et al., 2009). The chondrocytes in 
this zone display a hypertrophic phenotype, with the synthesis of type X collagen being 
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the classical marker. The large amount of collagen X in this zone confers structural 
integrity and transition to the subchondral bone by penetrating into the calcified zone, 
thereby anchoring the articular cartilage to the subchondral bone (Martel-Pelletier et al., 
2008).  
This organisation of the macromolecules enables normal, healthy articular cartilage to 
sustain extremely high pressures of up to 10 MPa (Kerin et al., 2002). 
1.1.1 Chondrocytes 
Chondrocytes are responsible for the maintenance of the cartilage matrix and have a 
high rate of metabolism. However, due to the hypocellular nature of cartilage, the 
overall metabolism of the tissue is quite low (Mankin, 1982), and due to the avascular 
nature of cartilage, chondrocytes rely on diffusion of oxygen from the synovial tissue 
(Coimbra et al., 2004, Muir, 1995). Therefore, chondrocytes must rely on anaerobic 
metabolism. Chondrocytes are known to be encapsulated within a pericellular 
environment, termed the chondron (Poole, 1997). Within the chondron, the 
chondrocytes are anchored to the type II collagen network by type VI collagen (Aigner 
and Stove, 2003). The pericellular environment is composed of two different layers: a 
glycocalyx, providing attachment for the chondrocyte, and fibrillar capsule, providing 
attachment for the ECM. The embedding of chondrocytes within this environment is 
thought to protect them from the high compression strengths in the joint during 
movement. However, the compressive force does affect cell metabolism (Urban, 1994) 
and excessive pressures to the cartilage can result in homeostatic imbalance and leads to 
cartilage degradation. 
1.1.2 Proteoglycans 
Proteoglycans are composed of a central protein core with numerous covalently 
attached glycosaminoglycan (GAG) chains. The GAG chains confer the biological 
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function of proteoglycans as their distinct physio-chemical properties provide hydration 
and swelling pressure (Gentili and Cancedda, 2009).  
The major proteoglycan found in articulating cartilage is aggrecan (Martel-Pelletier et 
al., 2008). Aggrecan has a large protein core (230 kDa) to which numerous GAGs and 
N-linked and O-linked oligosaccharide chains are covalently attached. The main GAGs 
are keratan sulphate and chondroitin sulphate. Keratan sulphate is a multi-repeat dimer 
of N-acetylglucosamine-galactose and chondroitin sulphate is a multi-repeat dimer of 
N-acetylgalactosamine-glucuronic acid (Kuettner, 1992). The protein core consists of 
three distinct globular domains, G1, G2 and G3 (Figure 1.2), which are stabilised by 
disulphide bridges. The G1 and G2 domains are located near the N-terminus and 
connected via a short interglobular domain, while the G3 domain is near the C-terminus 
and separated from the G2 domain by a long GAG attachment region. The G1 domain 
interacts non-covalently with hyaluronic acid (HA) and link protein (Martel-Pelletier et 
al., 2008) and the G3 domain is essential for the post-translational modification and 
secretion of aggrecan. The function of the G2 domain has yet to be elucidated. 
The proteoglycan content of the joint can also facilitate signalling in the joint (Gentili 
and Cancedda, 2009), as heparin sulphate can bind to a number of signalling molecules, 
including fibroblast growth factors and transforming growth factor-β (TGF-β) 1.  
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Figure 1.2 Structure of aggrecan.  
Protein structure of aggrecan showing a simplified depiction of the domain organization 
and glycosaminoglycan attachment areas. CS, chondroitin sulphate; KS, keratin 
sulphate; Ig, immunoglobulin. Adapted from Kiani et al. (2002). 
 
1.1.3 Collagens 
Collagens make up a family of closely related but distinct fibrous proteins (Gentili and 
Cancedda, 2009). There are more than 30 genes encoding collagen proteins and 
collagen-like proteins. Collagen is the predominant protein found in mammals, 
constituting the structural components of tissues and organs.  
Collagen proteins form a wide array of different structures, such as fibrils (type I, II, III) 
(Kolacna et al., 2007) and network-like sheets (type IV) (Jamshid et al., 2008). The 
characteristic amino acid sequence is Gly-Xaa-Yaa, where Xaa is proline every third 
residue and Yaa is hydroxyproline every seventh residue. The presence of glycine in 
this tri-peptide repeat helps to stabilise the collagen fibrils as it faces the interior of the 
helix, as the side chain of glycine is short and allows for tight association between the 
G1 G2 G3
CS chains
O-linked oligosaccharide
KS chains
N-linked oligosaccharide
Ig domain
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fibrils. Hydroxyproline residues help to stabilise the polypeptide chains and are critical 
to collagen formation (Kolacna et al., 2007).  
Type II collagen is the major fibrillar collagen found in articular cartilage. It is 
synthesised intracellularly as pro-α-chains which contain large pro-peptides at the N- 
and C-termini. These pro-peptides are separated from the central helix forming region 
by telopeptides and are essential for trimerisation of the pro-α-chains. Subsequently, this 
trimer is secreted from the chondrocyte and the pro-peptides are removed by 
proteolysis. The trimeric α-chains are then assembled into large collagen fibrils by 
covalent cross-linking in the telopeptide regions (Figure 1.3) (Martel-Pelletier et al., 
2008). 
Other collagen types, type IX, X and XI, co-exist with type II collagen in the 
articulating joint. Type IX is a member of the fibril-associated collagen with interrupted 
triple helix (FACIT) family of collagens and is cartilage specific. It does not form a 
fibril itself, but is found at the interface of type II/type XI fibrils. Collagen IX fibrils are 
thought to bridge the collagen network to the glycosaminoglycan network (Martel-
Pelletier et al., 2008). Type IX collagen can have chondroitin sulphate attached to the α2 
chain, and is sometimes thought of as a proteoglycan. 
Type XI collagen is another fibrillar collagen and is also cartilage specific. It is 
synthesised and secreted in a similar manner as type II collagen, except here only the C-
terminal pro-peptide is removed. Type XI collagens do not form their own unique 
fibrils, but associate with type II collagen molecules to form heterotypic fibrils. Type XI 
collagen is predominantly found in the thin fibrils of the pericellular network.  
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Figure 1.3 Collagen fibril formation.  
Collagen pro-α-chains from trimers intracellularly and are then secreted into the 
extracellular space and proteolytically cleaved. The trimers then assemble into large 
fibrils which are stabilised by cross-linking. The crosslinking is initiated by the 
oxidative deamination between lysine and hydroxylysine resides Adapted from Kadler 
et al. (1996). 
 
Type X collagen is termed a short chain collagen and its fibril is composed of 
homotrimeric α1(X) chains (Chan et al., 1995, Schmid and Linsenmayer, 1983). As 
mentioned earlier, the hypertrophic zone of the cartilage is rich in type X collagen, 
which confers both structural integrity and a transition to the subchondral bone. The 
expression of type X collagen is closely associated with hypertrophic chondrocytes and 
is often used as a marker for their presence in this zone (van der Kraan et al., 2001). 
Furthermore, it is postulated that type X collagen plays a role in cartilage mineralisation 
(Gibson and Flint, 1985). This may be due to the open lattice structure that type X 
Pro-peptide cleavage
Fibril assembly
Cross-linked fibril
Pro-peptides Pro-peptides
α-chain trimer
Intracellular
Extracellular
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collagen adopts that permits vascular invasion, calcification, and remodelling to proceed 
to the next phase of bone development (Kwan et al., 1991). 
1.1.4 Non-aggregating proteins 
Biglycan, fibromodulin and decorin are examples of non-aggregating proteoglycans 
found in articular cartilage (Kuettner, 1992, Gentili and Cancedda, 2009). They share a 
similar protein structure but differ in their GAG composition. Biglycan possesses two 
dermetan sulphate side chains, whereas decorin contains one. In contrast, fibromodulin 
contains multiple keratin sulphate chains attached to the protein core. Biglycan, 
fibromodulin and decorin are characterised by their ability to interact with collagen 
proteins. Biglycan is found in the pericellular matrix and binds type VI collagen, while 
decorin and fibromodulin both bind to the type II collagen fibrils (Kuettner, 1992).  
HA is a non-sulphated GAG and the size of the HA molecules in the joint decrease with 
age (Martin and Buckwalter, 2001). As HA binds aggrecan molecules (section 1.1.2) 
and this helps to attract water into the joint after the application of a compressive load to 
the cartilage, a decrease in the size of HA results in decreased water content in the joint. 
Link protein has a structure that is analogous to the G1 domain of aggrecan. It plays a 
number of key roles in cartilage such as the binding of aggrecan to the HA filaments 
and the protection of HA from degradation. Cleavage of link protein generates the LP3 
isoform, which can act as a growth factor to promote matrix production (Martel-
Pelletier et al., 2008). 
1.2 Arthritis 
1.2.1 Rheumatoid arthritis 
Rheumatoid arthritis (RA) is a disease characterised by systemic activation of the 
immune system, which is possibly initiated by the recognition of auto-antigens (de 
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Vries et al., 2005). Typically, RA affects about 1% of the population at a ratio of 3:1 
(female:male) and disease presentation usually occurs at the ages of 30 to 50 years 
(Majithia and Geraci, 2007). 
One of the distinguishing features of RA is the increase in the number of invasive cells 
into the joint space. There is increased thickening of the synovial lining by peripheral 
blood T cells, activated macrophages, B cells and synovial fibroblasts (Lundy et al., 
2007, Mauri and Ehrenstein, 2007, Lutzky et al., 2007, Muller-Ladner et al., 2007, 
Kinne et al., 2007). The synovial fibroblast is thought to instigate the major pathways 
that lead to joint destruction by producing inflammatory cytokines, such as interleukin-1 
(IL-1) and interleukin-6 (IL-6) (Chiu et al., 2008). The chronic activation of the immune 
system in the joint space leads to the release of inflammatory cytokines, such as IL-1 
and oncostatin M (OSM), which have been shown to synergistically increase levels of 
the matrix metalloproteases (MMPs), such as MMP-1 (Cawston et al., 1998). A further 
distinct feature of RA is the formation of locally invasive tissue, termed pannus, from 
synovial tissue. The pannus has a high level of MMP expression and invades the 
cartilage and subchondral bone, causing permanent tissue impairment (Lee and 
Weinblatt, 2001). 
1.2.2 Osteoarthritis 
Osteoarthritis (OA) is the most common form of arthritis, affecting the majority of 
individuals over the age of 65 years. However, it is a disease that is not just a disorder 
of the articular cartilage but affects most of the major tissues of the joint. The 
subchondral bone shows increased invasion into the tidemark of the cartilage and results 
in thinning of cartilage. This increased ossification in the subchondral bone is thought to 
occur due to reactivation of the secondary centre of ossification (Brandt et al., 2006). 
Cartilage damage in OA is thought to occur due to a number of different reasons such as 
10 
 
ageing, genetic factors as well as excessive loading. The degeneration of cartilage 
occurs due to an imbalance between the anabolic and catabolic pathways. Excessive 
loading of cartilage can cause increased collagen degradation and up-regulation of 
MMPs. This increase in the levels of MMPs leads to an increase in the turnover rate of 
the cartilage matrix. However, type II collagen gene expression in OA is shown to be 
up-regulated in the late stages of the disease, indicating that anabolism does occur, in an 
attempt to repair the damage (Goldring and Goldring, 2007). Nevertheless, the damage 
to the collagen network is irreversible at this point, as the chondrocyte cannot replicate 
the complex network as it did during development. 
1.3 Cytokines 
Cytokines are soluble or cell surface anchored molecules that play an essential role in 
mediating cell-cell interactions. Cytokines generally act through autocrine, juxtacrine 
and paracrine signalling by binding their specific receptors. They are important 
mediators and regulators of inflammation and cartilage degradation in the arthritides 
(Table 1.1) (Goldring and Goldring, 2004). In RA, the chronic inflammation results in 
an increased concentration of cytokines in the joint space. The cytokines can then 
interact with synovial fibroblasts or diffuse through the synovial fluid to the cartilage 
and cause an increase in the release of catabolic factors. 
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Catabolic Anti-inflammatory Anabolic 
IL-1 IL-4 Insulin-like growth factor-1 
Tumour necrosis factor-α IL-10 TGF-β1, 2, 3 
IL-17 IL-1 receptor antagonist Bone morphogenetic protein-2 
IL-18 
 
  
OSM 
 
  
IL-6     
Table 1.1 Classification of cytokines implicated in the modulation of chondrocyte 
metabolism. Adapted from Goldring and Goldring 2004. 
 
1.3.1 Interleukin-1 
The IL-1 family currently comprises of 11 structurally similar members with IL-1α and 
IL-1β being the best characterised members of the family (Kalliolias and C Liossis, 
2008). IL-1α and IL-1β are both synthesised as an inactive pro-form in the cytoplasm.  
IL-1α is then sequestered to the plasma membrane or the nucleus. IL-1β is processed at 
the plasma membrane by IL-1β converting enzyme (ICE) and secreted as the active 
protein. Only pro-IL-1α and the mature forms of IL-1α and IL-1β have biological 
activity.  
There are two specific IL-1 receptors, IL-1RI and IL-1RII, and both IL-1α and IL-1β 
can bind to them. IL-1RI is the biologically active receptor and contains a long 
cytoplasmic domain. Activation of IL-1RI by IL-1α or IL-1β results in the initiation of a 
number of pathways, such as the mitogen-activated protein kinase (MAPK) pathways. 
In contrast, IL-1RII is biologically inert and found on the cell surface as well as a 
soluble receptor (Arend, 2002). Henceforth all references pertaining to IL-1 will refer to 
IL-1α. 
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Numerous different groups have described involvement of IL-1 in arthritis (David et al., 
1985, Nobuyuki et al., 1988). IL-1 is secreted by a number of different cells within the 
joint space in arthritis (Cinzia et al., 1998). In RA, it is the synovial lining which is the 
major source of IL-1 production and conversely, cartilage is the major source of IL-1 
production in OA.  
Stimulation of chondrocytes with IL-1 results in the induction of a number of different 
pro-inflammatory mediators, such as IL-6 and leukaemia inhibitory factor (LIF) 
(Barksby et al., 2006). These data suggest that IL-1 is an important catabolic mediator 
in arthritic diseases. 
1.3.2 Oncostatin M 
OSM is a 28 kDa protein and belongs to the IL-6 family of cytokines (Pelletier and 
Martel-Pelletier, 2003). It is described to play an important role in the progression of 
RA. The addition of OSM to IL-1 or tumour necrosis factor-α (TNF-α) treated cartilage 
causes a reproducible increase in collagen release (Cawston et al., 1998, Hui et al., 
2003b). Interestingly, when OSM is added in combination with IL-1 there is a 
synergistic increase in collagen release and gene induction (Barksby et al., 2006, 
Morgan et al., 2006). Other members, such as IL-6 and LIF, cannot synergise directly 
with IL-1 as only the OSM-specific receptor is expressed on the surface of the 
chondrocyte (Rowan et al., 2001). However, the addition of soluble IL-6 receptor in 
combination with IL-6 does exhibit the same effect as the addition of OSM to IL-1 
treated cartilage. Elevated levels of IL-6 and sIL-6R have been documented in various 
arthritides, including RA (Houssiau et al., 1988, Robak et al., 1998). 
1.3.3 TGF-β 
The TGF-β superfamily consists of over 30 members and includes TGF-βs, activins and 
bone morphogenic proteins. There are three TGF-β isotypes in humans, called β1, β2 
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and β3, and all three isoforms are produced as inactive dimers (de Caestecker, 2004, 
Todorovic et al., 2005) and consist of the core TGF-β protein and pro-peptide, also 
known as latency-associated peptide. The mechanism of physiological activation of 
TGF-β has yet to be fully elucidated, although proteolytic cleavage and integrin-specific 
activation have been implicated (Saharinen et al., 1999, Wipff and Hinz, 2008). Active 
TGF-β can then bind its receptors and activate a number of different signalling 
pathways, including c-Jun N-terminal kinase (JNK) (van der Kraan et al., 2009). 
Historically, TGF-β has an anabolic role in cartilage (Table 1.1) as TGF-β activation 
stimulates ECM production and can counteract both TNF-α and IL-1 induced gene 
induction (Hui et al., 2001). However, recent evidence shows that TGF-β can cause 
significant MMP-13 up-regulation in aging cartilage (Blaney Davidson et al., 2009). 
This is due to a decrease in activin-like kinase (ALK) 5 receptor levels in aging 
cartilage, whereas ALK1 levels remain constant. Signalling through ALK1 leads to 
Smad1/5/8 activation and this leads to MMP-13 gene expression, but ALK5 stimulation 
leads to increased expression of cartilage matrix genes. 
1.4 Proteases 
Proteases are enzymes that hydrolyse the peptide bonds linking the amino acids in the 
polypeptide chain. Proteases are involved in a number of processes such as protein 
catabolism and specific protein cleavage. 
Based upon their catalytic mechanism, proteases can be classified into five distinct 
categories: 
 Serine; 
 Threonine; 
 Metallo; 
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 Aspartic; 
 Cysteine 
These five classes are implicated to be involved in arthritis with cysteine, aspartic and 
threonine proteases contributing to matrix degradation through intracellular pathways. 
Recently, intracellular uptake and lysosomal targeting of type II collagen has been 
characterised and using E64d, a broad spectrum cysteine protease inhibitor, caused 
collagen accumulation in lysosomes (Kjoller et al., 2004). Furthermore, cathepsin K, a 
novel cysteine collagenase, has been identified as a protease in the pathology of arthritis 
(Dejica et al., 2008), although the actual contribution of cathepsin K to cartilage 
catabolism in vivo has yet to be fully elucidated. 
Metallo- and serine proteases contribute to matrix degradation in the extracellular space 
(Cawston and Young, 2010). 
1.5 Matrix metalloproteases 
The MMPs are members of the metalloprotease family and utilise a divalent zinc cation 
to catalyse the hydrolysis of peptide bonds (Bode et al., 1993). There are 28 vertebrate 
MMP genes known to date and all MMPs share common features (Figure 1.4) 
(Sternlicht and Werb, 2001). Some of these common features include: 
 Synthesis as zymogens, with activation requiring removal of the pro-domain; 
 Cysteine switch motif PRGC(V/N)PD in the pro-domain (Nagase and Woessner, 
1999); 
 Zinc binding motif HEXXHXXGXXHS in the catalytic domain. 
1.5.1 MMP Structure 
The MMP domain structures are shown in Figure 1.4. 
 Figure 1.4 Domain structures of matrix metalloproteinases (MMPs).  
All MMPs have a catalytic domain, which also contains the zinc-binding motif, and pro-peptide that ensures latency. Some contain a furin recognition 
motif (Fu) that specifically allows for intracellular activation by furin-like proteases . Apart from MMP-7, -23 and -26 all contain a haemopexin domain 
which determines substrate specificity and is connected by a flexible hinge domain. Other domains include the fibronectin-like domains (F) and the 
vitronectin-like domain (V). Some MMPs are anchored to the cell surface through either a TM with cytoplasmic tail (Cyt) or a GPI anchor. MMP-23 is 
structurally unique as it contains a N-terminal TM (actually an N-terminal signal anchor), a cysteine array (CA) and a immunoglobulin-like domain (Ig-
like). Modified from Cawston and Wilson (2006). 
 
MMP-7, -26 
Minimal domain 
MMPs 
 
MMP-1, -3, -8, -10, -
12, -13, -18, -19, -20, -
22, -27 
Simple haemopexin 
domain MMPs 
 
MMP-2, -9 
Gelatin binding 
MMPs 
 
MMP-11, -28 
Furin activated 
MMPs 
 
MMP-21 
Vitronectin insert 
containing MMPs 
 
MMP-14, -15, -16, -24 
Transmembrane 
MMPs 
 
MMP-17, -25 
GPI-anchored 
MMPs 
 
MMP-23 
Type II 
transmembrane 
MMPs 
 
Pre Pro Catalytic Zn
Haemopexin
S S
Pre Pro Catalytic Zn
Pre Pro Catalytic Zn HaemopexinF F F
S S
Pre Pro Catalytic Zn HaemopexinFu
S S
Pre Pro Catalytic Zn HaemopexinFuV
S S
Pre Pro Catalytic Zn HaemopexinFu TM Cyt
S S
Pre Pro Catalytic Zn HaemopexinFu GPI
S S
TM Pro Catalytic ZnFu CA Ig-like
1
5
 
 
16 
 
The pre-domain encodes a signal peptide region that targets the protein for secretion and 
is removed shortly before the MMPs are secreted (Sternlicht and Werb, 2001). 
The pro-domain is up to 90 amino acids in length and contains the conserved 
PRGC(V/N)PD sequence. This motif is conserved between all MMPs with the 
exception of MMP-23, which has the sequence ALCLLPA instead (Velasco et al., 
1999). The Cys residue in these sequences is termed the cysteine switch and stably 
interacts with the catalytic zinc ion to maintain latency of pro-MMPs (Nagase and 
Woessner, 1999, Sternlicht and Werb, 2001). MMP-11, MMP-14, MMP-15, MMP-16, 
MMP-17, MMP-23, MMP-24, MMP-25, and MMP-28 contain a pro-protein processing 
motif RXKR in their pro-domain (Milner et al., 2008). This sequence can be cleaved 
intracellularly by pro-protein convertases resulting in the secretion of active MMPs 
(Kang et al., 2002). 
The catalytic domain contains the zinc binding motif, HEXXHXXGXXHS in MMPs, 
and a conserved Met residue, which forms a Met-turn structure (Bode et al., 1993). This 
domain also contains an extra zinc ion and three calcium ions that are essential for 
stability, structure and secretion of the MMP (Iyer et al., 2007). MMP-2 and -9 are 
unique as their catalytic domains contain three repeats homologous to the type II 
domains of fibronectin (Steffensen et al., 1995). These repeats allow for high affinity 
binding of collagens and help to localise them to the ECM. 
With the exception of MMP-7, -26 and -23, all MMPs possess a C-terminal haemopexin 
domain. This domain is composed of a calcium linked four bladed β-propeller structure 
in which each blade consists of four anti-parallel β-strands and a single α-helix (Gomis-
Rüth et al., 1996). It was demonstrated that without the haemopexin domain, MMP-1 
lost its collagenolytic ability but otherwise retained other substrate specificity. Instead 
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of a haemopexin domain, MMP-23 possesses a cysteine array, but attempts to 
characterise its substrate specificity have failed so far (Velasco et al., 1999). 
1.5.2 Collagenases 
The enzymatic degradation of the native collagen triple helix, at neutral pH, was 
demonstrated in the resorbing tadpole tail (Gross and Lapiere, 1962). The “classical” 
collagenases, MMP-1, MMP-8 and MMP-13, are mainly described to cleave fibrillar 
collagen, such as type II collagen, in vivo. All three of these collagenase genes are 
expressed in arthritic cartilage (Boris et al., 1997, Lynne et al., 2001). The key defining 
feature of the collagenases is their ability to cleave the collagen triple helix at a specific 
site, about a quarter length in from the C-terminus (Highberger et al., 1979). 
MMP-1, also known as collagenase-1, fibroblast collagenase or interstitial collagenase, 
has been purified from joint tissues (Cawston and Tyler, 1979, Okada et al., 1986) and 
synovial fluid from arthritic patients (Cawston et al., 1984). As MMP-1 is expressed by 
a number of cells within the joint, it is thought to be mainly associated with RA 
(Murphy et al., 2002). MMP-1 preferentially cleaves type I collagen then type III, with 
type II collagen degradation being the slowest (Welgus et al., 1981).  
MMP-8, also known as collagenase-2 and neutrophil collagenase, was originally 
thought to be only expressed in human neutrophil precursors. However, it has now been 
shown that a number of cells, such as chondrocytes and plasma cells, produce MMP-8 
(Van Lint and Libert, 2006). MMP-8 shows the same preference for collagen cleavage 
as MMP-1 (Hasty et al., 1987). 
MMP-13, also known as collagenase-3, was originally identified from a breast 
carcinoma cDNA library (Freije et al., 1994). MMP-13 expression is mostly restricted 
to chondrocytes and is therefore thought to drive disease progression in OA, where 
cartilage degradation is mainly chondrocyte driven (Murphy et al., 2002). Biochemical 
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characterisation of MMP-13 activity has shown that it preferentially cleaves type II 
collagen over type I and type III (Knäuper et al., 1996). 
1.5.3 Stromelysins 
There are three human stromelysins, MMP-3 (stromelysin-1), MMP-10 (stromelysin-2) 
and MMP-11 (stromelysin-3) (Sternlicht and Werb, 2001). MMP-3 was first identified 
as a proteoglycanase from rabbit bone culture. It was later shown that MMP-3 can also 
degrade other matrix components such as fibronectin and type IV collagen but not 
fibrillar collagens such as type I collagen (Murphy et al., 1981, Galloway et al., 1983). 
MMP-3 is able to activate all three collagenases in vitro (Ito and Nagase, 1988, Suzuki 
et al., 1990, Knäuper et al., 1996) to a “superactive” form (Windsor et al., 1993). 
MMP-10 was thought to be differentially regulated in regards to MMP-3 (Bord et al., 
1998). However, in normal cartilage MMP-3 and -10 are co-expressed and their 
expression is decreased in OA (Kevorkian et al., 2004). MMP-10 has substrate 
specificity similar to MMP-3 (Fosang et al., 1991, Busso et al., 1998). 
The third member of the stromelysin family, MMP-11, has a structure which is slightly 
different as it contains a furin recognition site (Figure 1.4). Like other MMPs, it is 
expressed during wound healing and development (Lefebvre et al., 1995, Okada et al., 
1997), but differs from the other stromelysins in its substrate specificity, as it is unable 
of cleaving the ECM (Noël et al., 1995). MMP-11 can cleave other proteins found in the 
extracellular compartment, such as serpins (Pei et al., 1994), implicating that it has an 
indirect role in ECM degradation by increasing the activity of other proteases. 
1.5.4 Regulation of MMP activity 
The significant role MMPs have in many biological processes, from wound healing 
through to tumour metastasis and cartilage matrix degradation indicates that their 
activity needs to be highly regulated. MMP activity is regulated at several levels from 
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transcription through to their activity in the ECM. Firstly, MMPs are inducible genes, 
whose expression is tightly regulated by pro- and anti-inflammatory cytokines and 
growth factors (Rowan, 2001) and ECM interactions, for example type I collagen 
binding to integrins can induce MMP-1 expression (Vogel et al., 1997). Secondly, the 
majority of MMPs are then secreted from the cell in their latent form and require 
activation (Figure 1.5). MMPs can be activated by previously activated MMPs in the 
ECM as well as a number of serine proteases (Milner et al., 2008). MMP activation can 
also be achieved in vitro by a number of different chemicals, such as organomercurial 
compounds (Van Wart and Birkedal-Hansen, 1990). Finally, MMP activity can be 
regulated by their interaction with endogenous inhibitors, tissue inhibitors of 
metalloproteases (TIMPs), and α2-macroglobulin (Visse and Nagase, 2003, 
Tchetverikov et al., 2003). 
 
Figure 1.5 Stepwise activation of MMPs.  
Pro-MMPs can be activated by proteases (top pathway) or nonproteolytic agents 
(bottom pathway). Cleavage within the bait region by proteases partially activates the 
MMP. Chemical activation relies on modification of the cysteine switch sulfhydryl 
(SX), resulting in partial activation of the MMP and intramolecular cleavage of the 
propeptide. In either pathway, full activation is attained by complete removal of the pro-
domain y intermolecular processing. Adapted from Visse and Nagase (2003).  
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1.5.5 Tissue inhibitors of metalloproteases 
TIMPs are the endogenous inhibitors of MMP enzymes and to date four TIMP 
homologues (TIMP-1, -2, -3 and -4) have been identified. TIMPs are small proteins 
(between 21 to 30 kDa) and inhibit MMPs in a 1:1 stoichiometry. All TIMPs inhibit all 
tested MMPs, with the exception of TIMP-1 that cannot inhibit MMP-14. TIMP-3 is 
unique in the fact that it can inhibit ADAMs as well as MMPs (Sternlicht and Werb, 
2001). 
In addition to their MMP inhibitory activity, TIMPs exhibit other biological functions. 
For example, TIMP-1 caused increased erythroid cell growth (Chesler et al., 1995). 
TIMP-2 overexpression in smooth muscle cells caused a decrease in proliferation while 
TIMP-3 overexpression results in apoptosis of these cells (Baker et al., 1998). 
1.6 Serine proteases 
Serine proteases belong to the protease family that causes peptide bond hydrolysis 
through a serine residue in their active site. Serine proteases play a role in a number of 
biological processes such as inflammation, blood clotting and cell signalling as well as 
digestion. The active site of serine proteases contain the so-called “catalytic triad” 
(Sigler et al., 1968, Blow et al., 1969, Steitz et al., 1969) which consists of a conserved 
group of three amino acid residues; serine, histidine and aspartic acid. The mechanism 
of hydrolysis involves the carboxyl group of the aspartic acid and the nitrogen of the 
histidine side chain accepting the hydrogen of the active site serine. This increases the 
electronegativity of the oxygen atom in the hydroxyl group; enabling the nucleophilic 
attack of the peptide bond. Recently, research has turned to how serine proteases can 
modulate their local environment through their proteolytic activity.  
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1.6.1 Classification of serine proteases 
The sequencing of the human genome revealed that there are over one hundred and 
seventy serine proteases (Quesada et al., 2009). Not all of these proteases share a 
chymotrypsin-like serine protease fold. In fact, the differences can range from slight 
changes to the amino acids surrounding the active site serine to different catalytic triads 
(Ekici et al., 2008). For this reason serine proteases have been classified into families or 
groups of related families (often termed “clans”) (Rawlings and Barrett, 1993). This 
classification is based upon two major criteria: 
 Evolutionary divergence in catalytic activity; 
 Convergence from separate evolutionary lines. 
Previous to this classification standard it was thought that serine endopeptidases 
belonged to either the chymotrypsin family or the subtilisin family. However, the 
rigorous standards used in classifying peptidases to these criteria highlighted that there 
are a large number of distinct serine endopeptidase families. 
1.6.2 Serine protease activity in cartilage degradation 
Early evidence showed that the MMP enzymes were directly responsible for the 
breakdown of the collagen network in articular cartilage (Cawston, 1996). At that time, 
the development of broad-spectrum MMP inhibitors was thought to be a promising 
therapeutic intervention in the arthritides. However, clinical trials identified 
musculoskeletal side-effects in patients taking these inhibitors (Nemunaitis et al., 1998) 
and led to their withdrawal from the clinic. 
Bovine nasal cartilage (BNC) has been used as a model of healthy cartilage. When 
cultured in the presence of IL-1+OSM, there is significant degradation of the collagen 
matrix (Cawston et al., 1995). In this model there are substantial levels of pro-
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collagenases by day 7, although activation rarely happens before day 10 in parallel with 
collagen release (Milner et al., 2006a). However, Milner et al. (2001) showed that the 
activation of the pro-collagenases by serine proteases is a critical control point in 
cartilage collagen degradation and highlighted a novel interaction between the serine 
and metalloprotease pathways. Primarily, the addition of plasminogen to IL-1+OSM-
treated BNC showed a significant increase in collagen release at day 7. This collagen 
release was found to be metalloprotease dependent since BB94, a general 
metalloprotease inhibitor, abrogated this release. Conversely, addition of α1-antitrypsin 
(α1-AT) to IL-1+OSM-treated BNC significantly reduced collagen degradation, even if 
α1-AT was only added at day 7 of the culture period. In fact, use of another broad-
spectrum trypsin-like serine protease inhibitor, ACITIC, displayed a similar trend. While 
the data do support that plasmin is a key activator of MMPs, other unknown serine 
proteases are likely to play a greater role since plasminogen is not expressed in this 
model (Dr J. M. Milner, personal communication). 
Furthermore, Milner et al. (2003) show that furin-like enzymes played an important role 
in cartilage collagen breakdown. However, only addition of the furin inhibitor between 
days 0 to 7 protected the collagen network. Addition of the inhibitor after day 7 did not 
have any protective effect on collagen degradation. The data strongly suggest that a 
second serine protease pathway exists in IL-1+OSM-treated cartilage, directly 
influencing MMP activity. 
Both studies strongly implicate soluble serine proteases in cartilage collagen 
degradation. On the other hand, there is evidence in the literature that implicates 
degradation of type II collagen in arthritis originating in the pericellular space, diffusing 
outwards during disease progression (Hollander et al., 1995).  Recently, expression 
profiling between OA and fracture to the neck of femur (NOF) cartilage showed that 46 
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serine protease genes were up-regulated in OA (Swingler et al., 2009) and Milner et al. 
(2006b) highlighted that expression of fibroblast activation protein alpha (FAPα), an 
integral membrane serine proteinase on chondrocyte membranes, is significantly higher 
in OA compared to normal cartilage. Together these reports highlight that 
transmembrane serine proteases could play an important role in pathogenesis as their 
cell surface localisation would support a hypothesis that pericellular degradation is 
initiated by serine proteases. While many of these proteases have been studied in other 
pathologies, such as tumour progression, not all of them have been studied in the 
context of arthritis.  
1.7 Type II transmembrane serine protease family 
Cloning of the enteropeptidase cDNA revealed that it has a similar sequence to hepsin 
(Kitamoto et al., 1994) and led to the subsequent discovery of the other 16 members of 
the type II transmembrane serine protease (TTSP) family. Based on the domain 
structure and phylogenetic analysis of the serine protease domain, TTSPs can be 
separated into four subfamilies (Figure 1.6). 
Members of the TTSP family have a very unique structure with a N-terminal 
transmembrane domain followed by a variable “stem region” and finally a C-terminal 
extracellular serine protease domain of high homology to chymotrypsin (Szabo and 
Bugge, 2008). Analysis of the amino acid sequence of the TTSPs suggests that they are 
synthesised as single chain zymogens and need to be proteolytically cleaved after an 
arginine or lysine residue near the catalytic domain (Szabo and Bugge, 2008). However, 
there is strong evidence for TTSP auto-activation as they show a high preference for 
cleavage after an arginine or lysine residue (see section 1.7.2). 
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Figure 1.6 Domain structure of the human TTSP family.  
TTSPs are grouped into four subfamilies based on domain structure and phylogenetic 
analysis of the serine protease domains. All members of this family contain a 
transmembrane domain and serine protease domain. Other domains include CUB, 
C1s/C1r urchin embryonic growth factor and bone morphogenetic protein-1 domain; 
FRZ, frizzled domain; LDLA, low-density lipoprotein receptor domain class A; MAM, 
a merpin, A5 antigen and receptor protein phosphatase µ domain; SEA, a single sea 
urchin sperm protein, enteropeptidase, agrin domain; SR, scavenger receptor cysteine-
rich domain. Adapted from Choi et al. (2009). 
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1.7.1 Matriptase  
Matriptase-1 (matriptase) is a TTSP, first identified as a secreted enzyme from breast 
cancer cells (Shi et al., 1993). Further characterisation showed that matriptase is a multi-
domain transmembrane serine protease that can degrade ECM (Lin et al., 1999, Lin et 
al., 1997). 
1.7.1.1 Matriptase structure 
The intracellular region of matriptase is fifty-four amino acids in length and, in 
conjunction with the transmembrane region, is postulated to associate with the 
cytoskeleton to help localise matriptase on the cell surface (Lin et al., 1997, Takeuchi et 
al., 2000). The cytoplasmic region of matriptase also contains consensus 
phosphorylation sites for protein kinase C and/or casein kinase II (Hooper et al., 2001). 
However, the role of this phosphorylation has yet to be determined. The extracellular 
region contains the serine protease domain as well as four low density lipoprotein 
(LDL) receptor domains, two Cls/Clr, urchin embryonic growth factor and bone 
morphogenic
 
protein 1 (CUB) domains and a sea urchin sperm protein, enterokinase,
 
agrin (SEA) domain (Figure 1.6) (Hooper et al., 2001). The LDLR and CUB domains 
are thought to be associated with protein-protein interactions on the cell surface and 
activation of matriptase (Oberst et al., 2003). The SEA domain is thought to play a role 
in the non-enzymatic shedding of the protease from the cell surface (Szabo and Bugge, 
2008). The serine protease domain has been crystallised (Friedrich et al., 2002) and 
shows that matriptase has narrow substrate specificity (section 1.7.1.3).  Although, 
matriptase has the same P1 specificity as trypsin, there is a well-defined extended 
specificity profile for matriptase. This extended specificity is primarily due to the 
localisation of the benzyl side chains of phenylalanine in the P2 and P4 binding pockets 
of matriptase, which is uncommon in chymotrypsin-like proteases (Friedrich et al., 
2002). 
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1.7.1.2 Matriptase activation 
Similar to most chymotrypsin-like proteases, matriptase is produced as an inactive 
single chain zymogen (Benaud et al., 2001). Activation of matriptase occurs through 
cleavage at arginine-614 to produce the canonical active two chain protease; the two 
chains are linked by a disulphide bridge (Takeuchi et al., 2000). 
The non-catalytic domains of matriptase are known to be important for activation 
(Oberst et al., 2003). Earlier data show that matriptase can be auto-activated by serum; 
this mechanism has not been elucidated (Benaud et al., 2001). Benaud et al. (2001) 
postulated that the CUB domain plays an important role in matriptase auto-activation, as 
C1r has a similar domain and is known to auto-activate as well. These data were 
corroborated by a later study which went on to show that the LDLR and SEA domains 
are also required (Oberst et al., 2003). However, the data presented about the role of the 
LDLR domains in matriptase activation are rather complex. Point mutations in the 
LDLR domains, that stop the formation of Ca
2+
 cages within the protease, abolish 
matriptase activation. But, when the LDLR domains are deleted matriptase activation 
actually increases. 
Matriptase can be shed from the cell surface, although the mechanism is not yet known 
(Benaud et al., 2001). There are reports that matriptase requires hepatocyte growth 
factor activator inhibitor-1 (HAI-1) to be shed from the membrane (Oberst et al., 2003). 
However, conflicting data show that HAI-1 is not essential (Miyake et al., 2010) and 
that only proteolysis within the SEA domain is crucial (Szabo and Bugge, 2008 and 
references therein). As stated by Miyake et al. (2010), the requirement of HAI-1 is 
likely to ensure that matripase does not undergo auto-activation in intracellular 
compartments and self-degrade. 
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1.7.1.3 Matriptase substrate specificity 
The substrate specificity for matriptase has been determined using a positional scanning 
library and phage substrate library (Takeuchi et al., 2000). Both libraries had their P1 
amino acid fixed as arginine. The positional scanning library showed the preferred 
substrate specificity for matriptase to be either R/K-X-S-R---A or X-R/K-S-R---A, 
where X is a non-basic amino acid. However, this study showed that glycine or 
phenylalanine residues are well tolerated in the P2 position, unlike in other canonical 
serine proteases such as thrombin. Furthermore, this study went on to test the activity of 
matriptase on protease-activated receptor 2 (PAR-2) and single-chain urokinase-type 
plasminogen
 
activator (uPA). In fact, matriptase did cause a biological response when 
incubated with PAR-2 overexpressing Xenopus oocytes, as PAR-2 contains the cleavage 
sequence of S-K-G-R. In contrast, matriptase could not activate PAR-1, -3 and -4 as 
they do not contain a matriptase consensus cleavage sequence. Furthermore, matriptase 
was shown to activate pro-uPA in vitro as well. The PAR-2 and uPA activation data 
presented in this study show that matriptase may have an important role in the 
pathogenesis of arthritis (Takeuchi et al., 2000). PAR-2 has recently been shown to be 
expressed in the synovial membrane in RA (Kelso et al., 2007) and its activation led to 
a downstream cytokine release in the synovial membrane. Furthermore, PAR-2 
activation in OA cartilage caused the activation of the extracellular signal-regulated 
kinase1/2 (ERK1/2) and p38 pathways (Boileau et al., 2007) both of which are 
important in the catabolism of the cartilage matrix. The role of uPA in arthritis has been 
documented previously (Jin et al., 2003) by the injection of uPA into the joint space of 
mice which resulted in bone erosion and synovial thickening. uPA causes the induction 
of MMPs in THP-1 monocytes by activating the ERK1/2 pathway (Menshikov et al., 
2006). However, direct evidence for the involvement of matriptase in the activation of 
PAR-2 and uPA in arthritis is still lacking. 
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1.7.2 Regulation of matriptase activity 
Serine proteases are well known to cleave ECM proteins (Milner et al., 2008) and 
therefore require tight regulation of their activity. But, with the recent emergence of 
PARs (section 1.9.1), this regulation is even more important and extends to matriptase. 
HAI-1 is found to be coexpressed and colocalised with matriptase. HAI-1 is a Kunitz-
type serine protease inhibitor (Shimomura et al., 1997), which have a different 
mechanism of inhibition and different secondary structure compared to the serpins 
(serine protease inhibitors). The primary loop extends into the active site of the protease 
and forms stable, reversible interactions with the active site (Creighton et al., 1993, 
Creighton and Charles, 1987, Kemmink and Creighton, 1993). However, data recently 
generated show that matriptase activity is not solely regulated by HAI-1. The serpins α1-
AT and antithrombin III have been shown to inhibit matriptase in vitro (Janciauskiene et 
al., 2008).  
The serpins also regulate serine protease activity and are the largest superfamily of 
protease inhibitors, present in all multicellular eukaryotes (Irving et al., 2000). Whilst 
the name serpin implies that they inhibit serine proteases, there is literature showing that 
some serpins are able to inhibit cysteine proteases (Schick et al., 1998). The serpins 
share a common protein fold (Al-Ayyoubi et al., 2004, Loebermann et al., 1984), 
consisting of three β-sheets, which adopt a twisted conformation, and nine α-helices. 
The serpins also contain a reactive centre loop (RCL) that constitutes the site of 
interaction with the target protease. The RCL contains the P1 and P1’ site and attracts 
the protease to the serpin. The RCL is usually found in an exposed conformation above 
the main body of the serpin (Elliott et al., 1998). The cleavage of the RCL by a serine 
protease causes a drastic change in conformation and results in the inability of the 
protease to complete peptide bond hydrolysis, thereby trapping the enzyme (Kaslik et 
al., 1995).  
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1.8 Membrane dipeptidyl peptidases 
The dipeptidyl peptidase (DPP) class of enzymes comprises non-classical serine 
proteases that are known to cleave the peptide bond on the carboxyl side of the proline 
residue in the sequence Pro-Xaa (Xaa≠Pro). The DPP group of enzymes includes 
intracellular enzymes such as: dipeptidyl peptidase II (also known as quiescent cell 
proline amino peptidase or dipeptidyl peptidase 7); dipeptidyl peptidase 8 (DPP8) and 
dipeptidyl peptidase 9 (DPP9). As well, some are active on the cell surface: dipeptidyl 
peptidase IV (DPPIV, also known as CD26) and FAPα (also known as seprase) (Chen 
et al., 2003). 
A lot of focus has been placed on the membrane DPP enzymes, FAPα and DPPIV, 
(Gorrell, 2005, Kelly, 2005) as they have been linked to a number of pathologies such 
as tumour invasiveness (Aoyama and Chen, 1990, Monsky et al., 1994) and type II 
diabetes (Reimer et al., 2002). These are thought to occur by the modulation of 
biological processes via Pro-specific N-terminal processing of biologically active 
peptides by DPPs (Busek et al., 2007, Proost et al., 1998).  
Evidence also exists for the modulation of these DPP enzymes in the joint tissues of 
patients with RA (Ellingsen et al., 2007, Gotoh et al., 1989, Kamori et al., 1991). Recent 
evidence has shown the expression of FAPα on the surface of chondrocytes from 
resorbing cartilage (Milner et al., 2006b). Furthermore, the combined inhibition of 
DPPIV and FAPα increases the invasion of rheumatoid arthritis synovial fibroblasts into 
articular cartilage (Ospelt et al., 2010). However, the dual inhibitor used in this study 
does not highlight whether inhibition of either DPPIV or FAPα alone would show a 
similar result. 
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1.8.1 Dipeptidyl peptidase IV 
DPPIV is the most studied member of the DPP family of enzymes. DPPIV is a 110 kDa 
glycoprotein that is catalytically active only as either a type 2 integral plasma membrane 
protein homodimer or a heterodimer with FAPα (Ajami et al., 2003). However, a small 
proportion appears to circulate in the plasma, cleaved from the membrane by an 
undetermined mechanism (Gotoh et al., 1989).  
The X-ray crystal structure of the DPPIV monomer has been elucidated and shows that 
it consists of two domains, an α/β-hydrolase domain and an eight bladed β-propeller 
domain (Aertgeerts et al., 2004). There are limited data showing that DPPIV exhibits 
endopeptidase activity and can actually cleave gelatin (Bermpohl et al., 1998) although 
the rate of cleavage for the denatured collagen fibrils is slow. However, the crystal 
structure highlights that the catalytic pocket is too small to accommodate large proteins. 
Further structure data show that DPPIV also contains nine N-glycosylation sites (Engel 
et al., 2003) and this could explain the ability of DPPIV to resist trypsin-induced 
extracellular cleavage and has been shown to be important for protein localisation to the 
cell membrane (Ajami et al., 2003).  
Adenosine deaminase (ADA) is known to bind to the monomeric and dimeric forms of 
DPPIV (Ajami et al., 2003) and this association plays an important role in regulating the 
activity of the cells of the immune system by counteracting the inhibition caused by 
extracellular adenosine (Wolberg et al., 1975). The inhibition of lymphocytes by 
extracellular adenosine is thought to occur through A2a receptor signalling which 
down-regulates the expression of co-stimulatory molecules on the surface of the T cell, 
such as CD25, and blocks proliferation (Huang et al., 1997). This observation is quite 
important in diseases such as RA where there is an increase in the amount of ADA 
isoforms in the synovial fluid (Iwaki-Egawa et al., 2001). Most of the T cells that reside 
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in synovial tissue are DPPIV
+
 low and this suggests that DPPIV
+
 T cells from the 
periphery actively penetrate into the synovium (Sedo et al., 2005) to continue to 
potentiate the disease state. Recent evidence suggests that this could be occurring in RA 
since there is an increase in the expression of DPPIV on the surface of monocytes and 
lymphocytes (Ellingsen et al., 2007). 
The role of ADA binding to DPPIV and the effects this has on the co-stimulatory 
activation of T cells still remains contradictory. There is a report stating that the co-
stimulatory role for ADA is irrespective of its ability to enzymatically degrade 
adenosine (Martin et al., 1995). Meanwhile, another report states that the activation of 
CD4
+
 and CD8
+
 T cells through DPPIV-mediated signalling was not dependent on 
activation of the ADA binding site but shown to be through the CD3 pathway (De 
Meester et al., 1995) which leads to activation and proliferation of T cells. It may be 
that binding of the ADA protein induces a conformational change in the DPPIV protein 
and causes the protein to exert a greater co-stimulatory response than DPPIV in the 
absence of ADA. 
The rate of plasminogen activation is shown to be increased by the association of 
DPPIV-ADA complex with the plasminogen type 2 receptor on the membrane of 
prostate cancer cells (Gonzalez-Gronow et al., 2004). This finding is interesting in so far 
as previous data have shown that the use of the protease inhibitor, α1-AT, possibly 
blocks a component of the plasminogen/plasmin cascade in a resorbing cartilage model 
(2003, Milner et al., 2001). Although chondrocytes do not secrete plasminogen 
themselves, when looking at the disease state of RA the roles of all the cell types in the 
joint space should be taken into account as there is an increase in the concentration of 
plasminogen in the synovial fluid (Belcher et al., 1996) and cartilage (Li et al., 2005). 
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DPPIV activity is known to modulate a number of pro-inflammatory chemokines and 
cytokines and the processing of the N-terminal ends of these peptides results in changes 
to both their receptor binding and functional properties (Table 1.2). DPPIV processing 
of full-length Regulated upon Activation, Normal T-cell Expressed, and Secreted 
(RANTES) (1-68) to cleaved RANTES (3-68) causes a noteworthy functional change 
(Proost et al., 1998) such that cleaved RANTES inhibited monocyte chemotaxis in 
comparison to full-length RANTES. A similar observation is seen in vitro for stromal 
cell-derived factor-1α (SDF-1α), whereby DPPIV cleavage of SDF-1α causes a 
reduction in leukocyte chemotaxis (Busso et al., 2005). Therefore, loss of DPPIV in the 
joint space may lead to unchecked activity of these cytokines and allow for the 
inflammatory response in the joint to be maintained rather than it cessation. 
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Substrate Effect upon cleavage by DPPIV Reference 
Substance P (SP) Decreased T cell proliferation (Covas et al., 1997) 
Neuropeptide Y (NPY) 
Decreased chemoattractive ability 
and activation of mononuclear cells 
(Mentlein, 1999) 
(Schwarz et al., 
1994) 
TNF-α 
Decreased IL-1β secretion by 
macrophages and monocytes 
(Bauvois et al., 1992) 
RANTES Decreased monocyte chemotaxis 
(Mentlein, 1999, 
Proost et al., 2001) 
Macrophage 
Inflammatory Protein-1β 
(MIP-1β) 
Decreased T cell and macrophage 
chemotaxis 
(Guan et al., 2004) 
Interferon-γ-inducible 
Protein (IP-10) 
Decreased T cell chemotaxis (Proost et al., 2001) 
SDF-1α Decreased leukocyte chemotaxis 
(Mentlein, 1999, 
Busso et al., 2005, 
Proost et al., 2001) 
Monokine induced by 
interferon-γ (MIG) 
Decreased T cell chemotaxis 
(Ludwig et al., 2002, 
Proost et al., 2001) 
Eotaxin 
Decreased degranulation of 
eosinophil and basophils 
(Mentlein, 1999, 
Proost et al., 2001) 
Monocyte Derived 
Chemokine (MDC) 
Reduced chemotaxis of monocytes, 
dendritic cells, activated 
lymphocytes and NK cells 
(Mentlein, 1999, 
Proost et al., 2001) 
 
Table 1.2 Substrates cleaved by DPPIV  
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1.8.2 Fibroblast activation protein-α 
FAPα was originally identified as an antigen on the surface of reactive stromal 
fibroblasts (Rettig et al., 1993) and also identified separately as seprase (Monsky et al., 
1994, Aoyama and Chen, 1990). Further analysis revealed that both FAPα and seprase 
encoded the same gene product (Chen and Kelly, 2003). 
FAPα is a type II transmembrane protein of 760 amino acids which anchors in the 
plasma membrane via an uncleaved signal sequence of approximately 20 amino acids 
and has a short, amino terminal, cytoplasmic domain of six amino acids (Goldstein et 
al., 1997, Pineiro-Sanchez et al., 1997). There is a small amount of data to indicate that 
a second cytosolic version of FAPα exists (Goldstein and Chen, 2000) and that this 
form of FAPα only encodes for the C-terminal region of the enzyme. 
The structure of FAPα was modelled on a closely related protease (Cheng et al., 2002) 
and it was found that the enzyme had a similar domain structure to DPPIV. It possesses 
an eight bladed β-propeller domain near the N-terminus and an α/β-hydrolase domain at 
the C-terminus. It is postulated that a pore exists in the β-propeller domain to allow 
substrate access to the catalytic domain and this was later confirmed by X-ray 
crystallography (Aertgeerts et al., 2005). 
FAPα has gelatinase activity (Aoyama and Chen, 1990, Monsky et al., 1994, Pineiro-
Sanchez et al., 1997) as well as dipeptidyl peptidase activity (Park et al., 1999) and both 
of these functions occur in the same catalytic pocket that is located in the α/β-hydrolase 
domain. FAPα has similar dipeptidyl peptidase substrate specificity to DPPIV but the 
rate of hydrolysis is about 100-fold less (Aertgeerts et al., 2005). The dipeptidyl 
peptidase and endopeptidase specificities of DPPIV and FAPα are due solely to the 
protonation state of a glutamate residue in the active site pocket. Aspartate-663 of 
DPPIV causes deprotonation of the glutamate-206 side chain that facilitates binding of 
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charged amino terminal groups (Aertgeerts et al., 2005).  However, the comparable 
residue in FAPα is alanine-657, and is essential for the endopeptidase activity of FAPα. 
This is because alanine-657 cannot deprotonate glutamate-204 in FAPα and favours 
binding of uncharged residues in the P2 pocket of the active site. The gelatinase activity 
of FAPα is much more pronounced than that for DPPIV but there was some uncertainty 
in the literature at first as to whether FAPα could cleave native collagen I (Park et al., 
1999). It has now been shown that FAPα cannot cleave native collagen fibrils but can 
cleave substrates which have previously been partially cleaved by MMPs (Christiansen 
et al., 2007). Another interesting finding is that N-terminal truncation of FAPα can 
actually increase the gelatinase activity but not the dipeptidyl peptidase activity of the 
enzyme (Chen et al., 2006a). There is speculation that the use of detergents in this 
experimental set-up may have caused a conformational change in the membrane bound 
form of FAPα and therefore activated the proteins ability to cleave gelatin, while in-vivo 
enzymatic truncation may be required before this can occur. Furthermore, it has been 
shown that FAPα forms a complex with DPPIV on the surface of fibroblasts allowing 
for their migration on a collagenous matrix (Ghersi et al., 2002). In this environment 
there will be other proteolytically active enzymes present to cause truncation of FAPα 
and thus activate its gelatinase activity.  
1.9 Cell signalling 
Cell signalling is a complex network of communication that governs cellular actions in 
response to changes in both the local and systemic environments. Undesirable changes 
in the signalling pathways results in serious pathological consequences such as cancer 
(Shaw and Cantley, 2006, Vincan and Barker, 2008) or irregular immune responses 
(Longo et al., 2008).  
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In basic terms, classical cell signalling is the binding of a signal molecule to a 
membrane receptor on the cell surface that causes the modulation of cell function. 
However, recent evidence is starting to shed light on a novel signalling mechanism that 
involves the direct contribution of proteases to cause a cellular response.  
1.9.1 Protease-activated receptors 
One mechanism by which serine proteases can act as signalling molecules is through the 
cleavage of the PARs, which are G-protein coupled receptors (GPCR). There are four 
PARs known to date; PAR-1, PAR-2, PAR-3 and PAR-4. Most of the data published on 
the PARs have been generated from endo- and epithelial cells. The modest amount of 
data on PAR-3 comes from work generated in this manner (McLaughlin et al., 2007) 
and leads to the possibility that PAR-3 modulates signalling through its ability to bind 
to PAR-1. However, little is known about the function of PAR-3 on the surface of 
“normal” cells. Therefore, researchers have transformed cell lines such as HEK-293 to 
tease out the role of PAR-3 (Ostrowska and Reiser, 2008). Whilst this study seems to 
suggest that PAR-3 can act independently of PAR-1 to cause IL-8 release, PAR-3 lacks 
the ability to interact with G-proteins due to the lack of a cytoplasmic tail (Ishihara et 
al., 1997). Contradictory data have been published showing that PAR-3 is not able to 
signal independently of PAR-1 (Kaufmann et al., 2005). The latter was shown by the 
use of PAR-3 and PAR-1 overexpression constructs in KOLF cells (fibroblasts from 
PAR knockout mice) where PAR-3 alone showed no ability to trigger a signal response 
after incubation with TFRGAP (the tethered ligand generated by cleavage of PAR-3). 
However, a definite increase in the amount of phosphorylated p42/44 could be observed 
when PAR-1 overexpressing cells were incubated with TFRGAP indicating that PAR-1 
is important is mediating signalling with PAR-3 acting as a co-stimulatory molecule.  
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PAR-1 activation is linked to fibroblast proliferation and the release of prostanglandin 
E2 and pro-collagen (Blanc-Brude et al., 2005, Sokolova et al., 2005). Furthermore, 
PAR-1 activation has been linked to the differentiation of fibroblasts to myofibroblasts 
(Bogatkevich et al., 2001, Materazzi et al., 2007).  
PAR-1 is known to be present on the surface of synovial fibroblasts in RA (Morris et 
al., 1996) and further work has shown that PAR-3 is also expressed on the surface of 
synovial fibroblasts from patients with rheumatic disease (Hirano et al., 2002). It should 
be noted that PAR-1 up-regulation is only seen in RA, this phenomenon is not seen in 
OA or normal synovium (Morris et al., 1996). PAR-1 activation by thrombin on the 
surface of these fibroblasts causes an up-regulation of RANTES gene expression 
(Hirano et al., 2002) thus indicating that this pathway could play an important role in 
the recruitment of inflammatory T cells and NK cells to the joint space thereby 
propagating the destructive mechanisms. More recent evidence has shown that synovial 
fibroblasts from the rheumatoid joint can be induced to produce IL-6 by PAR-1 
activation (Chiu et al., 2008) through the nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-B) pathway. This IL-6 production is independent of PAR-3 and 
PAR-4 as could be demonstrated by the use of small interfering ribonucleic acid 
(siRNA) to silence these genes as well as the use of specific PAR agonists. 
PAR-2 has recently been shown to be expressed in the synovial membrane in RA 
(Kelso et al., 2007) and its activation was found to lead to downstream cytokine release. 
One possible mechanism of PAR-2 activation in RA synovium could be its cleavage by 
mast cell tryptase (Nakano et al., 2007), as a novel form of mast cell tryptase is found at 
a high concentration in RA and correlates with increased PAR-2 mRNA expression. 
However, there is the possibility that other trypsin-like serine proteases could activate 
PAR-2 as well. Mast cells could play an important role as the source of these serine 
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proteases (Palmer et al., 2007) and could cause auto-activation of the PAR-2 receptors 
resulting in the perpetuation of the PAR-2 signal. This is supported by findings that 
mice lacking mast cells were resistant to RA (Lee et al., 2002). Recently, it has been 
shown that PAR-2 activation in OA cartilage caused the activation of the ERK1/2 and 
p38 pathways (Boileau et al., 2007) and these two pathways are important in the 
catabolism of the cartilage matrix. In this study co-stimulation of OA chondrocytes with 
IL-1β and PAR-2 activating peptide had a synergistic effect on the ERK1/2 pathway.  
Little information exists about the role of PAR-4 in the context of connective tissue 
cells. Nonetheless it has been shown that lipopolysaccharide and TNFα induce 
expression of PAR-4 on human primary bronchial fibroblasts (Ramachandran et al., 
2007) and that activation of PAR-4 counters the PAR-1 mediated proliferation of these 
cells. This ability of PAR-4 to antagonise the function of PAR-1 is interesting and 
requires further insight, mainly in the context of connective tissue cells. In endothelial 
cells PAR-1 and PAR-4 have been reported to counteract each other in the regulation of 
VEGF and endostatin release from platelets (Ma et al., 2005).  
Once the PARs are cleaved they remain constitutively active as the tethered ligand is 
always available to interact with the PAR. Therefore, after the activation of 
phospholipase C has occurred, signal attenuation occurs through the recruitment of β-
arrestins 1 and 2 (Wang and DeFea, 2006, DeFea et al., 2000) resulting in the 
desensitisation and endocytosis of the receptors for their degradation. 
1.10 Scope of this thesis 
Cartilage consists of an extensive extracellular matrix, composed mainly of 
proteoglycans and collagens, in which the chondrocytes are embedded. Proteolytic 
degradation of articular cartilage leads to joint dysfunction and is a major hallmark of 
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arthritis. While the loss of proteoglycan is rapid and reversible, the breakdown of the 
collagen network is slow and essentially irreversible.  
The major extracellular proteases involved in the breakdown of the cartilage matrix are 
the metallo- and serine proteases. Data from our group have highlighted that both 
protease families function through interacting cascades (Milner et al., 2001, 2003). 
MMP expression is increased in arthritis (Kevorkian et al., 2004) and correlates with the 
excessive degradation of the collagen network (Hollander et al., 1995). The 
collagenases (MMP-1, MMP-8 and MMP-13) are the key enzymes involved in collagen 
turnover and they mediate the cleavage of fibrillar collagen into characteristic three- and 
one-quarter fragments which is the major rate-limiting step in the breakdown of the 
cartilage ECM. The activation of the pro-collagenases is a key control point with 
regards to collagen matrix breakdown (Milner et al., 2001) and data have shown that 
serine proteases are involved (Milner et al., 2001, 2003). 
In OA, collagen degradation is initially observed around the chondrocyte before 
diffusing radially (Hollander et al., 1995). The increased expression of the 
transmembrane serine proteases DPPIV, FAPα and matriptase could be key mediators 
of the arthritides. These transmembrane serine proteases could play a vital role via their 
interaction with either soluble or membrane bound MMPs and localise collagenolytic 
activity to the cell surface. Therefore, characterising the role of novel transmembrane 
serine proteases in arthritis is important as it is an area of cartilage biology that has yet 
to be fully elucidated.  
Thus the aims of this thesis are: 
 Investigate the roles of FAPα and DPPIV in resorbing IL-1+OSM-treated 
cartilage. 
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 Study the role of matriptase in cartilage matrix degradation. 
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CHAPTER 2 
Materials and Methods 
2.1 Materials 
2.1.1 Biochemical assay reagents 
Papain (from Carica papaya), 2-Amino-2-hydroxymethyl-propane-1,3-diol 
hydrochloride (Tris-HCl), calcium chloride, sodium chloride, glucose, sodium azide, L-
cysteine hydrochloride, p-dimethylaminobenzaldehyde (DAB), -mercaptoethanol, o-
phenylenediamine (OPD), phosphate-citrate capsules, L-hydroxy-proline, bovine serum 
albumin (BSA), sodium dihydrogen phosphate and disodium hydrogen phosphate were 
obtained from Sigma-Aldrich Company Ltd. (Poole, UK). Chloramine T was purchased 
from BDH (Poole, UK). 2 ml O-ring screw-cap tubes were obtained from Sarstedt 
(Leicester, UK) and 1.5 ml eppendorfs obtained from Starlabs (Milton Keynes, UK). 
Maxisorp Nunc-immuno 96-well plates were obtained from Life Technologies Ltd. 
(Paisley, UK). Flat-bottomed and V-bottomed 96-well plates were obtained from Bibby 
Sterilin (Staffordshire, UK). Flexible 96-well sample plates and Optiphase “Supermix” 
scintillation fluid were obtained from PerkinElmer (Beaconsfield, UK). GP-7- amino-4-
methoxy coumarin (AMC), Z-GP-AMC and Boc-QAR-AMC were purchased from 
Bachem (Essex, UK). The general MMP substrate, FS-6, was obtained from Merck 
(Nottingham, UK). Pro-MMP-3ΔC was a gift from Dr R. Visse (Kennedy Institute, 
London, UK). Mono S FPLC column was obtained from GE Healthcare (Chalfont St. 
Giles, UK). FAPα was purchased from R&D systems (Abingdon, UK). Recombinant 
DPPIV was a gift from Dr H. Fan (Charité - Universitätsmedizin Berlin, Germany). 
Matriptase was a gift from Prof. Richard Leduc (Université de Sherbrooke, Canada). 
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2.1.1.1 Enzyme inhibitors 
Ferring pharmaceuticals (Saint-Prex, Switzerland) kindly donated the FAPα-specific 
inhibitor FE999044 and the DPPIV-specific inhibitor FE999011. Dr B. Gilmore and 
Prof. B. Walker (Queen’s University, Belfast, UK) kindly donated the FAPα inhibitor 
Z-GP-diphenylphosphonates (DPi) and the DPPIV inhibitors YP-DPi and GP-DPi. The 
FAPα inhibitors UAMC-583, UAMC-584 and UAMC-442 and the DPPIV inhibitors 
UAMC-374, Vildagliptin and AB192 were a gift from Prof. I. De Meester (University 
of Antwerp). The DPPIV inhibitors DPPI 1c and K579 were purchased from Tocris 
Bioscience (Bristol, UK). The cathepsin K inhibitor, L-873724, was a generous gift 
from Dr C. Black (Merck). The general metalloprotease inhibitor, GM-6001, and its 
negative control were purchased from Calbiochem (Nottingham, UK). All of the above 
inhibitors were dissolved in DMSO such that the highest final concentration of DMSO 
in the cartilage cultures was 0.1%. Before use they were diluted in culture medium and 
filter-sterilised through a 0.2 µm filter before addition to cartilage explants. SAM-11 
antibody was purchased from Santa Cruz Biotechnology Inc. (Heidelberg, Germany). 
ENMD-1068 was purchased from Enzo Life Sciences Ltd (Exeter, UK) and dissolved in 
PBS. Before use ENMD-1068 was diluted in culture medium and filter-sterilised 
through a 0.2 µm filter before addition to cartilage explants. 
2.1.2 Cell and tissue culture reagents 
Dulbecco’s modified Eagle’s medium (DMEM) and fetal calf serum (FCS) were 
obtained from Gibco BRL (Paisley, UK), and L-glutamine, amphotericin, penicillin-
streptomycin, collagenase (type I from Clostridium histolyticum), hyaluronidase (type I-
S from bovine testes) and trypsin (type III, from bovine pancreas) were obtained from 
Sigma-Aldrich Company Ltd. 96-well, 24-well and 6-well tissue culture plates were 
obtained from Corning/Costar UK Ltd. (High Wycombe, UK). Sterile 100 mm square 
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petri dishes and universals (20 and 5 ml) were obtained from Bibby Sterilin Ltd. 
Syringe filters (0.2 µm) were from Pall Gelman Sciences (Northampton, UK). Sterile 
disposable scalpel blades were from Swann-Morton (Sheffield, UK). Dulbecco’s 
phosphate buffered saline (DPBS) was obtained from Lonza (Wokingham, UK) and 
sterile 100 μm cell strainers from BD Falcon (Oxford, UK). IL-1 was a gift from Dr 
Keith Ray (GlaxoSmithKline, Stevenage, UK) and recombinant OSM was produced in-
house. IL-1 at 1 µg/ml in DMEM (with 0.1% BSA) was stored at -20C. OSM at 60 
µg/ml in DPBS (with 0.1% BSA) was stored at -80C. Immediately prior to use IL-1 
and OSM were diluted in culture medium and sterile filtered through a 0.2 µm filter. 
2.1.3 Molecular Biology reagents 
RNeasy Mini Kit and deoxyribonuclease (DNase) I were from Qiagen (Crawley, UK). 
Agarose (electrophoretic grade), MMLV and Superscript III were obtained from Life 
Technologies Ltd. Dialysis membrane was purchased from Medicell International Ltd. 
(London, UK). 
All reagents required for RNA work were molecular biology grade. All RNA work was 
performed under RNase-free conditions using RNase-free reagents and materials.  
2.1.4 Protein electrophoresis  
Ammonium persulfate (APS) was obtained from BDH (Poole, UK). -mercaptoethanol, 
and N,N,N’N’-tetramethylenediamine (TEMED) were obtained from Sigma-Aldrich 
Company Ltd. 40% (w/v) acrylamide/bis-acrylamide (37.5:1) solution was obtained 
from Anachem (Luton, UK). Sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE) molecular weight standards were obtained from 
Fermentas (York, UK). Silver staining kit was obtained from GE Healthcare (Chalfont 
St. Giles, UK). 
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2.1.5 Other reagents 
All other chemicals and biochemicals, unless otherwise stated, were commercially 
available analytical grade reagents obtained from Sigma-Aldrich Company Ltd., Fisher 
Scientific, Life Technologies or BDH. 
2.2 Cartilage explant culture 
Principle: Bovine nasal and human articular cartilage explants cultures are commonly 
used as a model for cartilage matrix degradation. Cartilage samples are stimulated with 
combinations of pro-inflammatory cytokines, inhibitors or proteases to influence 
cartilage homeostasis. Serum was excluded from cartilage explants as it contains 
chondroprotective agents such as IGF-1 (Luyten et al., 1988, Tyler, 1989, Hui et al., 
2001). The absence of serum does not affect tissue viability, with cartilage remaining 
responsive to fresh serum and exogenous growth factors (Hascall et al., 1983). 
2.2.1 Bovine nasal cartilage degradation assay 
Culture medium 
DMEM containing 25 mM HEPES, 2 mM L-glutamine, 100 U/ml penicillin, 100 g/ml 
streptomycin, 25 g/ml amphotericin. 
Dulbecco’s phosphate buffered saline (DPBS+) 
DPBS containing 100 U/ml penicillin, 100 g/ml streptomycin, 25 g/ml amphotericin. 
Phosphate buffer 
137 ml of 0.1 M NaH2PO4 and 63 ml 0.1 M NaHPO4, pH 6.5. 
 
Bovine nasal septum was obtained from a local abattoir after slaughter and used the 
same day or after overnight storage at 4C. The connective tissue sheath was removed 
from the cartilage and cut into 2 mm strips. Discs, 2 mm in diameter were punched out 
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of the centre of the cartilage strips using a sterilised hole punch; care was taken to avoid 
cartilage with obvious vasculature. Cartilage discs were washed twice in DPBS. In a 24-
well tissue culture plate, 3 discs per well were added in 600 l of culture medium. In a 
96-well tissue culture plate, 1 disc per well was added in 200 l of culture medium. The 
plates were then incubated overnight at 37C in 5% CO2/humidified air. 
Medium was removed from each well and replenished with 600 l fresh culture medium 
containing the appropriate cytokine(s) and test reagent(s) in a 24-well tissue culture 
plate. In a 96-well tissue culture plate each well was replenished with 200 l of fresh 
culture medium containing the appropriate cytokine(s) and test reagents(s). For each 
condition, 4 wells were used in the 24-well tissue culture plate format. Whilst, 6 wells 
per condition in the 96-well format. Plates were then incubated at 37C for 7 days. At 
day 7, supernatants were collected and cartilage discs replenished with identical test 
reagents to day 0. The experiment was continued for a further 7 days and at day 14, 
supernatants were removed and stored at -20C. At day 14, the cartilage explants were 
placed in capped Sarstedt tubes with phosphate buffer containing 4.5 mg/ml papain, 
5mM cysteine-HCl and 5mM ethylenedinitrilotetraacetic acid (EDTA). Following 
overnight (16-20 h) digestion at 65C, 450 µl phosphate buffer was added. 
2.2.2 Human articular cartilage degradation assay 
Reagents 
As described in section 2.2.1 
 
Human articular cartilage was obtained from patients undergoing total joint replacement 
surgery at the Freeman hospital provided under ethical approval and informed consent. 
The joints were stored at 4°C in DPBS+. Tissue was used up to 24 h after removal from 
the patient. Macroscopically normal cartilage was dissected and rinsed in DPBS+. Three 
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pieces of cartilage (approximately 2 mm x 2 mm x 2 mm in dimension) were treated as 
described in section 2.2.1. 
2.2.3 Hydroxyproline assay 
Principle: The hydroxyproline imino acid is found in few proteins other than collagen 
as the sequence glycine-proline-hydroxyproline occurs frequently in collagen. 
Therefore, collagen levels can be measured by assessing hydroxyproline levels. Proteins 
were acid hydrolysed into their constituent amino acids. Hydroxyproline was then 
oxidised by chloramine T to a pyrrole related compound, which was subsequently 
reacted with DAB to produce a red product. The absorbance was then measured at A560. 
Hydroxyproline was assayed using a microtitre modification of the assay described by 
Bergman and Loxley (1963). 
Acetate-citrate buffer 
420 mM sodium acetate, 130 mM tri-sodium citrate, 26 mM citric acid and 38.5% (v/v) 
propan-2-ol, pH 6. 
DAB  
4.5 M stock in 70% (v/v) perchloric acid, stored 4C. 
Chloramine T 
250 mM in dH2O, made fresh. 
 
Method 
Supernatants or cartilage digests (200 l) were mixed with 200 l of 12 M HCl in 2 ml 
o-ring screw-cap tubes. Samples were then hydrolysed in a hot-block for 20 h at 105C. 
The hydrolysates were dried in a centrifugal evaporator using an acid resistant 
integrated Savant Speed Vac (Life Sciences International, Basingstoke, UK) or Genevac 
47 
 
EZ-2 speedvac (Genevac Ltd, Ipswich, UK) for 2-3 h. Once dry, the residue was 
resuspended in 200 l dH2O and stored at room temperature until assayed. A 1 mg/ml 
stock of hydroxyproline was diluted in dH2O to give a series of standards (0-30 g/ml). 
On the day of use, 4.5 mM DAB was diluted 1:3 in propan-2-ol and 250 mM 
chloramine T was diluted 1:4 in acetate-citrate buffer. 40 l of sample or standard (neat 
or diluted in dH2O) was added in duplicate to a 96-well microtitre plate. 25 l of 65.5 
mM chloramine T was added. After 4 min, 150 l of 1.5 M DAB was added. The plate 
was then sealed with a plastic plate sealer and incubated for 35 min at 65C. The plate 
was then allowed to cool and the absorbance read at 560 nm (Sunrise microplate reader, 
Tecan). The hydroxyproline content of the samples was calculated from the standard 
curve. The release of hydroxyproline from the cartilage was then calculated using the 
following equation: 
% hydroxyproline release =  
[hydroxyproline in supernatants (g)]/[hydroxyproline in supernatants + 
hydroxyproline in cartilage digests (g)] x 100 
The % release of hydroxyproline was considered to be representative of the % release of 
collagen. 
2.3 mRNA extraction 
2.3.1 Bovine nasal chondrocyte isolation 
Principle: Bovine nasal septum was used as a source of primary chondrocytes. The 
cartilage was subjected to a three-step enzymatic digest to isolate the chondrocytes. 
DPBS+ 
DPBS + 100 U/ml penicillin, 100 g/ml streptomycin, 25 g/ml amphotericin. 
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Culture medium + 10% (v/v) FCS 
DMEM containing 25 mM HEPES, 10% (v/v) heat-inactivated FCS, 2 mM glutamine, 
100 U/ml penicillin, 100 g/ml streptomycin, 25 g/ml amphotericin. 
Hyaluronidase 
1 mg/ml in DPBS+. 
Trypsin 
2.5 mg/ml in DPBS+. 
Collagenase 
2.5 mg/ml in culture medium + 10% (v/v) FCS. 
 
Method 
Bovine nasal septum was obtained as described in section 3.2.1. The strips cut into 
small cubes and washed three times in DPBS. Before use, enzyme solutions were filter-
sterilised through a 0.2 m filter. The cartilage was incubated at 37°C for 15 min on a 
spiramixer, with hyaluronidase (3 ml/g cartilage). The supernatant was removed and the 
cartilage washed three times in DPBS. Cartilage was then incubated for 30 min at 37°C 
with trypsin (3 ml/g cartilage) on a spiramixer. The supernatant was removed and the 
cartilage washed twice in culture medium + FCS. The cartilage pieces were then 
incubated overnight at 37°C in a bacterial collagenase solution (3 ml/g cartilage) on a 
spiramixer. Tubes were allowed to stand for 15 min to permit the debris to settle. The 
supernatant was then passed through a sterile 100 μm cell strainer and chondrocytes 
pelleted by centrifugation (217 g for 5 min). Chondrocytes were resuspended in culture 
medium + 10% (v/v) FCS and 5x10
3
 cells plated into each well of 96-well tissue culture 
plates (200 μl culture medium + 10% (v/v) FCS/well). The bovine cells took 3-5 days to 
reach 70-80% confluence. Before cytokine stimulation, cells were washed twice in 
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DPBS to remove traces of serum and left for 24 h in 100 μl culture medium (serum 
free)/well.  
2.3.2 Cultivation of SW1353 cells 
Culture medium + 10% (v/v) FCS 
DMEM containing 25 mM HEPES, 10% (v/v) heat-inactivated FCS, 2 mM glutamine, 
100 U/ml penicillin, 100 g/ml streptomycin. 
 
SW1353 were maintained in culture medium + 10% (v/v) FCS and 5x10
3
 cells plated 
into each well of 96-well tissue culture plates (200 μl culture medium + 10% (v/v) 
FCS/well). The SW1353 cells took 3-5 days to reach 70-80% confluence. Before 
cytokine stimulation, cells were washed twice in DPBS to remove traces of serum and 
left for 24 h in 100 μl culture medium (serum free)/well.  
2.3.3 Extraction of RNA  
Method 
This was performed as per the manufacturer’s instructions. Briefly, after cytokine 
stimulation the plates were washed in ice-cold PBS and then 10 μl of ice-cold lysis 
buffer added per well. The lysates were then agitated for 2 min at medium speed on a 
flatbed mixer. The lysates were then transferred to V-bottomed 96-well plates and 
stored at -80°C. 
2.3.4 cDNA production from sidestep RNA extraction 
Method 
Lysates (5 µl), from section 2.3.3, were transferred to a new 96-well plate and diluted 
with 15 µl of PCR grade water. Diluted lysate (4 µl) was then transferred to a 96-well 
PCR plate and then 0.325 mM dNTPs and 0.2 μg random hexamers (Pd(N)6) added and 
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the mixture then incubated at 70°C for 5 min. The plate was then rapidly cooled on ice 
for two min. Then DTT (10 µM final concentration), RNaseOUT (5 U), MMLV (100 
U) and first strand buffer (50 mM Tris pH 8.3, 75 mM KCl and 3 mM MgCl2) added to 
the desired volume. The plate was then incubated for 50 min at 37°C and then for 15 
min at 70°C. The cDNA was then diluted with water before use for target gene 
detection and a further 1/100 fold dilution for housekeeping gene detection. 
All incubations were performed using the using the TP 600 PCR thermal cycler DICE 
(Takara). 
2.3.5 Human articular cartilage mRNA assay 
Principle: Cartilage is a highly specialised and unique tissue (section 1.1) with only a 
handful of cells embedded in a large ECM network. Interactions between chondrocytes 
and their matrix are significant and remodelling of the ECM by proteases can release 
cryptic information and bioactive molecules (Mott and Werb, 2004). A number of 
studies have studied the gene expression of chondrocytes grown in monolayer (Koshy et 
al., 2002). However, only few studies have been performed on gene expression in 
human cartilage that is actively resorbing. 
Culture medium 
DMEM containing 25 mM HEPES, 2 mM L-glutamine, 100 U/ml penicillin, 100 g/ml 
streptomycin, 25 g/ml amphotericin. 
DPBS+ 
DPBS containing 100 U/ml penicillin, 100 g/ml streptomycin, 25 g/ml amphotericin. 
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Method 
Human articular cartilage was obtained as described in section 2.2.2. The cartilage cut 
into small cubes and washed three times in DPBS. Cartilage (approximately 0.5 g) was 
then placed into a 12 well dish with 3 ml of culture medium. The plates were then 
incubated overnight at 37C in 5% CO2/humidified air to allow equilibration of the 
explants. 
Medium was removed from each well and replenished with 3 ml fresh culture medium 
containing the appropriate cytokine(s) and test reagent(s). For each condition and time 
point, 4 wells were used. At day 7, media samples were collected and stored at -20°C 
whilst cartilage chips were collected and stored at -80°C. 
2.3.6 RNA extraction from cartilage explants 
Principle: Trizol is a mixture of guanidinium thiocyanate and water-saturated phenol 
and is used to solubilise the cells and protein components in cartilage as well as nucleic 
acids. The guanidinium denatures proteins including RNases thereby protecting nucleic 
acid during extraction. The addition of chloroform during extraction and subsequent 
centrifugation separates the components into an upper aqueous phase, where the RNA 
locates to and the lower and intermediate phase where the DNA and protein mainly 
locate to (Chomczynski and Sacchi, 1987). RNA was then isolated using Qiagen mini 
columns that selectively binds to nucleic acids larger than 200 bp, while allowing 
protein to be excluded, DNase I is added to degrade contaminating genomic DNA. 
Finally, RNA is eluted with RNase-free water. 
 
Method  
Human cartilage was removed from the -80°C freezer and placed in stainless steel 
grinding vials (Retsch, Germany). The cartilage was then ground under the following 
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conditions: 5 cycles of cooling in liquid nitrogen for 3 min and then ground for 90 
seconds at 20Hz in a Retsch MM200 (Retsch, Germany). 
The powered cartilage was then placed in 5 ml of Trizol reagent (Life Technologies), 
vigorously shaken for 5 min and left at room temperature for 10 min. 
The suspension was then placed into 1.5 ml eppendorfs (Starlabs) and centrifuged at 
20,000 x g for 10 min at 4°C to remove any insoluble material. The supernatant was 
transferred to fresh eppendorfs and 450 µl chloroform added, then vortexed and left to 
incubate at room temperature for 10 min. The tubes were then centrifuged for 12,000 x 
g for 15 min at 4°C, the upper aqueous phase then transferred to a new tube and 100% 
ethanol (0.5 volume) added. This was then loaded onto a Qiagen mini column and the 
RNA purified according to the manufacturer’s instructions. Briefly, 700 µl of sample 
were applied to the RNeasy mini-spin column and centrifuged for 15 seconds at 8,000 x 
g. The flow-through was discarded and this step repeated until all the sample was 
applied to the column. The column was then washed to remove contaminants and then 
DNase I (3 U) added to the column for 15 min at room temperature. The column was 
then washed three times according to the manufacturer’s instructions. The RNA was 
eluted in diethyl pyrocarbonate (DEPC) water (30 µl). The purified RNA was 
immediately stored at -80°C. The RNA was then quantified by measuring the 
absorbance at 260 nm and 280 nm using a ND1000 spectrophotometer (Nanodrop, 
USA).  
2.3.7 Reverse transcription of cartilage explant mRNA 
Method 
Total RNA (1 µg) was diluted to a final volume of 11 μl with water and then 50 ng 
random hexamers and 0.5 mM (final concentration) dNTPs were added. This mixture 
was then incubated at 65°C for 5 min, then chilled on ice for 2 min and DTT (50 μM 
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final concentration), RNaseOUT (40 U), superscript III reverse transcriptase (200U), 
and first strand buffer (50 mM Tris pH 8.3, 75 mM KCl and 3 mM MgCl2) added to the 
desired volume. The reaction mixture was incubated at 25°C for 5 min then 50°C for 1 
h. The enzymes were then denatured by incubation at 70°C for 15 min. The cDNA was 
then diluted 1/100 for target gene determination and a further 1/5 for housekeeping 
genes. 
 
2.4 Real-time PCR 
2.4.1 Primer design 
Bovine forward and reverse primers were designed using the Universal Probelibrary 
software (Roche Applied Science, Burgess Hill, UK). PerfectProbe assay kits were 
received from PrimerDesign (Southampton, UK). TaqMan assay on demand kits were 
received from ABI (Warrington, UK). 
Primers were designed to span exon/intron boundaries to prevent the amplification of 
any contaminating genomic DNA. Primers were designed for bovine gene sequences 
and human gene sequences (Table 2.1). 
1 
 
Gene Primer (5'-3') Human Sequence Bovine Sequence 
FAPα 
Forward ATCTATGACCTTAGCAATGGAGAATTTGT ACCATGAAAAGTGTGAATGCTTCA 
Reverse GTTTTGATAGACATATGCTAATTTACTCCCAAC AGTATCTCCAAAGCTTTGAATAATCACTTTCT 
DPPIV 
Forward AGCCGTGGCGCCTGTAT CTGGTCATACGGAGGGTACG 
Reverse GTCAAGGTTGTCTTCTGGAGTTGG GGCTATTCCACACTTGAACACA 
18S rRNA 
18S rRNA 
Forward CGAATGGCTCATTAAATCAGTTATGG AGAAAGGGCTACCACATCCA 
Reverse TATTAGCTCTAGAATTACCACAGTTATCC CACCAGACTTGCCCTCCA 
Probe FAM-TCCTTTGGTCGCTCGCTCCTCTCCC-TAMRA  Not applicable 
MMP-1 
Forward AAGATGAAAGGTGGACCAAAATT CAAGCTAACTTTTGATGCCATAAC 
Reverse CCAAGAGAATGGCCGAGTTC GCATGTAGAACCGGTCTTTGA 
Probe FAM-CAGAGAGTACAACTTACATCGTGTTGCGGCTC-TAMRA  Not applicable 
 
MMP-13 
Forward AAATTATGGAGGAGATGCCCATT 
 
Reverse TCCTTGGAGTGGTCAAGACCTAA 
 
Probe FAM-CTACAACTTGTTTCTTGTTGCTGCGCATGA-TAMRA 
 
Matriptase 
ABI TaqMan assay on demands  
PAR-2 (F2RL1) 
 
MMP-3 
Forward TTCCGCCTGTCTCAAGATGATAT 
 
Reverse AAAGGACAAAGCAGGATCACAGTT  
 
Probe FAM-TCAGTCCCTCTATGGACCTCCCCCTGAC-TAMRA 
 
MMP-14 
Forward AGGCCGACATCATGATCTTCTTT  
 
Reverse AAGTGGGTGTCTCCTCCAATGTT  
 
Probe FAM-CCATGGCGACAGCACGCCCTT-TAMRA 
 
 
 
Table 2.1 Primers for real-time PCR.
5
4
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2.4.2 SYBR green real-time PCR 
Principle: SYBR green is a fluorescent dye that binds to the minor groove of the DNA 
helix. In solution the dye emits very little fluorescence, but upon binding to an 
exponentially increasing DNA amplicon, the dye emits fluorescence proportional to the 
amount of reaction product which is readily increased. 
 
Method 
SYBR green PCR reactions for bovine 18S rRNA, MMP-1 and MMP-13 genes were 
carried out in a total volume of 10 µl using 2.5µl of cDNA with 5 µl of SYBR green 
reaction mix (Clontech, Paris, France) and primers at 50 nM final concentration and 1X 
ROX reference dye. Thermal cycling conditions for these PCR reactions comprised a 
holding stage at 95°C for 10 seconds. This was followed by a three-step programme 
consisting of 95°C for 5 seconds, 55°C for 15 seconds and 72°C for 20 seconds, 
repeated for 40 cycles. 
SYBR green PCR reactions for FAPα and DPPIV genes were carried out in a total 
volume of 10 µl using 2.5 µl of cDNA with 4.92 µl of SYBR green reaction mix 
(Clontech, Paris, France) and primers at 100 nM final concentration and 1X ROX 
reference dye. Thermal cycling conditions for these PCR reactions comprised a holding 
stage of 95°C for 10 seconds. This was followed by a two-step programme consisting of 
95°C for 15 seconds and 60°C for 60 seconds, repeated for 40 cycles. 
For all reactions a melt curve analysis was then performed to confirm the amplification 
of a single specific product. All reactions were performed using the ABI PRISM 
7900HT sequence detector. 
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2.4.2 Probe based real-time PCR 
Principle: This method employs the use of a probe that anneals down-stream of a 
primer site. The probe has a reporter dye at the 5’ end and a quencher at the 3’ end. 
When the probe is intact both the quencher and reporter dye are in close proximity and 
emit little fluorescence. During extension of the primer sequence by Taq polymerase, 
the 5’ nuclease activity of Taq cleaves the probe from the DNA. The spatial separation 
of the reporter dye from the quencher increases the reporter signal. Thus with each cycle 
the fluorescence intensity increases in proportion to the amplicon product. 
 
Method  
Probe based PCR reactions were carried out in a total volume of 10 µl using 5 µl of 
cDNA with 3.3 µl of SIGMA mastermix (Poole, UK) and primers at 900 nM final 
concentration, probe at 150 nM final concentration and 1X ROX reference dye. Thermal 
cycling conditions comprised an activation stage at 95°C for 10 min. This was followed 
by a two-step programme consisting of 95°C for 15 seconds and 60°C for 60 seconds, 
repeated for 40 cycles. 
Human ST14 and F2RL1 assay on demand kits (Applied Biosystems, Warrington, UK) 
were used as described above, except 0.5 µl of the assay mix was added instead of 
primers and probe. 
All reactions were performed using the ABI PRISM 7900HT sequence detector. 
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2.5 Purification and characterisation of type II collagen 
2.5.1 Type II collagen purification 
Principle: Type II collagen is isolated using the method described by Miller and 
Rhodes (1982). After tissue homogenisation, proteoglycans need to be removed as they 
can amalgamate with collagen molecules and form insoluble aggregates at acid pH. 
Selective degradation of cross-links between the collagen molecules allows the collagen 
to solubilise in dilute acid solvents. Alternative precipitations from acidic to neutral salt 
solvents allow for purification of the collagen molecules. 
Proteoglycan extraction buffer 
4 M guanidium chloride, 50 mM Tris, pH 7.5, 0.02% (w/v) NaN3  
Collagen extraction buffer 
0.5 M acetic acid, pH 2.06, 0.02% (w/v) NaN3, 0.0005% (w/v) pepsin 
 
Method 
Human articular cartilage was used a source of human type II collagen; cartilage was 
dissected from joint tissues received from patients undergoing total joint replacement 
surgery and stored at -80°C. All tissue was collected with ethical approval and patient 
consent. 
Unless otherwise stated, all work was performed at 4°C. 
The cartilage was ground to a fine powder using the Specxmill as previously described 
(section 2.3.6). The powdered cartilage was then resuspended in proteoglycan extraction 
buffer and left to agitate for 48 h on a rocker (30 rpm). 
The suspension was then spun at 21,875 x g for 30 min and the pellet resuspended in 
collagen extraction buffer and left to shake for 24 h at 30 rpm. The solution was then 
spun at 21,875 x g for 1 h and the supernatant collected and stored at 4°C. The pellet 
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was resuspended in collagen extraction buffer and left to shake for 24 h at 30 rpm again. 
After this, the solution was centrifuged at 21,875 x g for 1 h, the supernatant collected 
and combined with that from the first spin. The pH of this solution was then brought to 
pH 7.6 with 50% (w/v) sodium hydroxide. Sodium chloride was then added very slowly 
to 27% (w/v) and the solution left for 24 h. It was then spun at 18,381 x g and the pellet 
resuspended in 0.5 M acetic acid and then sodium chloride added to a final 
concentration of 0.84 M. The solution was then spun for 1 h at 21,875 x g and the pellet 
redissolved in 0.5 M acetic acid, lyophilised (Labconco) and stored at -20°C. 
2.5.2 Preparation of dialysis tubing 
Method  
Regenerated cellulose dialysis tubing (Medicell International Ltd) with a molecular 
weight cut-off of 14kDa was boiled in 2 M Na2CO3 buffer to wash away any impurities 
and then stored in 40% (v/v) butanol at 4°C. 
2.5.3 Characterisation of enzyme activity on purified type II collagen 
Assay buffer 
50 mM Tris-HCl, pH 7.6, 1 M glucose, 200 mM NaCl, 5 mM CaCl2 and 0.02% (w/v) 
NaN3 
 
Method 
Lyophilised collagen was dissolved in 0.5 M acetic acid to a final concentration of 1 
mg/ml and then dialysed against assay buffer. In some reactions the collagen was 
denatured by incubation at 56°C for 30 min. Collagen (10 µg) was digested over a 24 h 
period at 37°C with 100 µM of enzyme. Samples were then separated on 6.5% SDS-
PAGE gels and visualised by silver staining as described in sections 2.5.4 and 2.5.5, 
respectively. 
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2.5.4 SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) 
Principle: SDS-PAGE allows for the size-dependent separation of proteins regardless 
of their electrochemical properties. Initially, samples are mixed with loading dye and 
heated to 105°C. All proteins in the sample are then uniformly coated with SDS, 
therefore having the same charge. The lower pH of the stacking gel results in the 
concentration of the proteins into a thin band. Upon entering the resolving gel, the pH 
increases and the proteins are now separated based on their molecular weight. 
4x Lower gel buffer (LGB) 
1.5 M TrisHCl pH 8.8, 0.4% (w/v) SDS. 
4x Upper gel buffer (UGB) 
0.5 M Tris HCl pH 6.8, 0.4% (w/v) SDS. 
Upper gel  
40% (w/v) bis/acrylamide diluted to 4.5% with water and 4x UGB. 
5x Final sample buffer (FSB) 
0.625 M Tris HCl pH 6.8, 40% (v/v) glycerol, 10% (w/v) SDS, 0.5% (w/v) 
bromophenol blue, 5% (v/v) -mercaptoethanol. 
10x Running Buffer 
250 mM Tris, 2 M glycine, 10% (w/v) SDS. 
 
Method 
Electrophoresis was carried out in a Bio-Rad Mini-Protean II apparatus with 1.0 mm 
spacers and combs. Polyacrylamide-bis-acrylamide was diluted with water and 3 ml of 
4x LGB to the required percentage (Table 2.2). All solutions were allowed to reach 
room temperature before mixing. Gel mixture (12 ml) was polymerised by the addition 
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of 20 l TEMED and 60 l APS (0.1% w/v) immediately before pouring the gel. The 
lower gel was overlaid with propan-2-ol to exclude oxygen and allowed to polymerise. 
Once set the propan-2-ol was washed off and a 4.5% bis/acrylamide stacking gel laid on 
top, combs were inserted and the stacker allowed to set. Upper gel (5 ml) was set with 
10 l TEMED and 30 l 0.2% (w/v) APS. The gel kit was assembled and filled with 1x 
running buffer. Samples were prepared as follows: 1x sample buffer was added 
appropriately to samples which were then boiled at 105C for 5 min. Molecular weight 
markers were “Pageruler” protein markers (Fermentas). Proteins were electrophoresed 
at constant 60 V, through the stacking gel, and then 80 V, through the separating gel 
until the dye front had migrated to the end of the separating gel. 
 
Percentage gel (%) 40% (w/v) acryl/bis 
solution (37.5:1) (ml) 
ddH2O (ml) 4x LGB    
(ml) 
10 3.0 6.0 3.0 
6.5 1.95 7.05 3.0 
Table 2.2 Preparation of SDS-PAGE gels. 
 
2.5.5 Visualisation of protein bands 
Principle: Silver staining (Heukeshoven and Dernick, 1985) employs the use of soluble 
silver ions to detect proteins after separation by SDS-PAGE. When a reducing agent, 
such as formaldehyde, is added the silver ions are reduced and this reduction is 
enhanced in the presence of protein. Addition of sodium carbonate forms insoluble 
silver carbonate and highlights protein bands in the gel. The reaction is stopped by the 
sequestering of the silver ions by a chelating agent, such as EDTA. 
 
61  
 
Fixing solution 
40% (v/v) ethanol, 10% (v/v) acetic acid  
Sensitising solution 
30% (v/v) ethanol, 6.8% (w/v) sodium acetate, 0.2% (w/v) sodium thiosulphate, 0.125% 
(v/v) glutaraldehyde 
Silver solution 
0.25% (w/v) silver nitrate 
Developing solution 
2.5% (w/v) sodium carbonate, 0.0074% (v/v) formaldehyde 
Stop solution 
1.5% (w/v) EDTA 
 
Method 
Proteins were separated by SDS-PAGE (section 2.5.4) and then the separating gel 
placed in fixing solution for 1 h. The fixing solution was then removed and replaced 
with sensitising solution for 1 h. Sensitising solution was then removed and the gel then 
washed with ddH2O for 15 min and this step was repeated 3 further times. Silver 
solution was then added and left for 1 h. The gel was then washed twice with ddH2O for 
1 min. Developing solution was then added and the reaction progressing for 4 to 6 min 
until the protein bands were of sufficient visibility. The reaction was then immediately 
stopped by the addition of stop solution for 1 h. Images were captured using the 
ChemiGenius II system and associated software (Syngene, Cambridge, UK). 
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2.6 Collagenase assay 
Principle: Collagen at neutral pH and at temperatures above 25°C forms into fibrils 
where individual collagen molecules associate to form a gel. [
3
H]-acetylated collagen 
was used to measure the collagenolytic activity in supernatant from bovine and human 
cartilage explants cultures. At the end of the assay, undigested collagen fibrils are spun 
down in the centrifuge and the amount of [
3
H] in the supernatant correlates to the 
amount of collagen digested. Using APMA in the assay, one can measure total 
collagenase activity in addition to active collagenase activity. 
 
Tris buffer 
100 mM Tris-HCl, pH 7.6, 15 mM CaCl2 and 0.02% (w/v) NaN3 
10mM APMA stock solution 
35.2 mg APMA was dissolved in 200 µl DMSO and made up to 10 ml with 100 mM 
Tris-HCl, pH 8.5. Stored in the dark at 4°C for up to 3 months  
Tris-APMA buffer 
APMA was diluted to 2 mM in Tris buffer 
Cacodylate buffer 
25 mM sodium cacodylate, pH 7.6, 0.05% (w/v) Brij-35 and 0.02% (w/v) NaN3 
[
3
H]-acetylated collagen 
Type I collagen was extracted and purified from calf skin (Cawston and Barrett, 1979). 
The purified collagen was freeze-dried and stored at -20°C. When required the collagen 
was thawed and redissolved in 0.2 M acetic acid at 4°C. Collagen was radiolabelled 
with [
3
H]-acetic anhydride (925 MBq; GE Healthcare (Chalfont St. Giles, UK)) as 
described in Cawston et al. (2001). 
Trypsin 
100 µg/ml trypsin in 1 mM HCl 
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Bacterial collagenase 
100 µg/ml bacterial collagenase in cacodylate buffer 
 
Method 
To a 96-well V-bottomed plate, 50 µl of Tris assay buffer ± APMA was added to each 
well followed by 10 µl sample in duplicate (neat or duplicated in cacodylate buffer) and 
40 µl cacodylate buffer. Three sets of controls were included in the assay: 
1. Cacodylate buffer (50 µl); 
2. Trypsin (1 µg); 
3. Bacterial collagenase (5 µg). 
50 µl of [
3
H]-acetylated collagen was then added to each well. The 96-well plate was 
incubated at 37°C (16-20 h) then centrifuged at 1056 x g at 4°C for 30 min in Sorvall 
RC5C Plus centrifuge. Supernatant (50 µl) was removed and placed in a flexible 96-
well sample plate with 200 µl of Optiphase “Supermix” scintillation fluid. Counts were 
read in a 1450 Micro-Beta Trilux liquid scintillation and luminescence counter 
(PerkinElmer). Collagenase activity was measured in units/ml, where one unit can 
degrade 1 µg of collagen per min at 37°C 
Equation for calculating collagenase activity (units/ml): 
=50/(total lysis-blank) x 1000/(sample volume (µl)) x 1/(time (min)) x (sample-
blank) 
 
2.7 Enzyme activity assays 
2.7.1 Dipeptidyl peptidase activity assays 
Principle: FAPα is the only member of the DPP family that has gelatinase activity 
(Aoyama and Chen, 1990, Monsky et al., 1994, Pineiro-Sanchez et al., 1997) as well as 
64  
 
dipeptidyl peptidase activity (Park et al., 1999) and both of these activities occur in the 
same catalytic pocket that is located in the α/β-hydrolase domain. However, the 
exopeptidase activity of FAPα is reported to be 100-fold lower compared to DPPIV 
(Aertgeerts et al., 2005). Therefore, using a fluorescent N-terminally blocked substrate 
allows one to probe for the endopeptidase activity of FAPα; using a non N-terminally 
blocked peptide will probe mainly for the exopeptidase activity. Cleavage of the 
proline-AMC bond in either case will release AMC, which is highly fluorescent. 
Exopeptidase activity is probed for using a fluorescent peptide mimetic, GP-AMC, 
which closely resembles in vivo substrates. Cleavage of the proline-AMC bond will 
release AMC, which is highly fluorescent. 
 
2.7.1.1 Endopeptidase activity assay 
Assay buffer 
25 mM Tris HCl, pH 7.9, 140 mM NaCl, 10 mM KCl, 0.01% (w/v) Brij-35. This was 
filtered through a 0.2 µm filter and pre-warmed to 37°C before use. 
Z-GP-AMC 
25 mM dissolved in methanol. Stored -20°C in the dark. 
FAPα 
1.2 µM in assay buffer. Stored at -20°C 
 
Z-GP-AMC was diluted to 62.5 µM in pre-warmed assay buffer and kept at 37°C in the 
dark. FAPα (120 pM final concentration) was mixed with either 10 µl of test reagent or 
assay buffer in 96-well white walled plates at 37°C for 30 min. 80 µl of 62.5 µM Z-GP-
AMC was added to each well (50 µM final concentration) and the plate incubated for 4 
h. Fluorescence was then measured immediately (λex 360 nm, λem 460 nm) in a Perkin 
Elmer LS-50B fluorimeter. 
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2.7.1.2 Exopeptidase activity assay 
Assay buffer 
25 mM Tris HCl, pH 7.9, 140 mM NaCl, 10 mM KCl, 0.01% (w/v) Brij-35. This was 
filtered through a 0.2 µm filter and pre-warmed to 37°C before use. 
GP-AMC 
25 mM dissolved in methanol. Stored -20°C in the dark. 
FAPα 
1.2 µM in assay buffer. Stored at -20°C 
DPPIV 
9.5 µM in 10 mM Tris-HCl, pH 7.6, 200 mM NaCl, 1 mM EDTA and 10% (v/v) 
glycerol buffer. Stored at -20°C 
 
GP-AMC was diluted to 62.5 µM in pre-warmed assay buffer and kept at 37°C in the 
dark. FAPα (120 pM final concentration) or DPPIV (50 pM final concentration) was 
mixed with either 10 µl of test reagent or assay buffer in 96-well white walled plates at 
37°C for 30 min. 80 µl of 62.5 µM GP-AMC was added to each well (50 µM final 
concentration) and the plate incubated for 4 h. Fluorescence was then measured 
immediately (λex 360 nm, λem 460 nm) in a Perkin Elmer LS-50B fluorimeter. 
2.7.2 Matriptase activity assay 
Principle: Matriptase activity is probed for using a fluorescent peptide mimetic, Boc-
QAR-AMC, which closely resembles in vivo substrates. Cleavage of the arginine-AMC 
bond will release AMC, which is highly fluorescent. 
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Assay buffer 
100 mM Tris HCl, pH 9, 500 µg/ml BSA, 0.01% (w/v) Brij-35. This was filtered 
through a 0.2 µm filter and pre-warmed to 37°C before use. 
Boc-QAR-AMC 
25 mM dissolved in methanol. Stored -20°C in the dark. 
Matriptase 
3.8 µM in 50 mM Tris HCl, pH9, 1 mM β-mercaptoethanol, 400 mM NaCl, 10% 
glycerol. Stored at -20°C 
 
Boc-QAR-AMC was diluted to 62.5 µM in pre-warmed assay buffer and kept at 37°C 
in the dark. Matriptase (10 nM final concentration) was mixed with either 10 µl of test 
reagent or assay buffer in 96-well white walled plates at 37°C for 30 min. 80 µl of 62.5 
µM Boc-QAR-AMC was added to each well (50 µM final concentration) the plate 
incubated for 30 min. Fluorescence was then measured immediately (λex 360 nm, λem 
460 nm) in a Perkin Elmer LS-50B fluorimeter. 
 
2.7.3 FS-6 assay 
Principle: FS-6 is a general MMP substrate that has increased reaction rates compared 
to previous peptide analogues (Neumann et al., 2004). Dpa is an internal quencher that 
limits the auto-fluorescence of the AMC, but MMP cleavage of the Gly-Leu peptide 
spatially separates the Dpa and AMC, with fluorescence increasing proportionally. 
 
Assay buffer 
100 mM Tris HCl, pH 7.5, 100 mM NaCl, 10 mM CaCl2, 0.1% (w/v) PEG-6000, 0.05% 
(w/v)  Brij-35. This was filtered through a 0.2 µm filter and pre-warmed to 37°C before 
use. 
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FS-6 (AMC-Lys-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2) 
5 mM dissolved in DMSO. Stored -20°C in the dark 
Pro-MMP-1 
1.4 µM in 20 mM Tris HCl ,pH7.2, 0.5 M NaCl, 0.05% (w/v) NaN3, 0.01% (w/v) Brij-
35. Stored at -80°C 
10 mM APMA stock solution 
35.2 mg APMA was dissolved in 200 µl DMSO and made up to 10 ml with 100 mM 
Tris-HCl, pH 8.5. Stored in the dark at 4°C for up to 3 months  
 
Method 
Pro-MMP-1 was activated by incubating with APMA (0.67 mM final concentration) or 
matriptase (0.28 µM final concentration) for 4 h. FS-6 was diluted to 6.25 µM in pre-
warmed assay buffer and kept at 37°C in the dark. MMP-1 (0.14 µM final 
concentration) was mixed with 10 µl assay buffer in 96-well white walled plates at 37°C 
for 30 min. 80 µl of 6.25 µM FS-6 was added to each well (5 µM final concentration) 
and fluorescence read after 5 min (λex 325 nm, λem 400 nm) in a Perkin Elmer LS-50B 
fluorimeter. 
2.7.4 Hide powder azure assay 
Principle: Proteins, from bovine hide, are covalently linked to the chromogen Remazol 
Brilliant Blue R. The substrate was then incubated with active enzyme and upon 
cleavage of labelled proteins from the hide powder there is an increase in blue product 
in the supernatant. The absorbance was then measured at A595. 
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Assay buffer 
100 mM Tris HCl, pH 7.5, 0.6 M sucrose, 100 mM NaCl, 10 mM CaCl2, 0.1% (w/v) 
PEG-6000, 0.05% (w/v) Brij-35. This was filtered through a 0.2 µm filter and pre-
warmed to 37°C before use. 
Hide azure solution  
3% (w/v) dissolved in assay buffer. 
Pro-MMP-1 
1.4 µM in 20 mM Tris HCl, pH7.2, 0.5 M NaCl, 0.05% (w/v) NaN3, 0.01% (w/v) Brij-
35. Stored at -80°C 
10mM APMA stock solution 
35.2 mg APMA was dissolved in 200 µl DMSO and made up to 10 ml with 100 mM 
Tris-HCl, pH 8.5. Stored in the dark at 4°C for up to 3 months  
 
Method 
Pro-MMP-1 was activated by incubating with APMA (0.67 mM final concentration) or 
matriptase (0.28 µM final concentration) for 4 h. MMP-1 (0.14 µM final concentration) 
was mixed with 1 ml of hide powder azure solution in 1.5 ml eppendorfs and incubated 
at 37°C for 4 h on an orbital shaker (1000 rpm). Then centrifuged at 1200 x g for 5 min 
and supernatant transferred to 96-well flat bottom plate in duplicate (100 µl/well). The 
absorbance was read at 595 nm (Sunrise microplate reader, Tecan). 
 
2.8 ELISA 
2.8.1 MMP-1 ELISA 
Principle: Monoclonal MMP-1 antibody was immobilised on Maxisorb 96-well plates. 
Samples were added to the plates and any MMP-1 present would bind to the antibody. 
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A secondary antibody, which is raised against a second distinct epitope, was added. 
Tertiary antibody, conjugated with HRP, recognising the secondary antibody was then 
added. A chromogenic substrate was then added and oxidised by HRP producing a 
coloured product. 
Phosphate buffered saline (PBS) 
8.1 mM Na2HPO4, 1.5 mM KH2PO4, 154 mM NaCl, 2.7 mM KCl, pH 7.4 
Wash buffer 
8.1 mM Na2HPO4, 1.5 mM KH2PO4, 150 mM NaCl, 2.7 mM KCl, 0.25 mM thimerosol 
and 0.1% (v/v) Tween 20, pH 7.0 
Blocking buffer 
1% (w/v) BSA in PBS 
Protein diluents 
0.05% (w/v) BSA in wash buffer 
Monoclonal antibody to human MMP-1 (RRU-CL1) 
2 µg/ml in protein diluent 
Rabbit anti-MMP-1 polyclonal antibody (B-anti-CL1) 
2 µg/ml in protein diluent 
Goat anti-rabbit IgG-HRP 
Diluted 1:1000 in protein diluent 
Phosphate-citrate buffer 
Dissolve one phosphate-citrate capsule per 100 ml of ddH2O 
OPD substrate solution 
Prepared immediately before use. 1 tablet (15mg) of OPD dissolved in 12 ml of 0.5 M 
phosphate-citrate buffer, pH 5.0. 
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Method 
Maxisorb 96-well plates were coated with RRU-CL1 overnight at 4°C (100 µl/well). 
The plates were washed once with wash buffer (400 µl/well) and blocked with blocking 
buffer (200 µl/well) overnight at 4°C. The plates were then washed three times in wash 
buffer. Standards (0-80 ng/ml) were prepared by diluting recombinant human pro-
MMP-1 in protein diluent. Samples and standards (100 µl/well) were added to the plates 
in duplicate and incubated at 4°C overnight. The plates were then washed three times 
with wash buffer and then incubated at room temperature for 2 h with B-anti-CL1 (100 
µl/well). The plates were washed three times in wash buffer and incubated at room 
temperature for 1 h with goat anti-rabbit IgG-HRP (100 µl/well). The plates were then 
washed three times in wash buffer and incubated with 100 µl per well of OPD substrate 
for approximately 5 min at room temperature. The reaction was stopped by the addition 
of 3 M H2SO4 (50 µl/well) and the absorbance read at 490 nm (TECAN Sunrise plate 
reader, Reading, UK). 
2.8.2 MMP-13 ELISA 
Principle: Monoclonal MMP-13 antibody was immobilised on Maxisorb 96-well 
plates. Samples were added to the plate and any MMP-13 present would bind to the 
antibody. A biotin conjugated secondary antibody, which is raised against a second 
distinct epitope, is added. Streptavidin conjugated HRP is then added and binds to the 
biotin labelled secondary antibody. A chromogenic substrate is then added and oxidised 
by HRP producing a coloured product. 
Monoclonal coating antibody to human MMP-13 
1.25 µg/ml in protein diluent 
Biotinylated detection anti-MMP-13 antibody 
125 ng/ml in protein diluent 
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Streptavidin-HRP  
Diluted 1:1000 in protein diluents 
 
Method 
Maxisorb 96-well plates were coated with coating antibody overnight at 4°C (100 
µl/well). The plates were washed once with wash buffer (400 µl/well) and blocked with 
blocking buffer (200 µl/well) overnight at 4°C. The plates were then washed three times 
in wash buffer. Standards (0-20 ng/ml) were prepared by diluting purified recombinant 
pro-MMP-13 in protein diluent. Samples and standards (100 µl/well) were added to the 
plates in duplicate and incubated at 4°C overnight. The plates were then washed three 
times with wash buffer and then incubated at room temperature for 2 h with detection 
antibody (100 µl/well). The plates were washed three times in wash buffer and 
incubated at room temperature for 30 min with Streptavidin-HRP (100 µl/well). The 
plates were then washed three times in wash buffer and incubated with 100 µl per well 
of OPD substrate for approximately 5 min at room temperature. The reaction was 
stopped by the addition of 3 M H2SO4 (50 µl/well) and the absorbance read at 490 nm 
(TECAN Sunrise plate reader, Reading, UK). 
 
2.9 N-terminal sequencing 
2.9.1 Recombinant pro-MMP-1 isolation by ion exchange chromatography 
Principle: Ion exchange chromatography relies on the differences between molecules in 
relation to their surface charge distribution, overall charge and charge density. MMP-1 
at neutral pH displays a net positive charge and binds to the negatively charged methyl 
sulfonate group in the column. Linear increments in the ionic strength of the buffer 
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causes elution of the bound proteins, with weakly interacting proteins eluting first at 
low ionic strength and strongly interacting proteins eluting last at high ionic strength. 
 
Materials 
Mono S HR 5/5 column. 
Buffer A 
20 mM Tris-HCl, pH 7.4, 5 mM CaCl2, 0.05% (w/v) Brij-35, 0.01% (w/v) NaN3 in 
ddH2O 
Buffer B 
Buffer A including 1 M NaCl 
 
Method 
Buffers were filtered through a 0.45 µm filter before use. The Mono S column was used 
on an ÄKTAexplorer 100 system (GE Healthcare, Chalfont St. Giles, UK) at room 
temperature. Partially purified recombinant pro-MMP-1 was generously donated by Dr 
J. Milner. Samples were diluted 10-fold in buffer A. The column was washed with 5 
column volumes (CV) of ddH2O to remove the storage buffer (20% ethanol). 10 CV of 
buffer A were passed through the column to equilibrate it. The sample was loaded and 
then washed with 2 CV of buffer A to remove unbound proteins. Next, the column was 
washed with a salt gradient (0 to 1 M NaCl) using buffer B (33 mM/min). The flow rate 
throughout the procedure was 1 ml/min. A280 was measured to trace the protein peaks. 
Fractions (0.5 ml) were collected. 
 
2.9.2 N-terminal sequencing of matriptase activated pro-MMPs 
Principle: The N-terminal amino acid sequence of proteins can be determined by 
Edman degradation. Samples are incubated with matriptase and then separated by SDS-
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PAGE and transferred onto PVDF membranes. The protein bands were visualised by 
Coomassie dye staining and excised. Samples were freed from the PVDF by immersion 
in organic solvents and the protein underwent 5 rounds of Edman degradation. Briefly, 
phenylisothiocyanate was reacted with the uncharged terminal amino group under 
alkaline conditions. The derivative is then acid treated to form a thiazolinone derivative 
and extracted into organic solvent and acid treated again to form phenylthiohydantoin 
amino acid derivative. The phenylthiohydantoin amino acid derivative is then identified 
by chromatography. 
 
Buffer 
25 mM sodium cacodylate, 10 mM CaCl2, 0.05% Brij, 0.02% azide pH 8 in ddH2O 
Matriptase 
3.8 µM in 50mM Tris HCl, pH9, 1mM β-mercaptoethanol, 400 mM NaCl, 10% (v/v) 
glycerol. Stored at -20°C. 
Pro-MMP-3ΔC 
22.4 µM in 50 mM TrisHCl (pH 7.5), 0.15 M NaCl, 10 mM CaCl2, 0.02% NaN3, 0.05% 
(w/v) Brij-35, 10% (v/v) glycerol. Stored at -80°C. 
Pro-MMP-1 
1.4 µM in 20 mM Tris-HCl, pH 7.4, 130 mM NaCl, 5 mM CaCl2, 0.05% (w/v) Brij-35, 
0.01% (w/v) NaN3. Stored at -80°C. 
GM6001 
50 mM in DMSO. Protected from light and stored at -80°C. 
5x Final sample buffer (FSB) 
0.625 M Tris HCl pH 6.8, 40% (v/v) glycerol, 10% (w/v) SDS, 0.5% (w/v) 
bromophenol blue, 5% (v/v) -mercaptoethanol. 
Transfer buffer 
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10 mM Caps, pH 11, 10% (v/v) methanol in ddH2O 
Staining solution 
0.25% (w/v) Coomassie brilliant blue G250, 40% (v/v) methanol, 10% (v/v) acetic acid 
Destaining solution 
40% (v/v) methanol, 10% (v/v) acetic acid  
 
Method 
1 µM pro-MMP was incubated with 0.28 µM matriptase (± GM6001, 50 µM final 
concentration) at 37°C for 1 to 4 h. Samples were then run on 10% SDS-polyacrylamide 
gels (section 2.5.4) and transferred to PVDF membranes by semi-dry electroblotting 
(Scie-Plas V20-SDB) for 90 min at 1mA/cm
2
. 
The protein bands were then visualised by placing the membranes in staining solution 
for 20 min and then destaining for 30 min. The bands were then excised and sent for N-
terminal sequencing. N-terminal sequence analysis was performed by Dr Joe Gray 
(Pinnacle, Newcastle University, UK). 
 
2.10 Statistics 
Statistical difference between parametric groups was assessed by one-way analysis of 
variance (ANOVA) with a Bonferroni post-hoc test. All non-parametric samples were 
assessed by Mann-Whitney U test. The SPSS 15.0 software package (SPSS UK Ltd, 
UK) was used in all instances. Significance levels were indicated as * = p ≤ 0.05, ** p ≤ 
0.01 and *** = p ≤ 0.001.  
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CHAPTER 3 
Investigating the role of FAPα in cartilage homeostasis 
3.1 Introduction 
The degradation of the cartilage collagen matrix is irreversible and a major hallmark of 
the rheumatic diseases. The key enzymes involved in cartilage degradation are the 
collagenases (section 1.5.2) which belong to the MMP family. All MMPs are 
synthesised as zymogens that require removal of their pro-domain for activity (section 
1.5.4), but the exact in vivo mechanisms of MMP activation are not fully understood. 
However, evidence from within our group shows that serine proteases play an important 
role in the regulation of MMP activity (Milner et al., 2001, 2003, 2008). The inhibition 
of either furin-like or trypsin-like cascades in IL-1+OSM-treated cartilage protects the 
collagen matrix significantly from cytokine-mediated degradation. All these 
observations clearly implicate serine proteases in pathological collagen turnover. 
Data implicate that type II collagen degradation occurs around the chondrocyte before 
being detected in other zones of the cartilage (Hollander et al., 1995). Recently, novel 
transmembrane serine proteases have been discovered to be up-regulated in OA 
cartilage compared to phenotypically normal cartilage (Figure 3.1). Research on newly 
discovered serine proteases is required as their cell surface localisation of these 
proteases would support a hypothesis that they have an important role in pericellular 
degradation of cartilage. 
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*** * 
* 
** 
 
 
Figure 3.1 Expression of transmembrane serine proteases are elevated in OA 
cartilage 
Gene expression levels in hip cartilage from patients with OA (closed circles; n = 13) or 
normal controls (open squares; n = 12) of DPPIV, FAPα and matriptase were 
determined by real-time PCR and normalised to the level of 18S rRNA. Significant 
differences between the normal and OA groups were determined using a two-sided 
Mann–Whitney U test. * = p<0.05, ** = p<0.01, *** = p<0.001. Data generated by Dr 
J. M. Milner, Newcastle University, U.K. 
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FAPα (section 1.8.2) expression was originally thought to be highly restricted to sites of 
tissue remodelling, on the surface of reactive stromal fibroblasts or synoviocytes (Bauer 
et al., 2006), at sites of tumour invasiveness and not to be expressed in normal adult 
tissues (Rettig et al., 1993). However, expression of this enzyme has recently been 
detected on the cell surface of chondrocytes upon stimulation with IL-1 and OSM 
(Milner et al., 2006b). Additionally, when BNC was treated with IL-1+OSM, there was 
a strong correlation between FAPα mRNA expression and increasing collagen 
degradation (Milner et al., 2006b), suggesting a role for this enzyme in the pathology of 
inflammatory arthritis. 
The β-propeller domain of FAPα plays a role in the interaction of the enzyme with other 
membrane bound proteins such as α3β1 integrin (Mueller et al., 1999, Zhang et al., 
1999) as well as components of the plasminogen activator receptor (Artym et al., 2002). 
This association with other membrane bound proteins indicates that FAPα has the 
ability to modulate cellular functions via the recruitment of intracellular signalling 
molecules such as integrin proteins (Nakahara et al., 1998). Furthermore, there is a 
substantial body of evidence showing that FAPα associates with a large number of 
molecules on the cell surface (Kelly, 2005, Monsky et al., 1994, Artym et al., 2002). 
One study showed that FAPα can associate with uPAR at invadopodia, suggesting a co-
operative role in ECM degradation and cellular invasion in cancer. Therefore, the 
rationale was that modulation of enzymatic FAPα activity in resorbing cartilage would 
alter collagen matrix degradation in cytokine-treated bovine cartilage. 
The aims of this chapter were to: 
 determine if FAPα gene expression is regulated by IL-1 and/or OSM in primary 
chondrocytes;  
 examine if FAPα possesses type II collagenolytic or gelatinolytic activity; 
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 investigate if FAPα enzyme activity has a role in the breakdown of the collagen 
matrix in IL-1+OSM-treated cartilage, using inhibitors designed to target FAPα; 
 assess if addition of exogenous active FAPα would influence IL-1+OSM-
induced cartilage breakdown. 
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3.2 Results 
3.2.1 Regulation of FAPα gene expression in primary chondrocytes 
FAPα expression has been shown to be elevated in SW1353 cells upon IL-1 and/or 
OSM stimulation (Milner et al., 2006b). The SW1353 chondrosarcoma cell line has 
been used routinely in place of primary human chondrocytes since such cells can 
dedifferentiate when cultured in monolayer (Bonaventure et al., 1994). However, recent 
data suggest that SW1353 cells have limited potential as a model to study chondrocyte 
gene expression as long-term culture shows that they exhibit an epithelial phenotype 
(Gebauer et al., 2005). Therefore, the regulation of FAPα gene expression in primary 
cells was investigated in bovine nasal chondrocytes. 
A modest increase of FAPα expression could be observed in IL-1+OSM-treated SW 
1353 cells (Figure 3.2). In contrast to findings by Milner et al. (2006b), however, this 
increase was not significant. FAPα gene regulation by IL-1 and OSM was then assessed 
in two different populations of bovine nasal chondrocytes (Figure 3.3). The data were 
rather variable between the populations with no discernable trend. MMP-1 gene 
expression was tested in SW1353 and primary cells (data not shown) and synergistic 
induction upon IL-1+OSM stimulation was observed as previously reported (Barksby et 
al., 2006). These results highlight the differences between SW1353 and primary cells.   
TGF-β1 has been shown to induce FAPα gene expression in a number of cell lines 
(Chen et al., 2009, Rettig et al., 1994). FAPα expression was also regulated by TGF-β1 
in SW1353 cells (Figure 3.2). Whilst TGF-β1 did induce FAPα expression in SW1353 
cells even in the presence of IL-1 and/or OSM (Figure 3.2), a similar trend was not 
observable in primary chondrocytes (Figure 3.3).  
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Figure 3.2 The regulation of FAPα gene expression in SW1353 chondrocyte cell 
line.  
SW1353 cells were treated with combinations of IL-1 (1 ng/ml) and OSM (10 ng/ml) ± 
TGF-β1 (10 ng/ml) for 24 h. Total RNA was extracted and FAPα gene expression 
determined by real-time PCR and normalised to 18S rRNA levels. The data from two 
representative experiments are shown and presented as fold induction relative to control. 
Results are expressed as mean ± SEM (n=4). ** = p < 0.01. 
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Figure 3.3 The regulation of FAPα gene expression in primary chondrocytes. 
Bovine nasal chondrocytes were treated with combinations of IL-1 and OSM ± TGF-β1 
(10 ng/ml) for 24 h. Total RNA was extracted and FAPα gene expression determined by 
real-time PCR and normalised to 18S rRNA levels. The data from two experiments are 
shown and are presented as fold induction relative to control. Results are expressed as 
mean ± SEM (n=4). 
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3.2.2 Effect of FAPα enzyme activity on type II collagen 
The hypothesis being tested in this experiment was that FAPα should contribute to 
matrix degradation by hydrolysis of denatured type II collagen. FAPα has been shown 
to have gelatinolytic activity (Levy et al., 1999) and as proteolysis is thought to occur in 
the pericellular compartment (Hollander et al., 1995), a transmembrane gelatinase could 
potentially expedite clearance of matrix proteins and therefore facilitate matrix 
degradation.  
Type II collagen was extracted as described in section 2.5. To ensure that the type II 
collagen had retained its native triple helical state during the extraction, the collagen 
was treated with trypsin. The type II collagen extracted from human cartilage still 
retained the native triple helical conformation as trypsin could not cleave the native 
collagen band but did hydrolyse the denatured collagen (Figure 3.4, lanes 4 and 5). In 
the experiment shown, FAPα is only able to cleave denatured collagen and shows for 
the first time that FAPα can degrade denatured type II collagen (Figure 3.4, lane 7). 
  
83  
 
 
Figure 3.4 FAPα proteolysis of type II collagen.  
Type II collagen (10 μg) from human articular cartilage was incubated at 37°C for 24 h 
in the presence or absence of proteases in 50 mM Tris-HCl, pH 7.6, 1 M glucose, 200 
mM NaCl, 5 mM CaCl2 buffer. Lane: (1) Native collagen (N); (2) Denatured collagen 
(D); (3) 4 µM trypsin; (4) Native collagen, 0.4 µM trypsin; (5) Denatured collagen, 0.4 
µM trypsin; (6) 0.1 µM FAPα; (7) Native collagen, 0.4 µM FAPα; (8) Denatured 
collagen, 0.4 µM FAPα. Digests were reduced and analysed by 6.5 % SDS–PAGE. The 
closed arrow indicates the position of the intact α(II) chain of type II collagen. The open 
arrow indicates the position of FAPα. The patterned arrows indicate the presence of 
unknown low molecular weight contaminants. Results are representative of 2 
independent experiments. 
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3.2.3 The effect of FAPα inhibitors on resorbing cartilage explants 
The aim of these experiments was to determine if FAPα enzyme activity contributed to 
cartilage collagen breakdown in response to cytokine stimulation. Inhibitors specifically 
targeting FAPα were added to cytokine-treated BNC and collagen release measured. 
 
3.2.3.1 Collagen release upon addition of FE999044 to resorbing nasal cartilages 
In the experiment shown (Figure 3.5), cartilage treated with IL-1+OSM yielded 49.84 ± 
14.21% collagen release, while the addition of 3 µM FE999044 yielded 50.23 ± 17.12% 
collagen release and the addition of 0.3 µM FE999044 yielded 60.72 ± 4.92% collagen 
release. The data show that there was no change in collagen release when resorbing 
cartilage was treated with FE999044. 
Recombinant human FAPα was used to test if FE999044 had potential to inhibit the 
enzymatic activity of FAPα in vitro. While FE999044 showed no inhibitory ability 
against the endopeptidase activity of FAPα (Figure 3.6a), it showed a strong ability to 
inhibit its exopeptidase activity (Figure 3.6b). Furthermore, FE999044 showed no cross-
reactivity to inhibit the enzymatic activity of recombinant DPPIV in vitro (Figure 3.7). 
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Figure 3.5 Effect of FE999044 on cartilage breakdown. 
Bovine nasal cartilage discs were cultured in medium ± IL-1+OSM (1 ng/ml and 10 
ng/ml respectively) ± FE999044 or DMSO control. Media were removed on day 7 and 
fresh reagents were added until day 14 when the experiment was ceased. As a measure 
of collagen release, the levels of hydroxyproline were assayed in day 7 and day 14 
media and in cartilage digests. Shown are the cumulative collagen release (day 7 + day 
14), expressed as a percentage of the total collagen. Results are expressed as mean ± SD 
(n=4) and representative of 3 independent experiments. 
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Figure 3.6 Effect of FE999044 on the enzymatic activity of FAPα 
FAPα activity was determined using the quenched fluorescent substrate, A) Z-GP-AMC 
or B) GP-AMC. FAPα (120 pM) with either FE999044 (10 µM) or DMSO as a solvent 
control were incubated in assay buffer for 30 min at 37°C. Substrate (50 µM) was then 
added and left for 4 h at 37°C. Fluorescence was then measured immediately (λex 360 
nm, λem 460 nm). The A) endopeptidase or B) exopeptidase activity was calculated. 
Results are expressed as mean ± SD (n=3) and representative of 2 independent 
experiments. *** = p < 0.001 against DMSO. 
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Figure 3.7 Effect of FE999044 on the enzymatic activity of DPPIV 
DPPIV activity was determined using the quenched fluorescent substrate, GP-AMC. 
DPPIV (50 pM) with either FE999044 (10 µM) or DMSO as a solvent control were 
incubated in assay buffer for 30 mins at 37°C. Substrate (50 µM) was then added and 
left for 1 h at 37°C. Fluorescence was then measured immediately (λex 360 nm, λem 460 
nm). The percentage activity was calculated. Results are expressed as mean ± SD (n=3) 
and representative of 2 separate experiments.  
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3.2.3.2 Collagen release upon addition of Z-GP-DPi to resorbing cartilage 
In the experiment shown (Figure 3.8), cartilage treated with IL-1+OSM and DMSO 
yielded 69.77 ± 7.73% collagen release. The addition of 150 µM Z-GP-DPi yielded 
65.93 ± 5.71% collagen release. No change in collagen release could be observed when 
resorbing cartilage was treated with Z-GP-DPi.  
It has been reported previously that dipeptide diphenylphosphonate inhibitors have short 
half-lives at physiological salt levels and 37°C (Lambeir et al., 1996). The activation of 
pro-collagenases in our bovine cartilage explant model is thought to occur around days 
10 to 12 (Milner et al., 2006a). However, addition of Z-GP-DPi between days 8 to 12 
inclusive showed no change in collagen release (Figure 3.9). 
Recombinant human FAPα was used to test if Z-GP-DPi had potential to curtail the 
enzyme activity of FAPα in vitro. Z-GP-DPi showed no inhibitory ability against either 
the endopeptidase activity of FAPα (Figure 3.10a), or exopeptidase activity (Figure 
3.10b). Additionally, Z-GP-DPi did not show any efficacy against recombinant DPPIV 
activity in vitro (Figure 3.11). Consequently, the use of Z-GP-DPi was discontinued as 
it exhibited no inhibitory potential. 
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Figure 3.8 Effect of Z-GP-DPi on cartilage breakdown.  
Bovine nasal cartilage discs were cultured in medium ± IL-1+OSM (1 ng/ml and 10 
ng/ml, respectively) ± Z-GP-DPi (150 µM) or DMSO control. Media were removed on 
day 7 and fresh reagents were added until day 14 when the experiment was ceased. As a 
measure of collagen release, the levels of hydroxyproline were assayed in day 7 and day 
14 media and in cartilage digests. Shown are the cumulative collagen release (days 7 + 
day 14), expressed as a percentage of the total collagen. Results are expressed as mean 
± SD (n=4) and representative of 3 separate experiments. 
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Figure 3.9 Multiple additions of Z-GP-DPi to cartilage show no protective effect.  
Bovine nasal cartilage discs were cultured in medium ± IL-1+OSM (1 ng/ml and 10 
ng/ml respectively) ± Z-GP-DPi or DMSO control. Media were removed on day 7 and 
fresh reagents added, Z-GP-DPi (150 µM final concentration) was added to the cartilage 
between days 8 to 12 (inclusive). The experiment was ceased at day 14. As a measure of 
collagen release, the levels of hydroxyproline were assayed in day 7 and day 14 media 
and in cartilage digests. Shown is the cumulative collagen release (days 7 + day 14), 
expressed as a percentage of the total collagen. Results are expressed as mean ± SD 
(n=4) and representative of 3 separate experiments. *** = p < 0.001 against IL-1+OSM 
alone. 
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Figure 3.10 Effect of Z-GP-DPi on the activity of FAPα.  
FAPα activity was determined using the quenched fluorescent substrate, A) Z-GP-AMC 
or B) GP-AMC. FAPα (120 pM) with either Z-GP-DPi or DMSO (0.1%) as a solvent 
control were incubated in assay buffer for 30 min at 37°C. Substrate (50 µM) was then 
added and left for 4 h at 37°C. Fluorescence was then measured immediately (λex 360 
nm, λem 460 nm). The percentage activity was calculated. Results are expressed as mean 
± SD (n=3) and representative of 2 separate experiments. 
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Figure 3.11 Effect of Z-GP-DPi on the enzymatic activity of DPPIV 
DPPIV activity was determined using the quenched fluorescent substrate, GP-AMC. 
DPPIV (50 pM) with either Z-GP-DPi or DMSO as a solvent control were incubated in 
assay buffer for 30 mins at 37°C. Substrate (50 µM) was then added to each well and 
left for 1 h at 37°C. Fluorescence was then measured immediately (λex 360 nm, λem 460 
nm). The percentage activity was calculated. Results are expressed as mean ± SD (n=3) 
and representative of 2 separate experiments. 
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3.2.3.3 Collagen release upon addition of UAMC-583 and -584 to resorbing bovine 
cartilage 
In the experiment shown (Figure 3.12), cartilage treated with IL-1+OSM and DMSO 
yielded 77.55 ± 13.27% collagen release. Addition of 10 µM UAMC-583 and UAMC-
584 yielded 78.91 ± 9.87% and 69.47 ± 11.62% collagen release, respectively. No 
change in collagen release could be detected when resorbing cartilage was treated with 
any of these FAPα inhibitors.  
Recombinant human FAPα was used to test if any of the inhibitors had potential to 
reduce the enzymatic activity of FAPα in vitro. UAMC-583 and -584 showed 
significant inhibitory ability against the endopeptidase activity of FAPα (Figure 3.13a) 
but not exopeptidase activity (Figure 3.13b).  
None of the FAPα inhibitors tested showed any affect against recombinant DPPIV 
activity in vitro (Figure 3.14). 
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Figure 3.12 Effect of FAPα inhibitors on cartilage breakdown.  
Bovine nasal cartilage discs were cultured in medium ± IL-1+OSM (1 ng/ml and 10 
ng/ml respectively). At days 0, 3, 7 and 10, the inhibitors UAMC-583 and -584 (10 µM) 
or DMSO control were added to cartilage. Media were removed on day 7 and fresh 
reagents added until day 14 when the experiment was ceased. As a measure of collagen 
release, the levels of hydroxyproline were assayed in day 7 and day 14 media and in 
cartilage digests. Shown is the cumulative collagen release (days 7 + day 14), expressed 
as a percentage of the total collagen. Results are expressed as mean ± SD (n=4) and 
representative of 3 separate experiments. 
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Figure 3.13 Effect of FAPα inhibitors on the activity of FAPα.  
FAPα activity was determined using the quenched fluorescent substrate, A) Z-GP-AMC 
or B) GP-AMC. FAPα (120 pM) with either FAPα inhibitors (10 µM) or DMSO (0.1%) 
as a solvent control were incubated in assay buffer for 30 min at 37°C. Substrate (50 
µM) was then added and left for 4 h at 37°C. Fluorescence was then measured 
immediately (λex 360 nm, λem 460 nm). The A) endopeptidase or B) exopeptidase 
activities were calculated. Results are expressed as mean ± SD (n=3) and are 
representative of 2 separate experiments. *** = p < 0.001 against DMSO. 
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Figure 3.14 Modulation of DPPIV activity by FAPα inhibitors 
DPPIV activity was determined using the quenched fluorescent substrate, GP-AMC. 
DPPIV (50 pM) with FAPα inhibitors (10 µM) or DMSO as a solvent control were 
incubated in assay buffer for 30 min at 37°C. Substrate (50 µM) was then added and left 
for 1 h at 37°C. Fluorescence was then measured immediately (λex 360 nm, λem 460 
nm). The percentage activity was calculated. Results are expressed as mean ± SD (n=3) 
and representative of 2 separate experiments. 
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3.2.4 Effect of FAPα on IL-1+OSM-treated bovine cartilage explant culture 
The hypothesis being tested in this experiment was that, if FAPα has a catabolic role in 
cartilage breakdown, the addition of active FAPα should lead to higher collagen release 
compared to IL-1+OSM treated cartilage. Milner et al. (2006a) showed that in IL-
1+OSM-treated cartilage the activation of pro-collagenases occurs around days 10 to 
12. Data from our group have highlighted that factors that expedite collagen release 
from this model are best identified at a time point soon after we expect to begin seeing 
collagen release. Therefore, the effect of exogenous FAPα was assessed at day 12.  
A modest decrease in collagen release could be observed with the addition of active 
FAPα compared to IL-1+OSM-treated bovine cartilage explants by day 12 (Figure 
3.15). However, this decrease was not significant in either experiment.  
98  
 
 
 
 
 
Figure 3.15 Effect of exogenous FAPα on cartilage breakdown.  
Bovine nasal cartilage discs were cultured in medium ± IL-1+OSM (1 ng/ml and 10 
ng/ml, respectively). Media removed on day 7 and fresh media ± FAPα (100 nM) were 
added until day 12 when the experiment was ceased. As a measure of collagen release, 
the levels of hydroxyproline were assayed in day 7 and day 12 media and in cartilage 
digests. Shown is the cumulative collagen release (days 7 + day 12), expressed as a 
percentage of the total collagen. Results are expressed as mean ± SD (n=6) and 
representative of 2 separate experiments. 
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3.3 Discussion 
3.3.1 IL-1+OSM does not regulate FAPα gene expression in primary chondrocytes  
Milner et al. (2006b) previously reported that FAPα gene expression was increased in 
OA cartilage and correlated with collagen release in IL-1+OSM-treated BNC. In 
addition, FAPα gene expression was detected in SW1353 chondrosarcoma cells 
although Gebauer et al. (2005) have described SW1353 chondrosarcoma cells to have 
limited potential as a model for gene expression in primary chondrocytes. The data 
presented here show that neither IL-1, OSM nor TGF-β1 regulate FAPα gene 
expression in primary bovine chondrocytes.  
FAPα expression was shown to be up-regulated during inflammation in RA and OA 
synovial cells (Bauer et al., 2006) and in cirrhotic livers (Levy et al., 1999). However, 
there is little information on the regulation of FAPα gene expression in these 
pathologies. Recently, the promoter sequence of FAPα has been analysed and three 
transcription factor binding sites have been identified; HOXA4 (homeobox A4), E2F1 
and EGR1 (early growth response protein 1) (Zhang et al., 2010). In this study, EGR1 
knockdown showed a fifty percent decrease in FAPα expression, while HOXA4 and 
E2F1 knockdowns did not show any effect on gene expression. EGR1 has previously 
been demonstrated to be up-regulated in OA cartilage compared to phenotypically 
normal cartilage (Wang et al., 2000). However, the role of EGR1 is arthritis remains 
unclear as EGR1 has been shown to repress the cartilage matrix genes, such as Col2a1, 
upon stimulation by IL-1β (Tan et al., 2003) or TNF-α (Rockel et al., 2009) and EGR1 
is required for maximal MMP-9 expression after TNF-α stimulation in carcinomas 
(Shin et al., 2010). Conversely, TGF-β1-stimulated fibroblasts show increased Col1a2 
and this effect was dependent on enhanced EGR1 binding to the promoter sequence 
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(Chen et al., 2006b). The enhanced EGR1 binding upon TGF-β1 stimulation could 
account for the increased FAPα expression seen in SW1353 cells. 
The data presented in this chapter show that FAPα gene expression is not regulated by 
IL-1 or OSM or TGF-β1 in primary chondrocyte culture. EGR1 was shown to be an 
early response gene to IL-1 stimulation in SW1353 chondrosarcoma cells (Vincenti and 
Brinckerhoff, 2001) and this would explain the result seen by Milner et al. (2006b). It is 
possible that EGR1 regulates FAPα gene expression in primary chondrocytes but EGR1 
may not be the major transcription factor regulating FAPα expression as Zhang et al. 
(2010) showed only fifty percent reduction when EGR1 was knocked down, indicating 
other transcription factors may be important as well. 
3.3.2 FAPα directly contributes to the degradation of denatured collagen 
FAPα possesses endopeptidase ability (Aertgeerts et al., 2005, Lee et al., 2006, Levy et 
al., 1999, Edosada et al., 2006) and can cleave gelatin derived from type I collagen 
(Aggarwal et al., 2007) as well as other macromolecular proteins such as α2-antiplasmin 
(Lee et al., 2004). Recently, Christiansen et al. (2007) showed that FAPα could cleave 
type I, III and IV collagen after the triple helix had been unwound by the action of 
MMPs. However, there was no report on the degradation of denatured type II collagen 
by FAPα until now, and alludes to the prospect that FAPα acts in concert with other 
proteases to potentiate pericellular cartilage degradation in OA (Hollander et al., 1995) 
or pannus invasion of the cartilage in RA (Lee and Weinblatt, 2001). 
In fact, FAPα is known to associate with a number of proteases and signalling 
molecules, such as MMP-2, MMP-14, uPAR and integrins, at the invadopodia of 
malignant cancer cells (Monsky et al., 1994) and DPPIV on lung fibroblasts (Ghersi et 
al., 2002). It is possible that FAPα acts as a focal point to bring transmembrane proteins 
together in order to facilitate ECM degradation.  
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3.3.3 FAPα enzyme activity does not affect cartilage degradation 
FAPα expression is usually increased in most malignant carcinomas (Garin-Chesa et al., 
1990). FAPα inhibitors are being designed to address this therapeutic need in the field 
of cancer. A study by Edosada et al. (2006) highlighted that by utilising the differences 
in substrate specificity between DPPIV and FAPα, specific inhibitors could be 
produced. The authors showed that N-blocked-boroProline derivatives exhibited high 
specificity for FAPα over DPPIV (Edosada et al., 2006, Tran et al., 2007). A second 
class of inhibitors, the dipeptide-derived diphenyl phosphonates have also been 
designed to target both FAPα and DPPIV (Lambeir et al., 1996). Unlike the boroProline 
inhibitors, modulating the N-terminal amino acids of these inhibitors did not affect the 
second order rate constant of inactivation of FAPα (Gilmore et al., 2006). 
So far the clinical use of FAPα inhibitors alone to treat carcinomas has shown little 
promise in clinical trials (Narra et al., 2007). This study was carried out using patients 
with metastatic colorectal carcinoma and highlighted that FAPα inhibition at earlier 
stages of the disease may have greater beneficial effects. However, two further studies 
using the same inhibitor in concert with traditional treatments showed no additional 
effect over the traditional treatment alone (Eager et al. 2009a, b).   
Complementary to the inhibitors, FAPα antibodies are being trialled to treat disease 
progression in advanced FAPα positive cancers (Scott et al., 2003, Tahtis et al., 2003). 
The FAPα antibodies used in these studies were shown to have minimal uptake into 
normal tissues after infusion. Furthermore, they showed no adverse side effects in the 
majority of the patients in the clinical trial. The long-term effects from targeting FAPα 
in cancer are still not known yet. The role of FAPα in the tumour microenvironment is 
complicated as FAPα positive stromal fibroblasts in the tumour environment are 
associated with increased survival (Ariga et al., 2001). However, an in vivo mouse 
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model of human breast cancer showed that FAPα expressing breast carcinoma cells 
actually increase tumour growth and microvessel density (Huang et al., 2004). 
Using FAPα specific inhibitors in IL-1+OSM-treated BNC did not diminish collagen 
release. All of the inhibitors used here, except Z-GP-DPi, did abrogate either the 
endopeptidase or exopeptidase activity of FAPα. However, without detailed information 
about the chemical structures of these FAPα specific inhibitors, no conclusions can be 
drawn as to why these inhibitors could not inhibit both activities. The active site of 
FAPα and DPPIV differs by one amino acid and this change affects the preferred 
activity of the enzyme. Aertgeerts et al. (2005) showed that Ala-657 in the active site of 
FAPα favours endopeptidase activity over dipeptidyl peptidase activity as uncharged 
residues are preferred in the P2 pocket. Steric hindrance between the inhibitor and the 
side chain of Ala-657 could result in a relatively weak binding of the inhibitor to the 
active site of FAPα. Consequently, if the substrate has a higher binding affinity to the 
active site then the inhibitor could be displaced from the active site, and explain why the 
inhibitors had no effect ex vivo.  
Addition of soluble recombinant FAPα did not influence cartilage degradation 
suggesting that FAPα enzyme activity does not play a role in the degradation of IL-
1+OSM-treated bovine cartilage. There is the possibility that the β-propeller domain of 
FAPα plays a greater role than the catalytic domain in the context of cartilage 
degradation. Monsky et al (1994) showed that FAPα was located at the invadopodia of 
melanoma cells and co-localised with a large number of other molecules, such as MMP-
2, MMP-14, uPAR and integrins. Artym et al. (2002) went on to show that FAPα and 
uPAR formed a complex on the surface of melanoma cells and that this was dependent 
on β1-chain integrin and the cytoskeleton. Furthermore, the β-propeller domain of FAPα 
has high homology to the β-propeller region of α3-chain integrin (Kelly, 2005) and this 
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domain of the α3-chain binds uPAR (Zhang et al., 2003). Articular chondrocytes 
predominantly express α5 and β1 integrin chains with α1 and α3 chains found at lower 
levels (Salter et al., 1992). Therefore, there is the distinct possibility that FAPα, in 
conjunction with integrins, could form large complexes at the chondrocyte membrane 
(Figure 3.16) and the main focal point of this hypothetical complex would be matrix 
degradation. However, these complexes could actually influence cell signalling as 
uPAR has been shown to influence signalling in conjunction with integrins and GPCRs 
(Binder et al., 2007). uPAR has also been shown to activate the JAK/STAT pathways in 
a kidney epithelial tumour cell line (Koshelnick et al., 1997) and this is thought to be 
mediated by the gp130 receptor. Data from our group show that activation of the gp130 
receptor, by OSM or IL-6 (in the presence of soluble IL-6 receptor), in cartilage can 
synergise with IL-1 and promote cartilage matrix degradation (Rowan et al., 2001). This 
suggests that FAPα may act more as a scaffold rather than a protease in terms of 
cartilage degradation. 
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Figure 3.16 Model of a putative FAPα super-complex on the chondrocyte cell 
surface 
FAPα forms complexes with uPAR (Artym et al., 2002) and through this binding comes 
into close proximity with α3β1 integrin (Zhang et al., 2003). This close association is 
likely to allow FAPα to associate with ECM proteins (Takada et al., 2007). MMP-2 has 
been shown to be closely associated with FAPα at the invadopodia of melanoma cells 
and MMP-14 is also postulated to be located there (Monsky et al., 1994). 
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3.4 Conclusion 
Milner et al. (2006b) previously reported that FAPα gene expression was increased in 
OA cartilage and correlated with collagen release in IL-1+OSM-treated BNC. The 
correlation of FAPα expression and collagen release suggested that FAPα had a 
catabolic role in cartilage matrix homeostasis. However, FAPα specific inhibitors have 
not corroborated this hypothesis as there is no change in collagen release observed with 
any of the inhibitors used (section 3.2.3). In fact, all the inhibitors, except Z-GP-DPi, 
utilised in this chapter were only able to inhibit either the endopeptidase activity or 
exopeptidase activity of FAPα, but not both. 
The cleavage of denatured type II collagen by FAPα does suggest that FAPα has a 
catabolic role in the degradation of the cartilage matrix (section 3.2.2). However, there 
is evidence for an anabolic role of FAPα as it has similar dipeptidyl peptidase activity as 
DPPIV. DPPIV cleavage of chemokines has been shown to decrease the inflammatory 
response (Table 1.2) and FAPα is likely to cleave the same chemokines, although this 
has yet to be confirmed. Taken together, the up-regulation of FAPα in OA is likely to 
have an anabolic effect with the cleavage of chemokines to dampen the inflammatory 
response and ultimately decrease MMP levels. Whilst the cleavage of denatured type II 
collagen is a catabolic process, this could be occurring to stimulate remodelling and 
repair of the surrounding matrix. As β1 integrin signalling has been shown to occur at 
the invadopodia of LOX cells (Nakahara et al., 1998), and this it has been previously 
shown that this is where FAPα localises to (Monsky et al., 1994). 
3.5 Summary 
 FAPα gene expression is not regulated by IL-1, OSM or TGF-β1 in primary 
chondrocytes. 
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 FAPα is able to cleave denatured type II collagen. 
 FAPα inhibitors targeting enzyme activity do not alter cartilage matrix 
degradation in the presence of IL-1+OSM. 
 Exogenous active FAPα does not expedite collagen breakdown from IL-
1+OSM-treated bovine cartilage. 
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CHAPTER 4 
Studying the role of DPPIV in cartilage homeostasis 
4.1 Introduction 
Recently, DPPIV (section 1.8.1) expression was found to be significantly increased in 
OA compared to normal cartilage (Figure 3.1) (Swingler et al., 2009). This corroborates 
an earlier finding that DPPIV is expressed on the surface of OA chondrocytes (Lapadula 
et al., 1995) and expression is decreased in areas where there is progressive worsening 
of the osteoarthritic lesions. Collagen-induced arthritis (CIA) in DPPIV
-/-
 mice was 
found to be more severe than in wild-type DPPIV
+/+
 mice (Busso et al., 2005). This 
down-regulation of DPPIV expression has important consequences on the joint 
environment as DPPIV is known to modulate the function of a number of inflammatory 
cytokines and chemokines (Table 1.2).  
Inhibition of DPPIV activity decreases pathogenesis in a CIA model (Tanaka et al., 
1997). At first these data appear to be contradictory to substrate data for DPPIV stated 
above, as DPPIV activity on inflammatory chemokines and neuropeptides modulates 
their function to cause a decrease in immune cell function and localisation to the joint 
space. However, data have shown that DPPIV inhibitors play a role in the up-regulation 
of TGF-β1 secretion (Reinhold et al., 2006) and this would lead to a decrease in T cell 
activity due to its immunosuppressive and chondroprotective (section 1.3.3) functions. 
As stated above DPPIV is involved in a number of immune cell functions and this 
inhibition could prevent a number of different pathways within the immune system that 
could cause this anti-arthritic effect. 
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In RA, DPPIV activity is shown to decrease in both the synovial membrane and fluid of 
patients (Gotoh et al., 1989, Kamori et al., 1991). Furthermore, there is a decrease in the 
serum levels of DPPIV that is inversely proportional to the degree of inflammation 
experienced in the joint (Busso et al., 2005), although recent data also show that DPPIV 
activity is actually higher in RA synovium compared to OA (Solau-Gervais et al., 
2007). However, the authors used homogenised synovium extracts to test for DPPIV 
activity and as a large number of T cells are shown to infiltrate the tissue in RA (section 
1.2.1), this finding is not unexpected as T cells are known to express high levels of 
DPPIV (Sedo et al., 2005).  
While previous data show that DPPIV levels decrease inversely to disease progression, 
but there are little data as to the role of DPPIV in cartilage. Therefore, the aim of this 
chapter was to elucidate the function DPPIV enzymatic activity plays in cytokine 
treated bovine cartilage.  
The aims of this chapter were to: 
 determine if DPPIV gene expression is regulated by IL-1 and/or OSM in 
primary chondrocytes; 
 investigate if DPPIV enzyme activity has a role in the breakdown of the collagen 
matrix in IL-1+OSM treated cartilage using inhibitors designed to target DPPIV; 
 examine if DPPIV possesses type II collagenolytic or gelatinolytic activity; 
 assess if addition of active DPPIV to IL-1+OSM-treated bovine cartilage would 
affect cartilage breakdown. 
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4.2 Results 
4.2.1 Regulation of DPPIV gene expression in SW1353 cells and primary 
chondrocytes 
DPPIV has been shown to be expressed on OA chondrocytes and expression is 
decreased in areas where there is progressive worsening of the osteoarthritic lesions 
(Lapadula et al., 1995). DPPIV knock-out mice with CIA have increased disease 
severity compared to wild-type mice (Busso et al., 2005). 
In SW1353 cells, stimulation with IL-1 and/or OSM caused an increase in DPPIV gene 
expression, and treatment with TGF-β1 in the presence of these pro-inflammatory 
cytokines significantly decreased DPPIV gene expression (Figure 4.1). However, 
SW1353 chondrosarcoma cells have limited potential as a model for chondrocyte gene 
expression, as mentioned previously (section 3.2.1). Therefore, the regulation of DPPIV 
gene expression was investigated in primary bovine chondrocytes to see if the result 
from SW1353 cells could be corroborated. 
MMP-1 gene expression was tested in SW1353 and primary cells (data not shown) and 
synergistic induction upon IL-1+OSM stimulation was observed as previously shown 
(Barksby et al., 2006). However, DPPIV gene expression in bovine chondrocytes was 
considerably varied between populations (Figure 4.2). While, one population of bovine 
chondrocytes showed similar DPPIV gene expression upon pro-inflammatory 
stimulation (Figure 4.2a), however the other population showed little difference (Figure 
4.2b). The effect of TGF-β1 alone on DPPIV gene expression showed a similar 
variation between the different populations, as one population showed a decrease 
comparable to SW1353 cells (Figure 4.2b) but the other an increase (Figure 4.2a). 
Therefore, the results seen with SW1353 cells were not reproducible in primary bovine 
chondrocyte cultures and highlight the differences between SW1353 and primary cells.   
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Figure 4.1 The regulation of DPPIV gene expression in SW1353 chondrocyte cell 
line.  
SW1353 cells were treated with combinations of IL-1 (1 ng/ml) and OSM (10 ng/ml) ± 
TGF-β1 (10 ng/ml) for 24 h. Total RNA was extracted and DPPIV gene expression 
determined by real-time PCR and normalised to 18S rRNA levels. The data from two 
representative experiments are shown and presented as fold induction relative to control. 
Results are expressed as mean ± SEM (n=5). ** = p < 0.01 
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Figure 4.2 The regulation of DPPIV gene expression in primary chondrocytes. 
Bovine chondrocyte cells were treated with combinations of IL-1 (1 ng/ml) and OSM 
(10 ng/ml) ± TGF-β1 (10 ng/ml) for 24 h. Total RNA was extracted and DPPIV gene 
expression determined by real-time PCR and normalised to 18S rRNA levels. The data 
from two representative experiments are shown and presented as fold induction relative 
to control. Results are expressed as mean ± SEM (n=5). *** = p < 0.001. 
  
0
100
200
300
400
500
600
700
800
900
1000
F
o
ld
 I
n
d
u
ct
io
n
 
-TGF-β1 
+TGF-β1 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
F
o
ld
 i
n
d
u
ct
io
n
 
-TGF-β1 
+TGF-β1 
*** 
* 
IL-1 
OSM 
 
-           -            +           +  
 
-           +            -           +  
*** 
 
*** 
 
B 
A 
112  
 
4.2.2 The effect of DPPIV inhibitors on resorbing cartilage explants 
To determine if DPPIV activity plays a role in cartilage matrix resorption, DPPIV 
inhibitors were added to IL-1+OSM-treated bovine cartilage and collagen release was 
measured. DPPIV inhibitors are now widely used in the clinic to treat type II diabetes 
and indicate that patients show good tolerance to all these compounds (Yazbeck et al., 
2009 and references therein). However, there are no data highlighting the impact that 
DPPIV inhibitors would play in resorbing cartilage. 
 
4.2.2.1 Collagen release upon addition of FE999011 to resorbing cartilage 
In the experiment shown (Figure 4.3), cartilage treated with IL-1+OSM yielded 79.16 ± 
8.86% collagen release. The addition of DMSO did decrease collagen release in this 
experiment, but this result is not reproducible between different cartilages (Prof. A. D. 
Rowan, personal communication). Addition of FE999011 over a range of 
concentrations resulted in no significant change in collagen release. 
Recombinant human DPPIV was used to test if FE999011 had potential to inhibit the 
enzymatic activity in vitro. FE999011 showed a strong ability to inhibit activity (Figure 
4.4) and therefore shows that the compound was still active when added to the cartilage 
explants. Furthermore, FE999011 showed no cross-reactivity to inhibit the enzymatic 
activity of recombinant FAPα in vitro (Figure 4.5). 
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Figure 4.3 Effect of FE999011 on cartilage breakdown. 
Bovine cartilage discs were cultured in medium ± IL-1+OSM (1 ng/ml and 10 ng/ml, 
respectively) ± FE999011 or DMSO control. Media were removed on day 7 and fresh 
reagents were added until day 14 when the experiment was ceased. As a measure of 
collagen release, the levels of hydroxyproline were assayed in day 7 and day 14 media 
and in cartilage digests. Shown is the cumulative collagen release (day 7 + day 14), 
expressed as a percentage of the total collagen. Results are expressed as mean ± SD 
(n=4) and representative of 3 separate experiments. * = p < 0.05. 
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Figure 4.4 Effect of FE999011 on the activity of DPPIV 
DPPIV activity was determined using the quenched fluorescent substrate, GP-AMC. 
DPPIV (50 pM) with either FE999011 or DMSO as a solvent control were incubated in 
assay buffer for 30 mins at 37°C. Substrate (50 µM) was then added and left for 1 h at 
37°C. Fluorescence was then measured immediately (λex 360 nm, λem 460 nm). The 
percentage activity was calculated. Results are expressed as mean ± SD (n=3) and 
representative of 2 separate experiments. *** = p < 0.001 against DMSO. 
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Figure 4.5 Effect of FE999011 on the enzymatic activity of FAPα 
FAPα activity was determined using the quenched fluorescent substrate, A) Z-GP-AMC 
or B) GP-AMC. FAPα (120 pM) with either FE999011 (10 µM) or DMSO as a solvent 
control were incubated in assay buffer for 30 min at 37°C. Substrate (50 µM) was then 
added and left for 4 h at 37°C. Fluorescence was then measured immediately (λex 360 
nm, λem 460 nm). The A) endopeptidase or B) exopeptidase activity was calculated. 
Results are expressed as mean ± SD (n=3) and representative of 2 separate experiments.  
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4.2.2.2 Collagen release upon addition of diphenylphosphonate inhibitors to 
resorbing cartilage 
In the experiment shown (Figure 4.6), cartilage treated with IL-1+OSM and DMSO 
yielded 69.77 ± 7.73% collagen release. The addition of 150 µM YP-DPi yielded 74.18 
± 4.25% collagen release and 150 µM GP-DPi yielded 58.38 ± 10.37% collagen release. 
The data show that there was no statistically significant change in collagen release when 
resorbing cartilage was treated with either YP-DPi or GP-DPi. Recombinant DPPIV 
was used to test whether GP-DPi or YP-DPi displayed any inhibitory action in vitro 
(Figure 4.7 and Figure 4.8, respectively). The data show that both inhibitors displayed a 
strong ability to inhibit DPPIV in vitro. 
It has been previously reported that dipeptide diphenylphosphonate inhibitors exhibit 
short half-lives at 37°C (Lambeir et al., 1996). The results show that both inhibitors lost 
approximately 20 - 30% of their inhibitory potential by 48 h (Figure 4.9). Therefore, if 
DPPIV activity is associated with cartilage collagen breakdown then the addition of the 
inhibitors would need to be added at a time point preceding and during pro-MMP 
activation. The activation of pro-collagenases in the bovine cartilage explants model is 
thought to occur around days 10 to 12 (Milner et al., 2006a). Addition of either inhibitor 
between days 8 to 12 inclusive showed no change in collagen release (Figure 4.10). 
Neither GP-DPi nor YP-DPi showed cross-reactivity to inhibit the enzymatic activity of 
recombinant FAPα in vitro (Figure 4.11). 
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Figure 4.6 Effect of diphenylphosphonate inhibitors on cartilage breakdown.  
Bovine cartilage discs were cultured in medium ± IL-1+OSM (1 ng/ml and 10 ng/ml, 
respectively) ± DPi (150 µM) or DMSO control. Media were removed on day 7 and 
fresh reagents were added until day 14 when the experiment was ceased. As a measure 
of collagen release, the levels of hydroxyproline were assayed in day 7 and day 14 
media and in cartilage digests. Shown is the cumulative collagen release (days 7 + day 
14) expressed as percentage of the total collagen. Results are expressed as mean ± SD 
(n=4) and representative of 3 separate experiments. 
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Figure 4.7 Inhibition of DPPIV activity by GP-DPi 
DPPIV activity was determined using the quenched fluorescent substrate, GP-AMC. 
DPPIV (50 pM) ± GP-DPi were incubated in assay buffer for 30 min at 37°C. Substrate 
(50 µM) was then added and left for 1 h at 37°C. Fluorescence was then measured 
immediately (λex 360 nm, λem 460 nm). The percentage activity was calculated. Results 
are expressed as mean ± SD (n=3) and representative of 2 separate experiments. *** = p 
< 0.001 against DMSO. 
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Figure 4.8 Inhibition of DPPIV activity by YP-DPi 
DPPIV activity was determined using a quenched fluorescent substrate, GP-AMC. 
DPPIV (50 pM) ± YP-DPi were incubated in assay buffer for 30 mins at 37°C. 
Substrate (50 µM) was then added and left for 1 h at 37°C. Fluorescence was then 
measured immediately (λex 360 nm, λem 460 nm). The percentage activity was 
calculated. Results are expressed as mean ± SD (n=3) and representative of 2 separate 
experiments. *** = p < 0.001 against DMSO. 
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Figure 4.9 Time course to measure the stability of diphenylphosphonates at 37°C 
0.1 µM GP-DPi (     ) and 1 µM YP-DPi (     ) were incubated in PBS at 37°C for 4, 24 
and 48 h time points. The inhibitory activity against DPPIV function was determined 
using a quenched fluorescent substrate, GP-AMC. DPPIV (50 pM) with either GP-DPi 
or YP-DPi were incubated in assay buffer for 30 min at 37°C. Substrate (50 µM) was 
then added to each well and left for 1 h at 37°C. Fluorescence was then measured 
immediately (λex 360 nm, λem 460 nm). The percentage activity was calculated. Results 
are expressed as mean ± SD (n=3). 
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Figure 4.10 Multiple additions of diphenylphosphonate inhibitors to cartilage show 
no protective effect 
Bovine cartilage discs were cultured in medium ± IL-1+OSM (1 ng/ml and 10 ng/ml, 
respectively) ± GP-DPi or YP-DPi or DMSO control. Media were removed on day 7 
and fresh reagents were added. Either GP-DPi or YP-DPi (150 µM final concentration) 
were added to the cartilage between days 8 to 12 (inclusive). The experiment was 
ceased at day 14. As a measure of collagen release, the levels of hydroxyproline were 
assayed in day 7 and day 14 media and in cartilage digests. Shown is the cumulative 
collagen release (days 7 + day 14), expressed as a percentage of the total collagen. 
Results are expressed as mean ± SD (n=4) and representative of 4 separate experiments. 
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Figure 4.11 Effect of diphenylphosphonate inhibitors on the activity of FAPα.  
FAPα activity was determined using the quenched fluorescent substrate, A) Z-GP-AMC 
or B) GP-AMC. FAPα (120 pM) ± DPi (150 µM) or DMSO as a solvent control were 
incubated in assay buffer for 30 min at 37°C. Substrate (50 µM) was then added and left 
for 4 h at 37°C. Fluorescence was then measured immediately (λex 360 nm, λem 460 
nm). The percentage activity was calculated. Results are expressed as mean ± SD (n=3) 
and representative of 2 separate experiments. 
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4.2.2.3 Collagen release upon addition of UAMC-374, vildagliptin and AB192 to 
resorbing cartilage 
There was no inhibition seen for any of the inhibitors tested (Figure 4.12). Recombinant 
human DPPIV was used to test if any of the inhibitors showed any potential to reduce 
the enzymatic activity of DPPIV in vitro (Figure 4.13). All of the inhibitors significantly 
decreased DPPIV activity compared to DMSO control, confirming the inhibitors were 
active when added to bovine cartilage. 
Moreover, none of the inhibitors tested showed any inhibitory affect against 
recombinant FAPα in vitro (Figure 4.14). 
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Figure 4.12 Effect of DPPIV inhibitors on cartilage breakdown.  
Bovine cartilage discs were cultured in medium ± IL-1+OSM (1 ng/ml and 10 ng/ml, 
respectively). At days 0, 3, 7 and 10, the inhibitors UAMC-374, vildagliptin and AB192 
(10 µM) or DMSO control were added to cartilage. Media were removed on day 7 and 
fresh reagents were added until day 14 when the experiment was ceased. As a measure 
of collagen release, the levels of hydroxyproline were assayed in day 7 and day 14 
media and in cartilage digests. Shown is the cumulative collagen release, expressed as a 
percentage of the total collagen. Results are expressed as mean ± SD (n=4) and 
representative of 8 separate experiments. 
 
  
0
10
20
30
40
50
60
70
80
90
100
P
er
ce
n
ta
g
e
 c
o
ll
a
g
en
 r
el
ea
se
 
IL-1+OSM 
DMSO 
UAMC-374 
Vildagliptin 
AB192 
-         +         +         +             +         +            
-         -         +         -             -         -            
 
-         -         -         +             -         -            
 
-         -         -         -             +         -            
 -         -         -         -             -         +            
 
125  
 
 
 
 
 
 
Figure 4.13 Modulation of DPPIV activity by DPPIV inhibitors 
DPPIV activity was determined using a quenched fluorescent substrate, GP-AMC. 
DPPIV (50 pM) with DPPIV inhibitors (10 µM) or DMSO as a solvent control were 
incubated in assay buffer for 30 min at 37°C. Substrate (50 µM) was then added to each 
well and left for 1 h at 37°C. Fluorescence was then measured immediately (λex 360 nm, 
λem 460 nm). The percentage activity was calculated. Results are expressed as mean ± 
SD (n=3) and representative of 2 separate experiments. *** = p < 0.001 against DMSO 
control. 
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Figure 4.14 Effect of DPPIV inhibitors on the activity of FAPα.  
FAPα activity was determined using the quenched fluorescent substrate, A) Z-GP-AMC 
or B) GP-AMC. FAPα (120 pM) with either DPPIV inhibitors (10 µM) or DMSO as a 
solvent control were incubated in assay buffer for 30 min at 37°C. Substrate (50 µM) 
was then added and left for 4 h at 37°C. Fluorescence was then measured immediately 
(λex 360 nm, λem 460 nm). The A) endopeptidase or B) exopeptidase activities were 
calculated. Results are expressed as mean ± SD (n=3) and are representative of 2 
separate experiments. 
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4.2.2.4 Collagen release upon addition of DPPI 1c to resorbing cartilage 
In the experiment shown (Figure 4.15), cartilage treated with IL-1+OSM yielded 79.16 
± 8.86% collagen release. The addition of a range of DPPI 1c concentrations did not 
affect cartilage matrix degradation after stimulation with IL-1+OSM.  
Recombinant human DPPIV was used to test if the inhibitor had potential to reduce the 
enzymatic activity of DPPIV in vitro (Figure 4.16). The inhibitor significantly 
decreased DPPIV activity compared to control, confirming that the inhibitor was active 
when added to bovine cartilage. The lack of any biological effect ex vivo in bovine 
cartilage led to the discontinuation of the use of DPPI 1c. DPP 1c did not inhibit 
recombinant FAPα activity in vitro (Figure 4.17). 
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Figure 4.15 Effect of DPPI 1c inhibitor on cartilage breakdown.  
Bovine cartilage discs were cultured in medium ± IL-1+OSM (1 ng/ml and 10 ng/ml, 
respectively) ± DPPI 1c. Media were removed on day 7 and fresh reagents added until 
day 14 when the experiment was ceased. As a measure of collagen release, the levels of 
hydroxyproline were assayed in day 7 and day 14 media and in cartilage digests. Shown 
is the cumulative collagen release, expressed as a percentage of the total collagen. 
Results are expressed as mean ± SD (n=4) and representative of 6 separate experiments. 
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Figure 4.16 Effect of DPPI 1c on the activity of DPPIV.  
DPPIV activity was determined using a quenched fluorescent substrate, GP-AMC. 
DPPIV (50 pM) ± DPPI 1c were incubated in assay buffer for 30 min at 37°C. Substrate 
(50 µM) was then added and left for 1 h at 37°C. Fluorescence was then measured 
immediately (λex 360 nm, λem 460 nm). The percentage activity was calculated. Results 
are expressed as mean ± SD (n=3) and representative of 3 separate experiments. *** = p 
< 0.001 against control. 
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Figure 4.17 Effect of DPPI 1c on the activity of FAPα.  
FAPα activity was determined using the quenched fluorescent substrate, A) Z-GP-AMC 
or B) GP-AMC. FAPα (120 pM) ± DPPI 1c (10 µM) were incubated in assay buffer for 
30 min at 37°C. Substrate (50 µM) was then added and left for 4 h at 37°C. 
Fluorescence was then measured immediately (λex 360 nm, λem 460 nm). The A) 
endopeptidase or B) exopeptidase activities were calculated. Results are expressed as 
mean ± SD (n=3) and are representative of 2 separate experiments. 
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4.2.2.5 Collagen release upon addition of K579 to resorbing cartilage 
The addition of K579 significantly reduced cartilage matrix degradation after 
stimulation with IL-1+OSM, resulting in almost complete protection of the cartilage 
matrix (Figure 4.18). 
Bovine cartilage treated with IL-1+OSM showed a significant increase in total 
collagenase levels at day 7 but no detectable increase in active collagenase levels 
(Figure 4.19a). The addition of K579 up to day 7 caused a significant decrease in total 
collagenase levels. There was a similar trend at day 14, as the addition of IL-1+OSM 
led to a significant increase in both total and active collagenase levels compared to 
control (Figure 4.19b). Again, the addition of K579 caused a significant decrease in 
total collagenase levels, and a significant decrease in active collagenase levels could be 
observed at day 14. Previous data have shown that inhibition of serine proteases leads to 
a significant decrease in collagenase levels (Milner et al., 2003). However, the 
mechanism behind this global reduction of collagenase levels has yet to be elucidated. 
Recombinant human DPPIV was used to test the potential of the inhibitor K579 to 
reduce the enzymatic activity of DPPIV in vitro (Figure 4.20). The inhibitor 
significantly decreased DPPIV activity over a range of concentrations compared to 
control. Even at concentrations as low as 50 nM, K579 reduced activity by 70%. K579 
showed no inhibition of recombinant FAPα activity in vitro (Figure 4.21). 
K579 is a nitrile based inhibitor (Prof. B. Walker, Queen’s University Belfast, UK, 
personal communication) and could potentially inhibit cathepsin K, a novel cysteine 
protease with collagenase activity (Dejica et al., 2008, Kafienah et al., 1998). L-873724 
is a selective cathepsin K inhibitor that has an IC50 in the sub-nanomolar range (Li et al., 
2006) and was added to IL-1+OSM-treated bovine cartilage. In the experiment shown, 
cartilage treated with IL-1+OSM yielded 81.56 ± 3.88% release at day 14. The addition 
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of L-873724 did not affect cartilage matrix degradation after stimulation with IL-
1+OSM (Figure 4.22) and in vitro assays using K579 showed no efficacy against 
cathepsin K (Prof. J. Mort, McGill University, Québec, Canada, personal 
communication). 
 
 
 
 
 
Figure 4.18 Effect of K579 inhibitor on cartilage breakdown.  
Bovine cartilage discs were cultured in medium ± IL-1+OSM (1 ng/ml and 10 ng/ml, 
respectively). At days 0, 3, 7 and 10, K579 (5 µM) or DMSO control were added to 
cartilage. Media were removed on day 7 and fresh reagents added until day 14 when the 
experiment was ceased. As a measure of collagen release, the levels of hydroxyproline 
were assayed in day 7 and day 14 media and in cartilage digests. Shown is the 
cumulative collagen release, expressed as a percentage of the total collagen. Results are 
expressed as mean ± SD (n=4) and representative of 6 separate experiments. *** = p < 
0.001 against untreated and ### = p < 0.001 against IL-1+OSM-treated cartilage. 
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Figure 4.19 The effect of K579 on collagenase activity from resorbing cartilage.  
Media from cartilage shown in Figure 4.18 were assayed for collagenase activity. Media 
were treated with APMA to test for total collagenase levels (pro- and active). A) Active 
and total collagenase activity for day 7 media and B) active and total collagenase 
activity for day 14 media. Results are expressed as mean ± SD (n=4) and representative 
of 2 separate experiments. *** = p < 0.001 against IL-1+OSM. 
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Figure 4.20 Effect of K579 on the activity of DPPIV.  
DPPIV activity was determined using the quenched fluorescent substrate, GP-AMC. 
DPPIV (50 pM) ± K579 (IC50 = 8 nM) or DMSO as a solvent control were incubated in 
assay buffer for 30 min at 37°C. Substrate (50 µM) was then added to each well and left 
for 1 h at 37°C. Fluorescence was then measured immediately (λex 360 nm, λem 460 
nm). The percentage activity was calculated. Results are expressed as mean ± SD (n=3) 
and representative of 2 separate experiments. *** = p < 0.001 against control. 
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Figure 4.21 Effect of K579 on the activity of FAPα.  
FAPα activity was determined using the quenched fluorescent substrate, A) Z-GP-AMC 
or B) GP-AMC. FAPα (120 pM) with either K579 (10 µM) or DMSO as a solvent 
control were incubated in assay buffer for 30 min at 37°C. Substrate (50 µM) was then 
added and left for 4 h at 37°C. Fluorescence was then measured immediately (λex 360 
nm, λem 460 nm). The A) endopeptidase or B) exopeptidase activities were calculated. 
Results are expressed as mean ± SD (n=3) and are representative of 2 separate 
experiments. 
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Figure 4.22 The effect of L-873724 on collagenase activity from resorbing bovine 
cartilage.  
Bovine cartilage discs were cultured in medium ± IL-1+OSM (1 ng/ml and 10 ng/ml, 
respectively). At days 0, 3, 7 and 10, L-873724 (10 nM) or DMSO control were added 
to cartilage. Media were removed on day 7 and fresh reagents added until day 14 when 
the experiment was ceased. As a measure of collagen release, the levels of 
hydroxyproline were assayed in day 14 media and in cartilage digests. Shown is the 
cumulative collagen release, expressed as a percentage of the total collagen. Results are 
expressed as mean ± SD (n=4) and representative of 2 separate experiments. 
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4.2.3 Effect of DPPIV on IL-1+OSM-treated cartilage explant culture 
The addition of K579 to IL-1+OSM-treated bovine cartilage showed a significant 
reduction in collagen release (Figure 4.18). Therefore, if DPPIV activity is playing a 
role in cartilage collagen breakdown, then does the addition of active DPPIV expedite 
collagen release for IL-1+OSM-treated cartilage? 
There was no increase in collagen release with the addition of active DPPIV to IL-
1+OSM-treated cartilage compared to IL-1+OSM alone (Figure 4.23).  
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Figure 4.23 Effect of active DPPIV on cartilage breakdown 
Bovine cartilage discs were cultured in medium ± IL-1+OSM (1 ng/ml and 10 ng/ml, 
respectively). Media were removed on day 7 and fresh media ± DPPIV (100 nM) were 
added until day 12 when the experiment was ceased. As a measure of collagen release, 
the levels of hydroxyproline were assayed in day 7 and day 12 media and in cartilage 
digests. Shown is the cumulative collagen release (days 7 + day 12) expressed as a 
percentage of the total collagen. Results are expressed as mean ± SD (n=6) and 
representative of 4 separate experiments. 
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4.2.4 Effect of DPPIV enzyme activity on type II collagen 
The addition of K579 to IL-1+OSM-treated bovine cartilage prevented collagen release 
(Figure 4.18). However, the addition of DPPIV to IL-1+OSM-treated cartilage failed to 
significantly increase collagen release (Figure 4.23).  
The hypothesis being tested in this experiment was whether DPPIV could degrade type 
II collagen. There are conflicting reports in the literature that claim DPPIV possesses 
gelatinase activity (Bermpohl et al., 1998), while other data suggest that DPPIV does 
not possess endopeptidase activity (Aertgeerts et al., 2005).  
Type II collagen was extracted from OA cartilage. To ensure that the type II collagen 
had retained its native triple helical state during the extraction, it was treated with 
trypsin, which confirmed that it still retained the native triple helical conformation: 
trypsin could not cleave the native collagen band but did hydrolyse the denatured 
collagen (Figure 4.24, lanes 4 and 5). In the experiment shown, DPPIV was not able to 
cleave native or denatured collagen (Figure 4.24, lanes 7 and 8). This confirms previous 
data that DPPIV does not have any gelatinase or endopeptidase activity (Aertgeerts et 
al., 2005). 
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Figure 4.24 Proteolysis of type II collagen by DPPIV. 
Type II collagen (10 μg) from human articular cartilage was incubated at 37°C for 24 h 
in the presence or absence of proteases in 50 mM Tris-HCl, pH 7.6, 1 M glucose, 200 
mM NaCl, 5 mM CaCl2 buffer. Lane: (1) Native collagen (N); (2) Denatured collagen 
(D); (3) 4 µM trypsin; (4) Native collagen, 0.4 µM trypsin; (5) Denatured collagen, 0.4 
µM trypsin; (6) 0.1 µM DPPIV; (7) Native collagen, 0.4 µM DPPIV; (8) Denatured 
collagen, 0.4 µM DPPIV. Digests were reduced and analysed by 6.5 % SDS–PAGE. 
The closed arrow indicates the position of the intact α(II) chain of type II collagen. The 
open arrow indicates the position of DPPIV. The patterned arrows indicate the presence 
of unknown low molecular weight contaminants. Results are representative of 2 
separate experiments. 
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4.3 Discussion 
4.3.1 IL-1+OSM do not regulate DPPIV gene expression in primary chondrocytes  
DPPIV gene expression has previously been reported to be increased in human OA 
cartilage compared to phenotypically normal cartilage (Swingler et al., 2009). As 
described in this chapter, DPPIV gene expression was increased in SW1353 
chondrosarcoma cells by the addition of IL-1 and/or OSM compared to un-treated cells 
but the increase upon stimulation with IL-1+OSM was less than that seen with either 
cytokine alone. When TGF-β1, with or without pro-inflammatory cytokines, was added 
to SW1353 cells, a decrease in the expression of DPPIV could be observed. However, 
Gebauer et al. (2005) showed that SW1353 chondrosarcoma cells have limited potential 
as a model of primary chondrocyte gene expression. Therefore, primary chondrocytes 
from bovine cartilage were treated with combinations of IL-1, OSM and TGF-β1 and 
DPPIV gene expression was determined. The results differed between the two different 
populations of cells and this indicates that DPPIV gene expression is not robustly 
regulated by IL-1 or OSM or TGF-β1 in primary cells. Attempts to examine the 
expression of DPPIV in IL-1+OSM-treated bovine cartilage have failed. Primers that 
work when used with RNA isolated from chondrocytes grown in monolayer; fail to 
work with RNA isolated directly from bovine cartilage. Commercially available primers 
(PrimerDesign PerfectProbe assays) have also failed to amplify DPPIV transcripts from 
bovine cartilage mRNA but do show amplification from bovine chondrocyte mRNA. 
This could be due to contamination being carried over from RNA isolation that 
interferes with detection of the DPPIV transcript. 
The promoter sequence of DPPIV has only been characterised in porcine cells and 
shows no consensus TATA-box sequence but two TATA-like sequences (Qvist et al., 
1998) and indicates that the transcription factors that initiate DPPIV gene expression 
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have yet to be elucidated. However, recent data suggest that promoter methylation plays 
an important role in regulating DPPIV gene expression in a number of different 
carcinomas (Tsuji et al., 2004, McGuinness and Wesley, 2008). Data presented in this 
chapter show that DPPIV is not regulated directly by IL-1, OSM or TGF-β1. Therefore, 
there is the possibility that the DPPIV promoter is methylated in normal chondrocytes 
and the degradation of the ECM releases cryptic peptide fragments that bind to Toll-like 
receptors. This can lead to activation of intracellular pathways (Zhang et al., 2008) that 
result in the demethylation of the DPPIV promoter resulting in the increased gene 
expression in OA (Swingler et al., 2009). 
4.3.2 Inhibition of DPPIV enzyme activity shows varied results 
The inhibition of DPPIV enzyme activity in resorbing bovine cartilage shows mixed 
results with only K579 showing any inhibitory activity when added to resorbing 
cartilage. While the other inhibitors all show significant DPPIV inhibition in vitro, there 
is no statistically significant effect on collagen release when they are added to IL-
1+OSM-treated bovine cartilage. An underlying issue could be that while the inhibitors 
show good in vitro inhibition, they cannot penetrate the cartilage matrix possibly due to 
binding to GAG or matrix proteins. Indeed, such a finding has previously been reported 
for MMP inhibitors (Janusz et al., 2006). 
Recently, there has been a large increase in the number of DPPIV inhibitors that have 
been approved for clinical use to treat type II diabetes (Lankas et al., 2005). In this 
study, the authors highlighted that vildagliptin, in addition to standard treatments, 
stabilised glycaemic control in type II diabetes treatment compared to traditional 
treatments alone. Vildagliptin has now been approved for clinical treatment of type II 
diabetes in Europe (Yazbeck et al., 2009) and a recent meta-analyses study has shown 
that DPPIV inhibitors are well tolerated by patients (Ligueros-Saylan et al., 2010). 
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Vildagliptin is reported to be a slow binding inhibitor of DPPIV with a low Ki (Hughes 
et al., 1999). However, vildagliptin showed no efficacy in preventing collage release 
from IL-1+OSM-treated cartilage, but K579 treatment did show significantly reduced 
collagen release. The DPPIV inhibitor K579 has a similar structure to vildagliptin 
(Takasaki et al., 2004) but displays better inhibitory constants as K579 forms longer 
lasting complexes with DPPIV.  
The in vivo efficacy of DPPIV inhibitors is greatly increased when supplied 
intravenously (De Meester et al., 1997), implying that the available inhibitor 
concentration at the target tissue is important. Therefore, if the other reversible 
inhibitors tested in this chapter, such as vildagliptin and UAMC-374, form short-lived 
complexes then their available concentration would a deciding factor for their potency 
in cartilage at physiological temperature. Brandt et al. (2005) showed incubating DPPIV 
with increasing concentration of vildagliptin showed an increase in the half-life of GLP-
1 and other DPPIV substrates. Therefore, if the inhibitor cannot penetrate the cartilage 
matrix, this would decrease the concentration of available inhibitor near the cell 
membrane. Additionally, if the inhibitor only forms short-lived complexes, the half-life 
of DPPIV substrates would be decreased to levels similar to uninhibited DPPIV half-
lives. Taken together this means that cartilage in the presence of an inhibitor that better 
penetrates the matrix and forms longer-lasting complexes, such as K579, could elicit 
different responses to inhibitors that cannot do either, possibly like vildagliptin.  
Therefore, K579 may affect the half-life of an unknown substrate and results in the 
protection of the cartilage matrix. But the other reversible inhibitors used in this study 
do not affect the half-life and therefore seem to have no effect in IL-1+OSM-treated 
cartilage. 
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K579 was shown to cause a decrease in pro- MMP levels seen, and this can be 
explained by a previous study showing that DPPIV inhibitors increase TGF-β1 
production (Reinhold et al., 2006). One possible mechanism for the increased TGF-β1 
production could be that DPPIV inhibitors could cause a conformational change and 
disrupt or prevent DPPIV binding to other cell surface proteins. Ishii et al. (2001) have 
shown that DPPIV co-localises with CD45 at lipid rafts and leads to the activation of 
ZAP70. Therefore, disruption of DPPIV-protein binding could elicit different responses, 
one consequence of this leading to increased TGF-β1 secretion. This phenomenon is 
likely to require DPPIV to still be bound to the membrane, as the addition of soluble 
DPPIV to IL-1+OSM-treated bovine cartilage did not show any increase in collagen 
release. 
In addition to this signalling role, DPPIV could form a “super-complex” on the surface 
of the chondrocyte in a similar fashion to FAPα (section 3.3.3) (Figure 4.25). FAPα has 
been shown to localise with a number of molecules, such as MMP-2, MMP-14, uPAR 
and integrins (Monsky et al., 1994). Ghersi et al. (2002) highlighted that DPPIV and 
FAPα dimers associate to form a complex on the invadopodia of WI-38 lung fibroblasts 
as they migrate over a collagen matrix. Additionally, DPPIV has 52% sequence 
homology to FAPα (Goldstein et al., 1997) with a similar β-propeller domain fold 
(Aertgeerts et al., 2004). Therefore, it is possible that DPPIV could be in close 
proximity to the same proteins which in turn associate with other membrane proteins, 
such as uPAR binding the gp130 receptor (Koshelnick et al., 1997). However, there are 
data to suggest that DPPIV binds to other proteins not reported to bind FAPα. 
Plasminogen binds to DPPIV and promotes an invasive phenotype in prostrate 
carcinoma cells (Gonzalez-Gronow et al. 2005a, b) , and DPPIV has also been shown to 
bind collagen through a cysteine-rich region located in the β-propeller domain (Hanski 
et al., 1988, Loster et al., 1995). In particular, the binding of collagen by DPPIV is 
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important as it would increase the rate of collagen turnover in the proximity of this 
complex. 
 
 
Figure 4.25 Model of a putative DPPIV “super-complex” on the chondrocyte cell 
surface 
DPPIV has been shown to bind collagen (Hanski et al., 1988) and associate with FAPα 
to form a tetramer on the surface of melanoma cells (Ghersi et al., 2002). This would 
bring the membrane in close proximity to the collagen network. FAPα localises with 
α3β1 integrin (Zhang et al., 2003) and this is likely to increase association to the 
collagen network (Takada et al., 2007). Localisation of MMP-2 and MMP-14 (Monsky 
et al., 1994) as well as uPAR (Artym et al., 2002) to this area increases the rate of ECM 
proteolysis. 
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Through the mechanisms highlighted above, it does not seem likely that DPPIV plays 
any direct role on the proteolysis of matrix proteins. Rather, DPPIV acts either as a 
scaffold to localise catabolic factors to sites of tissue remodelling or facilitates the 
degradation of de novo fragments produced after the action of MMPs or other serine 
proteases. It is unlikely that DPPIV can degrade larger peptides or proteins as Asp-663 
in the active site of DPPIV causes deprotonation of the glutamate-206 side chain that 
facilitates binding of charged amino terminal groups (Aertgeerts et al., 2005). In fact, 
larger peptides could be degraded by DPPIV only if they possess an unfolded N-
terminal region that can be stabilised by the negative charge of the glutamate side-chain. 
However, conflicting data show that DPPIV can degrade type I through to type V 
collagen with approximately 50% of the collagen degraded within 24 hours (Bermpohl 
et al., 1998). The data presented in this chapter show that DPPIV cannot cleave type II 
collagen and conform to data from Aertgeerts et al. (2005) that DPPIV does not possess 
endopeptidase activity. 
4.4 Summary 
 DPPIV gene expression is not regulated by IL-1 or OSM or TGF-β1 in primary 
chondrocytes. 
 K579 decreases cartilage matrix degradation in the presence of IL-1+OSM. 
 K579 significantly reduces total collagenase levels from IL-1+OSM-treated 
cartilage. 
 Exogenous active DPPIV does not expedite collagen breakdown from IL-
1+OSM-treated bovine cartilage. 
 DPPIV is unable to cleave denatured type II collagen. 
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CHAPTER 5 
Elucidating the role of matriptase in cartilage homeostasis 
5.1 Introduction 
Recently, matriptase (section 1.7) expression was found to be significantly increased in 
OA compared to normal cartilage (Figure 3.1). Additionally, the increase in matriptase 
gene expression was detectable at the protein level as well.   
Matriptase is a well characterised target in cancer as it can promote metastasis through a 
number of different mechanisms, such as activation of pro-hepatocyte growth factor 
(HGF) and pro-uPA (section 1.7.1.3). Furthermore, matriptase has been demonstrated to 
activate pro-MMP-3 (Jin et al., 2006), and addition of active MMP-3 to IL-1+OSM-
treated cartilage has previously shown to expedite collagenolysis (Milner et al., 2001). 
Therefore, the hypothesis was that up-regulation of matriptase would increase cartilage 
matrix degradation. 
The aim of this chapter was to: 
 determine the role matriptase plays in collagen degradation of human OA 
cartilage. 
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5.2 Results 
5.2.1 The effect of matriptase on IL-1+OSM-treated bovine cartilage 
In the experiment shown (Figure 5.1), the addition of matriptase to IL-1+OSM-treated 
cartilage significantly increased collagen release compared to IL-1+OSM-treated 
cartilage alone. The addition of matriptase alone to bovine cartilage has been shown to 
cause no collagen release (data not shown).  
  
 
 
Figure 5.1 Matriptase expedites collagen release from IL-1+OSM-treated bovine 
cartilage 
Bovine cartilage was cultured in medium ± matriptase (100 nM) ± IL-1+OSM (1 and 10 
ng/ml, respectively). Media were removed on day 7 and fresh reagents were added until 
day 12 when the experiment was ceased. As a measure of collagen release, the levels of 
hydroxyproline were assayed in day 7 and day 12 media and in cartilage digests. Shown 
is the cumulative collagen release (day 7 + day 12) expressed as a percentage of the 
total collagen. Results are expressed as mean ± SD (n=6) and representative of 4 
separate experiments. *** = p < 0.001. 
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5.2.2 Matriptase-mediated activation of pro-MMPs 
The addition of matriptase to IL-1+OSM-treated cartilage expedited collagen release 
(Figure 5.1). Milner et al. (2006a) highlighted that IL-1+OSM treatment produces a 
large quantity of pro-MMPs from day 3 but activation of these does not typically occur 
until after day 10.  
Jin et al. (2006) has reported that matriptase activates pro-MMP-3. However, there is no 
evidence reported for matriptase-activation of other pro-MMPs. The increased collagen 
release by matriptase was likely to be due to the activation of a pro-collagenase or pro-
collagenase activator, such as MMP-3. Therefore, I assessed if matriptase could directly 
activate pro-MMP-1or -13 to cause the increase in collagen release. 
 
5.2.2.1 MMP activity after incubation with matriptase  
In both experiments matriptase-activated MMP-1 showed significantly less activity than 
APMA-activated MMP-1. This indicates that matriptase does activate pro-MMP-1; 
however, the resulting MMP-1 species is less active than the one generated by APMA 
(Figure 5.2). Matriptase was not able to cleave either substrate tested in this experiment 
(data not shown). 
There was little change between APMA-activated MMP-3 and matriptase-activated 
MMP-3, when tested with FS-6 (data not shown). Matriptase was not able to activate 
pro-MMP-13 (Dr J. M. Milner, personal communication). 
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Figure 5.2 Influence of matriptase on MMP-1 activity in vitro. 
Pro-MMP-1 (1.4 µM) was incubated ± matriptase (100 nM) or ± APMA (0.67 mM) for 
4 h at 37°C. Activated MMP-1 was then incubated with either A) FS-6 (50 µM) or B) 
hide powder azure (3% w/v). The data from two separate experiments are shown and 
presented as activity relative to matriptase-activated MMP-1. Results are expressed as 
mean ± SD (n=5). *** = p < 0.001 
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5.2.2.2 Direct activation of MMPs by matriptase in vitro 
Matriptase has been previously reported to activate pro-MMP-3 (Jin et al., 2006), but the 
exact site(s) of matriptase cleavage has not been elucidated. The general metalloprotease 
inhibitor GM6001 was used to abrogate MMP activity, therefore any cleavage detected in 
the presence of GM6001 would be due to matriptase activity. In the presence of GM6001 
matriptase was found to cleave MMP-3 after arginine-37, -74 and -84 (Figure 5.3). 
Cleavage after arginine-37 and -84 by matriptase is to be expected as they are the 
consensus cleavage sites for other members of the S1 serine protease family, specifically 
plasma kallikrein and trypsin, respectively (Woessner and Nagase, 2000 and references 
therein). Cleavage after arginine-74 occurs within the cysteine switch domain. In the 
absence of GM6001, the only sequence found was that of the full-length active protease, 
starting at phenylalanine-83, indicating the presence of some active MMP in the 
preparation.  This corroborates the result seen in section 5.2.2.1 as MMP-3 auto-activation 
occurs at a faster rate than matriptase activation of MMP-3. Therefore, there would be no 
difference between APMA-activated and matriptase-activated pro-MMP-3 when tested 
with FS-6, as the fully active species would be generated in both cases. 
Matriptase only cleaved MMP-1 after arginine-72 in the presence of GM6001 (Figure 5.3); 
again showing that matriptase is able to cleave within the cysteine switch domain of 
MMPs. In the absence of GM6001, cleavage after threonine-64 and phenylalanine-81 
occurred as reported previously (Woessner and Nagase, 2000 and references therein). 
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Figure 5.3 Activation of pro-MMPs by matriptase. 
N-terminal sequence analyses were performed on MMP-1 and -3 after 1 – 4 h of incubation with matriptase. The data presented show several known 
serine protease cleavage sites (Woessner and Nagase, 2000) within the propeptide regions. The bait region is boxed whilst the cysteine switch region 
is underlined, whilst the sequence in italics represents the full-length mature MMP. Cleavage sites marked with large closed arrows are for 
matriptase (+GM6001), whilst those denoted by the large open arrows are matriptase (-GM6001). Ct = chymotrypsin; He = human neutrophil 
elastase; Pk = plasma kallikrein; Tp = trypsin. 
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5.2.3 The effect of matriptase on human OA cartilage 
The activation of pro-MMP-1 and -3 by matriptase causes increased collagen release 
from IL-1+OSM treated cartilage (Figure 5.1). Although Cawston et al. (1998) has 
shown that treatment of OA cartilage with IL-1+OSM is unable to stimulate collagen 
release, this is probably due to a lack of pro-MMP activation as there are large 
quantities of MMP-1 produced. Therefore, matriptase was added to human OA cartilage 
in explant culture in an attempt to stimulate collagen release as it would be able to 
activate pro-MMPs. 
 
5.2.3.1 The effect of matriptase on collagen release from OA cartilage  
Addition of matriptase to human OA cartilage resulted in significant collagen release at 
day 7 and day 14 (Figure 5.4).  
The addition of IL-1 and OSM to human OA cartilage showed no significant collagen 
release at day 7 or at day 14. These data were in-line with previous literature stating that 
only about 25% of all OA cartilage responds to pro-inflammatory cytokine stimuli 
(Cawston et al., 1998). However, the addition of matriptase to IL-1+OSM-treated 
cartilage caused significant collagen release at both time points (Figure 5.4). 
Interestingly, the collagen release was very similar between untreated and IL-1+OSM-
treated cartilage incubated with matriptase implicating that the collagen release 
mediated by matriptase was independent of the pro-inflammatory stimulus. 
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Figure 5.4 The effect of matriptase on collagen release from human OA cartilage. 
Human OA cartilage was cultured in medium ± matriptase (100 nM) ± IL-1+OSM (1 
and 10 ng/ml, respectively). Media were removed on day 7 and fresh reagents were 
added until day 14 when the experiment was ceased. As a measure of collagen release, 
the levels of hydroxyproline were assayed in day 7 and day 14 media and in cartilage 
digests. Shown are the collagen release at day 7 and cumulative collagen release 
expressed as a percentage of the total collagen. Results are expressed as mean ± SD 
(n=4) and representative of 4 separate experiments. ** = p < 0.01 against untreated and 
## = p < 0.01 against IL-1+OSM-treated cartilage. 
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5.2.3.2 The effect of matriptase on collagenase activity in OA cartilage  
Untreated OA cartilage showed no increase in active or total collagenase activity at day 
7 or day 14. However, the addition of matriptase to the culture medium showed a 
significant increase in active and total collagenase activity at day 7 (Figure 5.5a) and 
correlated with the increase in collagen release (Figure 5.4). A similar increase was not 
seen at day 14 for either active or total collagenase levels (Figure 5.5b), even though an 
increase in collagen release could be observed. 
IL-1+OSM-treated OA cartilage showed significant levels of total collagenase activity 
at both day 7 and day 14, but little or no detectable active collagenase activity was 
observable at either time point. This result shows that while pro-MMPs are synthesised 
by OA chondrocytes, they are not activated to cause collagenolysis. This is in-line with 
previously published findings that show a minority of all OA cartilages respond to 
treatment with IL-1+OSM (Cawston et al., 1998). The addition of matriptase to IL-
1+OSM-treated cartilage showed an interesting trend. At day 7, a significant increase in 
active collagenase levels was noted and this corresponds with the increase in collagen 
release (Figure 5.4). However, total collagenase activity was significantly decreased at 
day 7 when compared to IL-1+OSM-treated cartilage. 15.55 ± 1.86 units/ml of total 
collagenase activity were in the media from IL-1+OSM+matriptase-treated cartilage, in 
comparison to the 30.71 ± 5.81 units/ml in the media from IL-1+OSM treated cartilage. 
There was a slight difference in active collagenase levels at day 14 but this did not reach 
significance. The total collagenase activity in both media samples showed no 
observable difference. 
156  
 
 
 
 
 
 
Figure 5.5 The effect of matriptase on collagenase activity from human OA 
cartilage.  
Media from matriptase-treated cartilage shown in Figure 5.4 were assayed for 
collagenase activity. Media were treated with APMA to test for total collagenase levels 
(pro and active). A) Active and total collagenase activity for day 7 media and B) active 
and total collagenase activity for day 14 media. Results are expressed as mean ± SD 
(n=4) and representative of 2 separate experiments. *** = p < 0.001 against untreated 
and ### = p < 0.001 against IL-1+OSM-treated cartilage. 
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5.2.3.3 The effect of matriptase on MMP-1 and MMP-13 protein levels in OA 
cartilage  
The addition of matriptase to untreated cartilage caused a significant increase in MMP-1 
protein levels at both day 7 and 14 (Figure 5.6a), but there was no significant change in 
the MMP-13 levels at either time point (Figure 5.6b). Treatment of cartilage with IL-
1+OSM caused a significant increase in both MMP-1 and MMP-13 protein levels at day 
7 and 14. This result corroborates findings with the collagenase activity (section 
5.2.3.2). 
When matriptase was added to IL-1+OSM-treated cartilage, there was a significant 
decrease in MMP-1 levels at both day 7 and 14, but little change in MMP-13 protein 
levels at both time points. The low protein level observed for MMP-1 at day 7 may 
explain the significant decrease in collagenase activity (Figure 5.5). 
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Figure 5.6 The effect of matriptase on total collagenase protein levels from human 
OA cartilage.  
Media from matriptase-treated cartilage shown in Figure 5.4 were assayed for total 
collagenase protein levels. A) MMP-1 and B) MMP-13 protein levels were determined 
by sandwich ELISA. Results are expressed as mean ± SD (n=4) and representative of 2 
separate experiments. *** = p < 0.001 against day 7 untreated cartilage, ### = p < 0.001 
against day 14 untreated cartilage, +++ = p < 0.001 against day 7 IL-1+OSM-treated 
cartilage and ††† = p < 0.001 against day 14 IL-1+OSM-treated cartilage 
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5.2.4 The effect of metalloprotease and cathepsin K specific inhibitor on 
matriptase-mediated cartilage degradation 
The aim of these experiments was to test if a novel type II collagenase, such as 
cathepsin K (Dejica et al., 2008), is mediating the degradation of the matrix or if this 
was solely MMP dependent. GM6001 is a metalloprotease-specific inhibitor with in 
vitro MMP inhibition in the low nanomolar range (Levy et al., 1998). L-873724 is a 
selective cathepsin K inhibitor that has an IC50 in the sub-nanomolar range (Li et al., 
2006). 
Addition of GM6001 to matriptase-treated OA cartilage (Figure 5.7) resulted in 
significantly decreased collagen release at day 7 and day 14. But GM6001 negative 
control did not affect collagen release (data not shown). 
Cathepsin K is a cysteine protease that can cleave the triple helix of type II collagen 
(Kafienah et al., 1998). Previous work implicates that it has a role in collagen turnover 
in OA (Dejica et al., 2008). The inhibitor L-873724 is a potent inhibitor of cathepsin K 
(Li et al., 2006) and has been shown to decrease the generation of type II collagen 
fragments in situ (Dejica et al., 2008). The addition of L-873724 to OA cartilage caused 
no change in collagen release at day 7 or day 14 (Figure 5.7). 
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Figure 5.7 The effect of MMP and cathepsin K specific inhibitors on matriptase 
mediated collagen release. 
Human OA cartilage was cultured ± matriptase (100 nM). The general MMP inhibitor 
GM6001 (10 µM) and the cathepsin K inhibitor L-873724 (10 nM) were added to the 
cartilage at days 0 and 7. DMSO was added as a solvent control. Media were removed 
on day 7 and fresh reagents added until day 14 when the experiment was ceased. As a 
measure of collagen release, the levels of hydroxyproline were assayed in day 7 and day 
14 media and in cartilage digests. Shown are the collagen release at day 7 and 
cumulative collagen release expressed as a percentage of the total collagen. Results are 
expressed as mean ± SD (n=4) and representative of 4 separate experiments. *** = p < 
0.001 
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5.2.5 Matriptase induced gene expression in OA cartilage 
Matriptase is able to cause collagen release in the absence of pro-inflammatory stimuli 
(Figure 5.4) and significantly increase collagenase levels (Figure 5.5 and 5.6) from OA 
cartilage. This collagen release has been shown to be metalloprotease-dependent (Figure 
5.7). The aim of these experiments was to assess if matriptase activity could directly 
induce gene expression in OA cartilage. 
The addition of matriptase to “live” cartilage showed significant collagen release as 
seen previously (Figure 5.8), but the addition of matriptase to “dead” cartilage did not 
show any increase in collagen release compared to untreated cartilage. 
Treatment of OA cartilage with matriptase significantly increased MMP-1 and MMP-3 
mRNA levels compared to control cartilage (Figure 5.9). There was an increase in 
MMP-13 mRNA levels but this did not reach significance. This increase in MMP-1 and 
MMP-3 gene expression indicates that matriptase is able to activate cell signalling 
cascades either directly or indirectly.  
The addition of di-isopropyl phosphorofluoridate (DFP)-inactivated matriptase to OA 
cartilage did not cause an increase in any MMP mRNA levels (data not shown). This 
result highlights that matriptase activity is required to cause collagenase gene 
expression in the absence of pro-inflammatory stimuli. 
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Figure 5.8 Intracellular signalling is required for matriptase-mediated degradation 
of OA cartilage. 
OA cartilage was isolated on the day of surgery and either placed immediately at 37°C 
(Live) or freeze-thawed three times (Dead) and then left at 37°C for 24 h. Cartilage ± 
matriptase (100 nM) was left to culture for 7 days. Shown is the collagen release at day 
7 with collagen release expressed as a percentage of the total collagen. Results are 
expressed as mean ± SD (n=4) and representative of 1 experiment. *** = p < 0.001 
against control, ### = p < 0.001 against live cartilage. 
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Figure 5.9 Matriptase induced MMP gene expression in OA cartilage. 
OA cartilage was treated with matriptase (100 nM) for 7 days. Total RNA was extracted 
and MMP-1, -3 and -13 gene expression was determined by real-time PCR. 18S rRNA 
levels were determined for normalisation. The data from 2 separate experiments are 
shown and presented as fold induction relative to control. Results are expressed as mean 
± SEM (n=4). ** = p < 0.01 and *** = p <0.001. 
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5.2.6 Matriptase activates PAR-2 in OA cartilage to mediate the degradation of the 
collagen matrix  
In the absence of pro-inflammatory cytokines, matriptase alone could not induce 
significant collagen degradation in bovine cartilage (Dr J. M. Milner, personal 
communication) or human NOF cartilage (Figure 5.10). Therefore, matriptase must 
induce collagenase gene expression (Figure 5.9) through activation of a receptor found 
only in OA cartilage.  
PAR-2 is a well characterised substrate for matriptase (Takeuchi et al., 2000, Wang et 
al., 2008) and activation of PAR-2 has been shown to increase MMP expression in OA 
osteoblasts (Amiable et al., 2009). As PAR-2 expression is reported to be up-regulated 
in OA cartilage (Xiang et al., 2006), I hypothesised that matriptase-driven cartilage 
degradation was mediated through PAR-2 activation. 
Addition of matriptase to the cartilage resulted in significant collagen release at day 7 as 
previously noted (Figure 5.11). The addition of both PAR-2 inhibitors significantly 
reduced the observed matriptase-mediated collagen release almost to basal levels, 
indicating that matriptase does act through PAR-2 to mediate breakdown of OA 
cartilage. 
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Figure 5.10 The effect of matriptase on collagen release from human NOF 
cartilage 
Human NOF cartilage was cultured in medium ± matriptase (100 nM) ± IL-1+OSM (1 
and 10 ng/ml, respectively). Media were removed on day 7 and fresh reagents were 
added until day 14 when the experiment was ceased. As a measure of collagen release, 
the levels of hydroxyproline were assayed in day 7 and day 14 media and in cartilage 
digests. Shown are the collagen release at day 7 and cumulative collagen release 
expressed as a percentage of the total collagen. Results are expressed as mean ± SD 
(n=4) and representative of 1 experiment. 
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Figure 5.11 The effect of PAR-2 specific inhibitors on matriptase-mediated 
collagen release. 
Human OA cartilage explants were pre-incubated ± SAM-11 (400 ng/ml final 
concentration) or the same antibody that had been previously heat-denatured (SAM-
11
b
), or ± ENMD-1068 (10 mM final concentration) for 72 h. Subsequently, matriptase 
(100 nM) was added such that the SAM-11 antibody and ENMD-1068 were at final 
concentrations of 200 ng/ml and 5 mM, respectively, for 7 days. Shown is the collagen 
release at day 7 and collagen release expressed as a percentage of the total collagen. 
Results are expressed as mean ± SD (n=4) and representative of 3 separate experiments. 
*** = p < 0.001 against control, ### = p < 0.01 against matriptase-treated cartilage and 
+++ = p < 0.001 against heat-denatured antibody control. 
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5.3 Discussion 
5.3.1 Matriptase activation of pro-MMPs 
Milner et al. (2001) showed that activation of the pro-collagenases in IL-1+OSM-
treated cartilage was a key rate-limiting step in collagen breakdown. Plasminogen 
addition at day 0 to IL-1+OSM-treated bovine cartilage resulted in increased breakdown 
of the collagen network by day 7 compared to IL-1+OSM alone. Data in this chapter 
show that addition of matriptase at day 7 accelerated collagen release from IL-1+OSM-
treated bovine cartilage. Therefore, matriptase is likely to activate pro-MMPs that are 
synthesised upon stimulation with IL-1+OSM and this expedites collagen release. 
Jin et al. (2006) demonstrated that matriptase could directly activate pro-MMP-3 within 
3 h. However, they found that matriptase non-specifically degraded pro-MMP-1, which 
conflicts with the data presented here. Our group found that pro-MMP-1 was not 
degraded in a non-specific manner in the presence of matriptase over 24 h (Dr J. M. 
Milner, personal communication) and has significantly greater activity compared to pro-
MMP-1 alone (data not shown). In fact, N-terminal sequencing showed that matriptase 
activated MMP-1 and MMP-3 by cleaving the Arg-Cys bond in the cysteine switch 
region. After activation of pro-MMP-3 by matriptase, active MMP-3 can then cleave the 
N-terminus of pro-MMP-1 to generate a species that has higher activity (He et al., 1989, 
Murphy et al., 1987, Windsor et al., 1993). These data indicate that matriptase can 
directly activate pro-MMP-1 and pro-MMP-3. This in turn can lead to degradation of 
the collagen matrix as MMP-1 can directly cleave type II collagen (section 1.5.2) and 
MMP-3 can directly activate other pro-collagenases as well as other pro-MMPs (section 
1.5.3). 
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5.3.2 Effect of matriptase on human OA cartilage 
The breakdown of human OA cartilage by matriptase was described in this chapter. 
Human OA cartilage has previously been described to be highly resistant to pro-
inflammatory-mediated breakdown despite increased expression of collagenolytic 
MMPs (Cawston et al., 1998). Although this observation could never be fully explained, 
it is likely that there is a failure in MMP activation. 
Addition of matriptase to OA cartilage led to a significant increase in collagen release. 
These data show that matriptase activity in IL-1+OSM-treated cartilage is in-line with 
previous studies from our group (Milner et al., 2001, 2006b, 2003). However, the 
significant increase in collagen release by matriptase in the absence of pro-
inflammatory cytokines is an extremely important finding. Matriptase represents the 
most potent stimulus for OA cartilage described to date. In the absence of pro-
inflammatory cytokines, matriptase-mediated matrix breakdown could be due to the 
activation of latent growth factors or proteases. Previous in vitro data have shown that 
pro-HGF, pro-uPA and PAR-2 are matriptase substrates (Lee et al., 2000, Takeuchi et 
al., 2000), and further studies have shown that HGF induced MMP expression in 
endothelial (Wang and Keiser, 2000) and cancer cells (Monvoisin et al., 2002). The 
matriptase-mediated increase in collagenase activity and MMP protein levels in the 
absence of pro-inflammatory cytokines does highlight the possibility that activation of 
bioactive molecules might play an important role. 
5.3.3 Matriptase induced collagen release is dependent on MMP activity 
The addition of pro-inflammatory cytokines to human OA cartilage showed a 
significant increase in both total collagenase activity and protein levels. However, when 
matriptase was added in the presence of pro-inflammatory cytokines, there was a 
significant decrease in MMP-1 protein levels and collagenase activity. These data 
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implicate that the degradation of type II collagen could be mediated through a novel 
collagenase. 
Kafienah et al. (1998) demonstrated that cathepsin K, a cysteine protease, could cleave 
native type I and II collagens and that this cleavage occurred at the N-terminus of the 
triple helix. Further data generated by Dejica et al. (2008) showed that a cathepsin K-
specific neoepitope was detectable in OA cartilage. However, the data presented here 
indicate that matriptase-mediated collagen release was dependent on MMP activity and 
that inhibition of cathepsin K had little effect. 
5.3.4 Matriptase directly induces gene expression 
The data generated so far show that matriptase is a potent mediator of collagen 
degradation in OA cartilage. So far, the activation of pro-MMPs has been highlighted as 
one mechanism matriptase acts through to effect this collagen degradation. However, 
data show that matriptase can stimulate similar levels of collagen release in the presence 
or absence of pro-inflammatory cytokines. In addition, the MMP-1 protein levels are 
similar between the two conditions. The data presented here support intracellular 
signalling to be a key requirement for matriptase-mediated collagen degradation. 
MMP-1 and MMP-3 gene expression are significantly up-regulated upon the addition of 
matriptase. MMP-13 expression is also up-regulated, although this was not statistically 
significant. As stated earlier, HGF is shown to increase MMP expression in a number of 
different cell types (Monvoisin et al., 2002, Wang and Keiser, 2000) and is activated by 
matriptase (Lee et al., 2000). Increased levels of HGF have been shown in OA cartilage 
(Pfander et al., 1999) and HGF can cause induction of MMP-13 gene transcription 
through the activation of MAPK pathways (Reboul et al., 2001). However, Guevremont 
et al. (2003) showed that HGF is not expressed by OA chondrocytes but by subchondral 
bone osteoblasts and diffuses from there to the radial zone of the cartilage. 
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Pro-uPA is another substrate activated by matriptase (Lee et al., 2000) and plays an 
important role in arthritis (Li et al., 2005, Busso and So, 1997). Matriptase activating 
pro-uPA is a possible mechanism that could cause the observed collagen breakdown in 
OA cartilage. However, data from our group have shown that addition of plasminogen 
to OA cartilage has little effect on collagen release without pro-inflammatory stimuli 
(Milner et al., 2001). Furthermore, unpublished data from our group show that 
plasminogen is not expressed by OA cartilage (Dr J. M. Milner, personal 
communication). These data indicate that in our cartilage explant model the uPA-
plasmin system would cause neither collagen release nor de novo synthesis of MMP 
directly, but would be able to activate any pro-MMP present. 
Previous reports have shown that activation of PAR-2 by a PAR-2-activating peptide 
induces MMP-1 and MMP-13 gene expression in OA chondrocytes (Boileau et al., 
2007), correlating with the results presented in this chapter.  
5.3.5 Matriptase activates PAR-2 in OA cartilage 
The induction of collagenase gene expression by matriptase must involve the activation 
of intracellular signalling pathways to initiate gene transcription. Reports in the 
literature show that the expression of PARs (section 1.9.1) is significantly higher in OA 
cartilage compared to normal cartilage. One report states that all four known PARs are 
expressed by OA chondrocytes (Kirilak et al., 2006) while another just detected PAR-2 
expression (Xiang et al., 2006). 
PAR-2 activation involves proteolytic release of a tethered ligand which can be 
mimicked by use of a PAR-2-activating peptide (Hollenberg et al., 1997). Takeuchi et 
al. (2000) demonstrated that matriptase activated PAR-2 using PAR-2 overexpressing 
Xenopus oocytes but not with any other PAR expressing Xenopus oocytes. Our group 
confirmed that matriptase can activate PAR-2 in vivo (Prof. A. D. Rowan, personal 
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communication) using PAR-2 knock-out mice in synovial perfusions assays as 
described previously for β-tryptase (Palmer et al., 2007). 
ENMD-1068 is a synthetic inhibitor that has been shown to inhibit proteolytic 
activation of PAR-2 (Kelso et al., 2006) and decreased IL-1β and TNF-α expression 
from rheumatoid synovium (Kelso et al., 2007). The use of ENMD-1068 or a PAR-2 
neutralising antibody (SAM-11) significantly blocked matriptase-induced collagen 
release, further substantiating that PAR-2 activation is required for matriptase-mediated 
collagenolysis.  
Finally, when matriptase was added to phenotypically normal cartilage, there was no 
detectable change in collagen release even in the presence of pro-inflammatory stimuli. 
As PAR-2 expression is higher in OA than normal chondrocytes (Kirilak et al., 2006), 
these data indicate that the activation of PAR-2 is a key point in arthritis. 
The destabilisation of the medial meniscus (DMM) surgical murine model of OA has 
been reported to result in arthritic lesions similar to those observed in aged mice 
(Glasson et al., 2007). Due to the sensitivity of the DMM model in regards to disease 
modification, this model has been proposed to be a good choice for challenging gene 
knock-out mice with OA when compared to established models such as anterior cruciate 
ligament transection. Using this model, Ferrell et al. (2010) highlighted that PAR-2-
deficient mice do not exhibit any signs of pathology compared to wild-type mice.  
Interestingly, when OA cartilage was pre-incubated for 72 hours before the addition of 
matriptase, there was a reduction in collagen release (Figure 5.11) compared to OA 
cartilage treated immediately (Figure 5.8). This implies that upon removal of the 
mechanical forces generated during abnormal joint loading, PAR-2 expression 
decreases rapidly to a similar level found in NOF cartilage (Figure 5.10). In fact, this 
finding was corroborated using the DMM model as PAR-2 was detectable in cartilage 
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from sham-operated mice but significantly increased in cartilage from DMM mice. But 
matriptase was only detectable in the latter (Prof. A. D. Rowan, personal 
communication).  
5.4 Conclusion 
Although the factors that lead to the development of OA lesions have yet to be fully 
identified, biomechanical instability of the joint is thought to be a major contributor. 
The data presented in this chapter show that in an OA cartilage explant model, 
matriptase can act at a number of levels to mediate collagen breakdown (Figure 5.12).  
There is an increase in expression of matriptase and PAR-2 after injury to the joint. 
Activation of PAR-2 by matriptase activates stress pathways within the chondrocyte 
(Boileau et al., 2007) and leads to MMP-1, -3 and -13 gene expression. Subsequently, 
matriptase can activate MMP-1 and -3 and this finally leads to the breakdown of the 
collagen matrix. 
Inhibitors targeted to PAR-2 or matriptase are novel therapeutic directions for the 
treatment of arthritis. Takeuchi et al. (1999) showed that inhibition of matriptase 
activity decreased PC3 prostate carcinoma size. Further work showed that a synthetic 
matriptase inhibitor, CVS-3983, displayed a similar trend in another mouse model of 
prostate cancer (Uhland, 2006). Recently, Darragh et al. (2010) developed an inhibitory 
antibody that was specific for matriptase and matriptase-specific cancers. Further 
development of inhibitors, against PAR-2 and matriptase, which can overcome the 
specific issues presented by cartilage, will be highly beneficial. 
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Figure 5.12 Matriptase-mediated pathways leading to collagen matrix degradation. 
The final common pathway of collagen degradation is MMP dependent as GM6001 
completely blocks collagen release. Inhibition of PAR-2 signalling blocks cartilage 
degradation suggesting this to be a major pathway in the absence of pro-inflammatory 
stimuli. The activation mechanisms involved in vivo are likely to be more complex than 
shown here, possibly including other growth factors and serine protease zymogens. 
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5.5 Summary 
 Matriptase instigated collagen release independent of IL-1+OSM. 
 Collagenase activity and protein levels were reduced in the presence of 
matriptase. 
 The collagen release was solely dependent on MMP activity. 
 Matriptase activated pro-MMP-1 and pro-MMP-3 as determined by N-terminal 
sequencing. 
 Matriptase induced MMP-1 and MMP-3 gene expression in OA cartilage. 
 Inhibition of PAR-2 significantly reduced matriptase-mediated collagen 
degradation from OA cartilage. 
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CHAPTER 6 
General Discussion 
In the context of arthritis pathology, the main aim of this thesis has been to examine 
whether the activity of FAPα, DPPIV or matriptase promote collagen release and 
collagenase activation in resorbing bovine and human cartilages. 
6.1 General perspective 
Articular cartilage provides a friction-free surface to permit joint articulation and is an 
unusual tissue since it is hypocellular being populated by a single cell-type, the 
chondrocyte. During disease states, abnormal stimuli including abnormal loading, as 
well as pro-inflammatory stimuli such as IL-1 (Goldring and Goldring, 2007), prevail 
that lead to uncontrolled ECM turnover.  
Although, there are a large number of different forms of arthritis, RA and OA are the 
most common afflictions. RA is a disease characterised by systemic activation of the 
immune system, which is possibly initiated by the recognition of auto-antigens (de 
Vries et al., 2005). The chronic activation of the immune system in the joint space leads 
to the release of inflammatory cytokines, such as IL-1 and OSM, which have been 
shown to synergistically increase levels of the MMPs (Cawston et al., 1998). OA is the 
most common form of arthritis, affecting the majority of individuals over the age of 65 
years. Cartilage damage in OA is thought to occur due to a number of different reasons 
such as ageing, genetic factors as well as excessive loading. The degeneration of 
cartilage occurs due to an imbalance between the anabolic and catabolic pathways. 
Excessive loading of cartilage can cause increased collagen degradation and up-
regulation of MMPs. In both diseases there is an increase in the levels of MMPs leading 
to the enhanced turnover of the cartilage matrix.  
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MMPs are the key rate-limiting enzymes that degrade the collagen matrix in arthritis 
and inhibition of these enzymes would be an attractive prospect. However, broad-
spectrum MMP inhibitors have shown a clear lack of efficacy in clinical trials for the 
treatment of arthritis (Cawston and Young, 2010 and references therein). These 
inhibitors exhibited severe musculoskeletal side-effects, which were reversed when the 
compound was withdrawn (Nemunaitis et al., 1998). 
Although, synthetic MMP inhibitors have proven to be ineffective, several new 
treatments have been approved for use in arthritis. One treatment in clinical use is anti-
TNF therapy that dampens the inflammatory response, and therefore halts cartilage 
degradation (Maini and Feldmann, 2002). However, despite its clinical use, a substantial 
fraction of patients have no meaningful clinical response to anti-TNF treatments (Kievit 
et al., 2007). 
Previous data from our group showed that serine proteases play an important role in 
cartilage degradation through the activation of pro-MMPs (Milner et al., 2001, 2003). 
While sequencing of the human genome has identified over one hundred and seventy 
serine protease genes (Quesada et al., 2009), the exact serine proteases expressed in 
cartilage, and the role they play, during disease progression have yet to be fully 
elucidated. Recently, FAPα, DPPIV and matriptase expression were found to be 
increased in OA cartilage compared to NOF cartilage (Milner et al., 2006b, Swingler et 
al., 2009). The aim of this thesis was to determine the role of these novel 
transmembrane serine proteases in the context of cartilage degradation. 
6.2 Dipeptidyl peptidases in cartilage breakdown 
FAPα and DPPIV are both members of the DPP family (section 1.8) and both are 
therapeutic targets in a number of disease models. Inhibition of DPPIV has been a very 
successful strategy for the treatment of type II diabetes (Pratley and Salsali, 2007). 
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Although, targeting FAPα directly in cancer has not proven as successful (Huang et al., 
2004, Ostermann et al., 2008), its use as a biomarker for anti-cancer drug delivery 
shows promise (Bauer et al., 2004). 
Previous data implied a protective role for DPPIV in disease pathology. DPPIV is up-
regulated on the surface of OA chondrocytes (Lapadula et al., 1995) and expression is 
decreased in areas where there is progressive worsening of the osteoarthritic lesions. In 
RA, DPPIV activity is shown to decrease in both the synovial membrane and fluid of 
patients (Gotoh et al., 1989, Kamori et al., 1991). Furthermore, there is a decrease in the 
serum levels of DPPIV that is inversely proportional to the degree of inflammation 
experienced in the joint (Busso et al., 2005). FAPα expression has recently been 
detected on the cell surface of chondrocytes upon stimulation with IL-1 and OSM 
(Milner et al., 2006b). FAPα expression has also been detected on the surface of 
rheumatoid arthritis synovial fibroblasts (Bauer et al., 2006). FAPα has gelatinase 
activity (Aoyama and Chen, 1990, Monsky et al., 1994, Pineiro-Sanchez et al., 1997) as 
well as dipeptidyl peptidase activity (Park et al., 1999) and both of these activities occur 
in the same catalytic pocket located in the α/β-hydrolase domain. FAPα expression is 
involved with cell migration through collagen matrices (Ghersi et al., 2002) and 
correlates with collagen turnover in IL-1+OSM treated cartilage (Milner et al., 2006b).  
The loss of DPPIV in both RA and OA is associated with increased disease pathology 
and implies that inactivation of chemokines within the joint space is an important 
protective mechanism against cartilage matrix breakdown. However, the expression of 
FAPα during collagen remodelling implicates a catabolic role. Taken together these 
findings implicate that DPPIV and FAPα activity play different but important roles in 
cartilage biology. 
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The molecular mechanisms of how DPPIV activity affects the cartilage matrix during 
arthritis are unclear. In this thesis, soluble DPPIV has not been shown to have an effect 
on IL-1+OSM-treated cartilage (section 4.2.3). However, experiments also show that 
inhibition of membrane-bound DPPIV activity decreases collagen degradation (section 
4.2.2). Data suggest that DPPIV inhibitors play a role in the up-regulation of TGF-β1 
secretion in T cells (Reinhold et al., 2006). Ishii et al. (2001) have shown that DPPIV 
co-localises with CD45 at lipid rafts and leads to the activation of ZAP70. Therefore, 
DPPIV inhibitors could cause a conformational change and disrupt or prevent DPPIV 
binding to other cell surface proteins, such as CD45, and this leads to TGF-β1 secretion. 
TGF-β1 (section 1.3.3) has been shown to have a differential role in cartilage (Blaney 
Davidson et al., 2007). Previous data from our group show that TGF-β1 can 
significantly reduce collagen release and collagenase levels from cytokine-treated 
cartilage (Hui et al., 2003a, Hui et al., 2001) and this is thought to occur through the 
receptor ALK5 (Blaney Davidson et al., 2009). However, during aging there is a 
reduction in the levels of ALK5 and an increase in ALK1 levels and this correlates with 
increased MMP-13 production in OA. Therefore, the global reduction of collagenase 
levels seen in this thesis when K579 was added to IL-1+OSM-treated bovine cartilage 
(section 4.2.2.5) could be caused by ALK5 activation by TGF-β1 as bovine cartilage is 
a model of healthy cartilage. Nonetheless, measuring changes in TGF-β1 levels would 
be problematic as large quantities of latent TGF-β1 are stored in the normal cartilage 
matrix (Pedrozo et al., 1998). This implies that DPPIV is involved in chondrocyte 
signalling if increased TGF-β1 levels are the mechanism of cartilage protection for 
DPPIV inhibition. 
As mentioned earlier, DPPIV inhibitors are in clinical use in the treatment of type II 
diabetes. In this thesis, it has been demonstrated that inhibition of DPPIV is 
chondroprotective, but the use of DPPIV inhibitors to treat arthritis may be problematic. 
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Busso et al. (2005) highlighted that collagen-induced arthritis in DPPIV
-/-
 mice was 
more severe than in wild-type DPPIV
+/+
 mice. Furthermore, DPPIV expression is 
decreased in areas where there is progressive worsening of the osteoarthritic lesions 
(Lapadula et al., 1995).  
The endopeptidase activity of DPPIV has been evaluated in this thesis and it was found 
that DPPIV could not cleave denatured type II collagen (section 4.2.4). This contradicts 
the study by Bermphol et al. (1998) that highlighted DPPIV could cleave denatured 
collagens and rules this out as a mechanism for the decreased collagen release from IL-
1+OSM-treated cartilage by DPPIV inhibition (section 4.2.2.5). 
The role of FAPα in cartilage matrix breakdown during the arthritides remains unclear. 
Experiments in this thesis showed that inhibition of FAPα activity does not affect 
collagen degradation (section 3.2.3). Chen et al. (2006a) speculate that N-terminal 
truncation is required to enhance gelatinase activity but not the dipeptidyl peptidase 
activity of FAPα and this truncation might change the active site in vivo to alter 
inhibitor binding. This finding might also suggest why soluble FAPα does not affect 
collagen degradation in IL-1+OSM-treated cartilage (section 3.2.4). However, there is 
no direct evidence for FAPα activity to be involved in ECM degradation other than its 
localisation at the invadopodia of melanoma cells (Artym et al., 2002, Ghersi et al., 
2002) and close proximity to proteins such as MMPs. To date only a small number of 
FAPα substrates have been identified. In this thesis FAPα has been demonstrated to 
degrade denatured type II collagen (section 3.2.2). This finding is in-line with data 
published by Christiansen et al. (2007) that show degradation of denatured type I and III 
collagens, and α2-antiplasmin has been described to be another natural FAPα substrate 
(Lee et al., 2004).  
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Work presented in this thesis shows that the regulation of DPPIV (section 4.2.1) and 
FAPα (section 3.2.1) gene expression in chondrocytes does not involve pro-
inflammatory cytokines. DPPIV and FAPα have been described to be up-regulated in 
OA cartilage compared to normal (Milner et al., 2006b, Swingler et al., 2009). The 
increased gene transcription in cartilage could be due to a number of different pathways. 
Cartilage has to sustain extreme loads (section 1.1) and therefore mechanical loading 
may regulate DPPIV and/or FAPα gene expression in chondrocytes. A number of 
studies have shown that mechanical loading of chondrocytes activates a number of 
signalling pathways (Pingguan-Murphy et al., 2005, Bougault et al., 2008). Another 
pathway could be the TLR pathway and it has recently been described to play a role in 
OA chondrocytes (Zhang et al., 2008). Endogenous ligands recognised by the TLRs 
could include ECM catabolites such as heparin sulphate (Johnson et al., 2002). This 
pathway could play an important role in the bovine model as previous data from our 
group showed elevation of FAPα during breakdown of the collagen matrix (Milner et 
al., 2006b). In this model, the addition of IL-1+OSM to cartilage would initiate 
breakdown of the cartilage matrix. Pro-MMPs would be synthesised and activated, 
ECM proteins would then be degraded to reveal cryptic epitopes that could bind to an 
unidentified TLR and drive FAPα expression. 
In conclusion, experiments in this thesis have been undertaken to broaden the 
understanding of the role FAPα and DPPIV play in cartilage homeostasis. The data 
suggest that FAPα enzyme activity has little effect in our cartilage model but can 
degrade denatured type II collagen. Although FAPα can degrade denatured type II 
collagen, the importance of this finding is unclear. In the bovine model, FAPα gene 
expression is found to increase after day 10 (Milner et al., 2006b), but MMP-2 and 
MMP-9 are expressed at 10- to 100-fold higher levels than FAPα (Milner et al., 2006a) 
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at this time point. Consequently, is FAPα adding to this gelatinolytic activity at the cell 
surface? 
 Inhibition of DPPIV enzyme activity shows mixed results and needs to be explored 
further. However, questions still remain about the molecular mechanisms involved in all 
of these observations. One possibility is that the β-propeller domain of FAPα or DPPIV 
could play an important role in recruiting receptors and proteases to increase matrix 
breakdown (Figure 4.26). 
6.3 Matriptase in cartilage breakdown 
Matriptase is a member of the TTSP family (section 1.7) that is becoming a target for 
therapeutic intervention in a number of cancers (Bugge et al., 2009, Szabo and Bugge, 
2008). Matriptase expression has been shown to be up-regulated in OA cartilage 
compared to normal (Swingler et al., 2009). In a murine model of OA, matriptase 
expression is increased when the knee joint is destabilised (Prof. A. D. Rowan, personal 
communication).  In this thesis matriptase was shown to enhance the degradation of IL-
1+OSM-treated cartilage (section 5.2.1) in a manner similar to plasmin (Milner et al., 
2001). Matriptase was also demonstrated to directly activate pro-MMP-1 and -3 (section 
5.2.2). Previous data have shown that if active MMP-3 is added at day 0 to IL-1+OSM-
treated cartilage significant collagen release is seen by day 7 (Milner et al., 2001). 
Matriptase has been shown to be potent mediator of collagen degradation in human OA 
cartilage (section 5.2.3). Human OA cartilage has previously been described to be 
highly resistant to pro-inflammatory-mediated breakdown despite the increased 
expression of collagenolytic MMPs (Cawston et al., 1998). In the presence of IL-
1+OSM, matriptase is likely to activate pro-MMPs analogous to the IL-1+OSM-treated 
bovine cartilage. However, the most striking finding was that matriptase is able to cause 
collagen degradation in human OA cartilage in the absence of pro-inflammatory 
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cytokines (section 5.2.3). The extent of collagen release, typically around 30% by day 
14, was unprecedented compared to any previously used stimulus. This therefore 
represents the most potent stimulus for OA cartilage to be described to date. This result 
has not been seen previously, as plasmin was only able to cause collagen degradation in 
OA cartilage in concert with IL-1+OSM (Milner et al., 2001). 
The degradation of OA cartilage by matriptase is metalloprotease-dependent, most 
probably via MMPs (section 5.2.4) but interestingly the collagenase levels in samples 
treated with matriptase were lower than in samples treated with IL-1+OSM (sections 
5.2.3.2 and 5.2.3.3). Previous data have shown that MMPs can localise to the cell 
membrane via interaction with cell surface receptors (Emonard et al., 2005). 
Furthermore, data have recently shown that the CUB domains of matriptase facilitate 
protein-protein interactions to transmembrane proteins such as TMEFF1 and HAI-1 (Ge 
et al., 2006, Inouye et al., 2010). The functions of the non-catalytic domains of 
matriptase have not been fully elucidated in the context of arthritis, but could play an 
important role in substrate recognition or binding. Conversely, matriptase-mediated 
cartilage breakdown could cause distinct gene expression compared to IL-1+OSM 
treatment, such that uncharacterised proteins are localising MMPs to the chondrocyte 
surface and expedite collagen degradation. 
Matriptase-induced collagen breakdown is dependent on intracellular signalling events 
in chondrocytes to cause de novo MMP production (section 5.2.5). The signalling was 
via activation of PAR-2 by matriptase (section 5.2.6) as PAR-2 inhibition blocked 
collagen release from OA cartilage. PAR-2 has been shown to be elevated in murine 
models of arthritis (Busso et al., 2005). However, I have demonstrated that PAR-2 
activation has a profound impact on the cartilage matrix. This is corroborated by Ferrell 
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et al. (2010) as PAR-2
-/-
 mice show significantly less cartilage and bone erosion than 
wild-type mice in two experimental murine models of OA. 
Experiments in this thesis have shown that matriptase plays an important role in the 
breakdown of the cartilage collagen matrix by causing MMP synthesis, activation and 
finally collagen breakdown. One of the key observations has been that matriptase-
mediated activation of the PAR-2 signalling pathway is a key requirement for collagen 
breakdown from arthritic cartilage in the absence of pro-inflammatory cytokines. The 
PAR-2 pathway needs to be examined in greater detail as there is little information on 
the genes that are regulated upon PAR-2 activation. Only a report by Tanaka et al. 
(2008) has shown that IL-8 is up-regulated upon PAR-2 activation in epithelial cell 
lines. 
Matriptase inhibitors are currently being designed to suppress tumour growth and 
metastasis. However, the catalytic domain of matriptase shares a similar fold to 
chymotrypsin and therefore an inhibitor against matriptase would have to be extremely 
specific to avoid off-target effects. The matriptase inhibitor CVS-3983 has been shown 
to supress prostate cancer growth but shows slight cross-reactivity with trypsin and 
factor Xa proteases (Galkin et al., 2004). Schweinitz et al. (2009) have shown a similar 
trend where the most potent matriptase inhibitor (sub-nanomolar Ki) also displayed 
potent cross-reactivity with factor Xa. Another problem regarding the clinical use of 
matriptase inhibitors is that matriptase has been shown to play an important role in 
epithelial barrier formation and function (List et al., 2002, Buzza et al., 2010). These 
studies have used constitutive matriptase knockouts or low matriptase expression mice 
and provide strong evidence for a role in development. Recently, List et al. (2009) 
generated conditional matriptase knockout mice and showed that ablation of matriptase 
expression between 8 to 28 weeks postnatal caused a loss in epithelial integrity, 
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resulting in severe epithelial organ dysfunction. Taken together these data highlight the 
requirement for matriptase inhibitors specific and designed so as not to adversely affect 
epithelial tissues and organs in order to be of clinical relevance in the treatment of 
arthritis. 
6.4 Future work 
The work in this thesis has raised a number of questions about the role of 
transmembrane serine proteases in cartilage matrix homeostasis. Further work will be 
required to address these questions as well as confirm some of the conclusions drawn in 
this study. 
 Develop an in vitro transgenic cartilage model to assess protease function on the 
cartilage matrix. Treatment of cartilage with siRNA is prohibitively expensive 
but retroviral gene transfer has been shown to allow long-term expression of 
transgenes (Kafienah et al., 2003). In theory, chondrocytes could be transfected 
with two plasmid constructs; one plasmid would be under TET-off control and 
express TGF-β3 to help promote cartilage matrix formation in vitro. The second 
plasmid would be under the control of the enhancer cumate (Mullick et al., 
2006) and express a transgene or small homologous (sh) RNA. Initially, 
transduced chondrocytes would be cultured in the presence of cumate and 
doxycycline. This would allow TGF-β3 expression and the generation of 
engineered “tissue”, and not the transgene. Withdrawal of cumate and 
doxycycline would stop TGF-β3 expression and permit transgene or shRNA 
expression. 
 Use bimolecular fluorescence complementation to assess if DPPIV or FAPα 
associate with other proteases at the cell surface of OA chondrocytes. 
Bimolecular fluorescence complementation is based upon complementation of 
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two separately expressed fragments of GFP or derivates which are fused to 
putative interacting proteins. 
 Grover and Roughley (2006) developed a conditional cartilage-specific 
knockout mouse model. As the expression of Cre recombinase was under 
control of both the type II collagen promoter and a doxycycline response 
element, this overcame the embryonic lethal phenotype that universal gene 
knockout mice often displayed. This mouse is then crossed with another strain of 
mouse where the gene of interest lies between two loxP sites. The resulting 
progeny could then be fed on a diet supplemented with doxycycline to repress 
target gene expression. Therefore, if we generate cartilage-specific DPPIV and 
FAPα knockout mice and then initiate arthritis either by injection of collagen 
into their tail-base or by destabilization of the medial meniscus. This would 
show whether these enzymes play a role in either inflammatory arthritis or in an 
OA-like model.  
 Characterise the role of the non-catalytic domains of matriptase to test whether 
they are important in cartilage matrix breakdown. The CUB domains have been 
shown to facilitate the binding of matriptase to other transmembrane proteins. 
Inouye et al. (2010) highlight that the interaction between CUB domain II of 
matriptase and the second Kunitz domain of HAI-1 facilitates the binding of the 
first Kunitz domain of HAI-1 to the catalytic domain of matriptase. Therefore, 
expression of the individual tagged domains will allow for the identification of 
novel binding partners of matriptase and determine their functions in the context 
of arthritis. 
 Generate cartilage-specific matriptase knockout mice and initiate arthritis by 
destabilization of the medial meniscus. This would highlight whether matriptase 
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knockout would protect cartilage from degradation as shown for PAR-2 
knockout mice (Ferrell et al., 2010). 
 
6.5 Summary 
The most significant finding of this thesis is the breakdown of the cartilage collagen 
network by the transmembrane serine protease, matriptase. Studies within this 
department have provided evidence for the role of serine proteinases in the activation of 
pro-MMPs in cartilage (Milner et al., 2001, 2003). My data have demonstrated for the 
first time that matriptase plays an important role in cartilage breakdown by the 
activation of PAR-2 and pro-MMP-1 and -3. Data from our group have confirmed this 
finding in vivo using a murine model of OA. Finally, the data presented in this thesis 
show that investigating the role of dipeptidyl peptidases with pharmacological inhibitors 
is hindered by their lack of ex vivo efficacy in the context of arthritis. Consequently, the 
data from these studies require confirmation by alternative techniques.  
The findings in this thesis highlight the need to further characterise the role of novel 
transmembrane serine proteases in cartilage. Such endeavour may well realise the 
potential of serine protease inhibitors as future therapeutic agents for the arthritides. 
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